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Abstract 
The objective of this study was to assess the usefulness of provincial administrative 
databases in carrying out surveillance on depressive disorders. Electronic Medical 
Records (EMR) at three family practice clinics in St. John 's were audited based on a 
sample of patients classified as being diagnosed or not diagnosed with a depressive 
disorder. The EMR served as the "gold standard", which was then compared to these 
same patients investigated through the use of various case definitions applied against the 
provincial hospital and physician administrative databases. Variables used in the 
development of the case definitions were depressive disorders diagnoses (either in 
hospital or physician claims data), date of diagnosis, and service providers type (general 
practitioners vs. psychiatrists). This study found that provincial hospital and physician 
databases are useful for carrying out surveillance on depressive disorders using certain 
types of case definitions. The inclusion of medications dispensed to patients was found to 
increase the sensitivity and decrease the false negative rate for certain case definitions. 
The availability of prescription data from population-based Pharmacy Networks in the 
development of case definitions presents an opportunity for the development of more 
advanced surveillance methods for depressive disorders in Canada. 
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ORGANIZATION OF THE DISSERTATION 
This dissertation is organized into five chapters as follows : Chapter I provides 
background information on the purpose of the study, the research problem, and the 
rationale for this study. Chapter 2 describes the background information about depressive 
disorders, as well as a review of the relevant literature on surveillance of depressive 
disorders using various methods, particularly administrative databases. Chapter 3 outlines 
the methods used to address the research questions, while the results of this study are 
organized in Chapter 4. Chapter 5 presents a discussion of findings in relation to the 
existing literature, as well as a summary of the strengths and limitations of methods 
employed in this study. 
CHAPTER ONE: INTRODUCTION 
This chapter provides background information on the purpose and objectives of the 
study, the research problem, and the rationale for this study. It also outlines the 
organization of the dissertation. 
1.1 Purpose 
The purpose of this study was to assess the usefulness and validity of using provincial 
administrative databases for carrying out surveillance on depressive disorders. Depressive 
disorders focused on in this study included major depressive disorder, dysthymic 
disorder, and depressive disorders not otherwise specified (e.g. , minor depressive 
disorder, recurrent brief depressive disorder). 
1.2 Objectives 
The objectives of this study were: 
- To develop valid case definitions for surveillance of depressive disorders 
among the adult population in Newfoundland and Labrador using 
administrative data; 
- To investigate predictive factors associated with diagnoses of depressive 
disorders, based on select case definitions. 
1.3 Research Questions 
The specific research questions addressed in this study were: 
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Can provincial administrative databases be used to identify patients with 
depressive disorders in Newfoundland and Labrador, and ultimately for the 
surveillance of depressive disorders? 
- What is the sensitivity, specificity, and positive and negative predictive values 
of select case definitions? 
- What is the most appropriate case definition(s) for studying depressive 
disorders using administrative databases? 
- What factors (e.g. , medical conditions such as anxiety) are associated with 
depressive disorders coding/billing? 
1.4 The Research Problem 
Mental disorders are common worldwide and are associated with considerable socio-
economic burden. Depressive disorders are one of the most common categories of mental 
disorders (Rihrner & Angst, 2005), and often accompanies other chronic diseases such as 
cardiovascular disease, diabetes, cancer and rheumatoid arthritis. Depressive disorders 
include major depressive disorder, dysthymic disorder, and depressive disorders not 
otherwise specified. The prevalence of major depressive disorder in Canada is estimated 
at 4.8% (Health Canada, 2006), with women being more impacted than men (Rihmer & 
Angst, 2005). The economic burden of mental disorders in Canada was estimated to be 
$51 billion in 2003 (Lim eta!., 2008). 
One of the first challenges in building epidemiologic knowledge of any health 
condition is to establish the burden associated with it. The field of psychiatric 
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epidemiology has been slow in meeting this challenge, in part because of disagreements 
about thresholds regarding the presence of the condition, and because of the failure to 
establish a reliable measure (Eaton et al., 2008). 
While there have been regional studies of mental illnesses in Canada, there is a dearth 
of national and provincial data available on the prevalence/magnitude of mental illnesses 
overall. The partitioning of health systems across community and acute care services at 
the provincial level has fostered a fragmented approach to the collection of data on 
interventions specific to mental health. As a result, we do not have an accurate picture of 
the incidence, prevalence or nature of mental disorders in Canada, which hinders our 
ability to evaluate the effectiveness of policies, programs, and services aimed at mental 
health. As well, the lack of a comprehensive national surveillance system specific to 
mental disorders impedes efforts to monitor and subsequently improve mental health care 
delivery. 
This study was undertaken to address this challenge by assessing the usefulness and 
validity of using administrative databases for surveillance of depressive disorders among 
the adult population in Newfoundland and Labrador. 
1.5 Rationale for Using Administrative Data for Surveillance of Depressive 
Disorders 
A number of methods can be employed in conducting surveillance with the selection 
of the method depending mostly on information needed and resources available. The 
most commonly recognized and used source of data in surveillance are administrative 
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databases and surveys. However, both sources have their limitations- the former because 
of concerns about the accuracy of diagnostic information, and the latter because of 
concerns regarding the validity of self-reporting of diagnosis (Lix eta!., 2008). 
Administrative databases are increasingly being used for many types of research in 
economically developed countries given their benefits, such as larger sample size, lower 
cost, and increased generalizability (Harpe, 2009). Administrative databases may include 
a wide variety of data fields since they can be linked together at the individual level , and 
include large numbers of patients spanning many years. While they are considered a 
valuable source for many types of research, administrative databases have not been 
widely used for public health surveillance. This may be due to the fact that some 
investigators lack familiarity with database research in general (Harpe, 2009). If used 
appropriately, administrative data targeted at a specific segment of the population (e.g., 
people with depressive disorders) can be an extremely useful tool for monitoring, 
planning and programming across the health care system, and ultimately provide 
evidence that can be used to improve the health of the population. 
In Canada, the planning and delivery of mental health services is an area that the 
provincial and territorial governments have primary jurisdiction. The federal government, 
primarily through Health Canada and Public Health Agency of Canada, collaborate with 
the provinces and territories in a variety of ways in an effort to develop responsive, 
coordinated and efficient mental health service systems. 
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CHAPTER TWO: LITERATURE REVIEW 
This chapter provides background information on depressive disorders, including its 
epidemiology, etiology, clinical features and risk factors. The existing literature on the 
survei llance of depressive disorders using various methods, particularly administrative 
databases, is also presented. 
2.1 Depressive Disorders 
Depressive disorders have been described as one of the most common illnesses of 
humankind, but are only recently recognized as a major health problem (Akiskal, 2005). 
The World Health Organization (WHO) has ranked depression fourth in a list of the most 
urgent health problems worldwide, and estimated that mental health disorders are the 
leading cause of disability in the USA and Canada (2002), accounting for 25% of all 
years of life lost to disability and premature mortality (World Health Organization, 2004). 
Depressive disorders encompass a group of psychiatric disorders in which 
pathological moods and related psychomotor disturbances dominate the clinical picture. 
Depressive disorders are best considered as syndromes, rather than discrete diseases, 
given they consist of a cluster of signs and symptoms, sustained over a variable period of 
time. In combination this represents a marked change in an individual's functioning and 
tends to recur, often in periodic or cyclical manner. It should be noted that a syndrome is 
a set of symptoms or conditions that occur together and suggests the presence of a certain 
disease or an increased chance of developing the disease. A disease is the actual 
diagnosed impairment of health or a condition of abnormal functioning. 
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Depressive disorders include maJor depressive disorder, dysthymic disorder, and 
depressive disorders not otherwise specified. Major depressive disorder is the most 
frequent depressive disorder. Clinically, major depressive episodes and dysthymic 
disorder are frequently co-morbid disorders. The following section describes clinical 
features of major depressive disorders, dysthymic disorders, and depressive disorders not 
otherwise specified. 
2.1.1 Major Depressive Disorder 
Episodes of major depressive disorders can begin over a period of weeks or even 
months. The Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition -
Text Revision (DSM-IV-TR) diagnosis of major depressive disorder (AkiskaL 2005) 
requires: ( 1) depressed mood or decreased interest in usual activities, and (2) at least four 
additional classic depressive signs and symptoms (e.g., poor appetite or overeating, 
insomnia or hypersomnia, low energy or fatigue, low self-esteem, poor concentration or 
difficulty making decisions, feelings of hopelessness), (3) sustained for at least two 
weeks, and ( 4) cannot be explained by another process known to cause depressive 
symptoms (e.g., normal bereavement, certain physical conditions commonly associated 
with depression, or another mental disorder). Appendix A-1 presents the DSM-IV -TR 
diagnostic criteria for major depressive disorder. 
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2.1.2 Dysthymic Disorder 
Dysthymia refers to a sub-affective condition having the following conditions: (I) 
low-grade chronicity for at least two years, (2) insidious onset with origin often in 
childhood or adolescence, and (3) persistent or intermittent course (Akiskal. 2005). 
Dysthymia is distinguished from chronic depressive disorders by the fact that it is not a 
sequel to major depressive disorder. In fact, patients may complain that they have always 
been depressed. Thus, most cases of dysthymia are of early onset beginning either in 
childhood or adolescence. Appendix A-2 presents DSM-IV-TR diagnostic criteria for 
major depressive disorder. 
2.1.3 Depressive Disorder Not Otherwise Specified 
DSM-IV-TR criteria for depressive disorder not otherwise specified are presented in 
Appendix A-3. Use of the term 'Depressive disorder not otherwise specified ' is justified 
when the depressive features do not merge into a full syndrome, failing to meet the 2-
week duration threshold, especially when they occur in association with other disorders, 
life situations or physiological conditions (Akiskal, 2005). Examples of disorders in this 
category include those sometimes described as minor depressive disorders, or a recurrent 
brief depressive disorder. 
2.1.3.1 Minor Depressive Disorder 
Minor depressive disorders are mostly observed in pnmary care settings. The 
depression IS sub-threshold, milder than major depressive disorder, yet not protracted 
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enough to be considered dysthymic (Akiskal, 2005). From such a sub-syndromal 
symptomatic depressive base, individuals predisposed to depressive illness may well 
fluctuate in and out of the various subtypes of depressive disorders. Appendix A-4 
presents DSM-TV-TR diagnostic criteria for minor depressive disorder. 
2.1.3.2 Recurrent Brief Depressive Disorder 
Recurrent brief depressive disorders are considered short-lived depressions that 
usually recur on a monthly basis but are not menstrually related (Akiskal , 2005). Such 
patients are believed to be more prevalent in primary care than in psychiatric settings. 
Appendix A-5 presents DSM-IV-TR diagnostic criteria for recurrent brief depressive 
disorder. 
2.2 Epidemiology of Depressive Disorders 
2.2.1 Prevalence and Incidence of Depressive Disorders 
Depressive disorders are the most frequent psychiatric illnesses, both m the 
community and other clinical settings such as secondary and tertiary care centres 
(Akiskal , 2005). In addition to the frequent and serious complications (e.g. , suicide) that 
accompany such disorders, they are also strongly associated with limitations in well-
being and daily functioning, which may be equal to or greater than those of several other 
chronic conditions. The lifetime and 1-year prevalence of major depressive disorder are 
estimated at 4.9% and 2.7%, respectively (Akiskal, 2005 ; Wittchen & Jacobi , 2005), 
while the prevalence of major depression was estimated to be approximately 16%-20%. 
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The lifetime, 1-year/6-month, and current (!-month) prevalence of different forms of 
DSM-IV-TR depressive disorders, according to the eight major community surveys using 
specific diagnostic instruments performed in the United States and Europe, are shown in 
Table 2.1 (Akiskal, 2005; Wittchen & Jacobi , 2005). It should be noted that, because of 
the tendency to forget over time (particularly in the case of male subjects), period 
prevalence and lifetime prevalence may be less reliable than current (point) prevalence. 
However, when attempting to estimate the number or rate of people with any one type of 
depressive disorder in the population at any given time, one needs to be cautious, as the 
true values are substantially lower than the sum of the prevalences of specific depressive 
disorders. This is because one patient might have more than one diagnosis, and different 
forms of depression may have a substantial overlap both cross-sectionally and 
longitudinally (Akiskal , 2005). In addition, a patient's diagnosis may change over time 
(e.g. , from dysthymic disorder to major depressive disorder). It is important to note that 
these studies presented in Table 2.1 are partly different with regard to diagnostic scope 
and instruments and sampling methods. Sample sizes also varied considerably between 
studies from n = 250 to n > 10,000 subjects. The most frequently used diagnostic 
instrument was the Composite International Diagnostic Interview (CIDI), which was 
designed for clinicians, but can be administered by trained non-clinicians as well. Other 
instruments used were the Schedules for Clinical Assessment in Neuropsychiatry 
(SCAN) and the Mini International Neuropsychiatric Interview (MfNf), both of which 
require clinically trained interviewers. There seemed to be a tendency for experts with 
experience in cross-sectional clinical interviews, such as the SCAN, to consistently rate 
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lower depression prevalences than those working with non-clinician interviews, such as 
the CIDI (Wittchen & Jacobi, 2005). 
Table 2.1: Lifetime, !-Year, and Current (1-Month) Prevalence of Depressive 
Disorders* 
Lifetime 1-Yr Current 
Prevalence(%) Prevalence(%) Prevalence(%) 
Major depressive episode Range 5- 17 3- 10 2- 7 
Average 12 7 4 
Dysthymic disorder Range 3- 6 3 3 
Average 5 n/a** n/a 
Minor depressive disorder Range 10 2 n/a 
Average n/a n/a n/a 
Recurrent brief depressive Range 16 4- 8 5 
disorder Average n/a 6 n/a 
Full depressive 20-25 1(}.-15 5--10 
disorders spectrum 
* According to Eight Large-Scale Population Studies Conducted in the United States and Europe. 
**Not available 
A comparison of studies conducted in ten different countries published lifetime and 1-
year prevalence of major depression for people between the ages of 18-65, standardized 
to the USA age and sex distribution (Akiskal, 2005). The lifetime prevalence varied 
between 1.5% and 19.0%, with the lowest figures found in Taiwan, Hong Kong, and 
Korea. The highest figure was found in Beirut, Lebanon. The 1-year prevalence ranged 
from 0.8% in Taiwan to 5.8% in New Zealand. 
A recent review by Eaton et a!. , (2008) reported that the 1-year prevalence of major 
depressive disorders ranged from 0.64% in Taipei to 15.4% in Udmurtia (a federal area in 
Russia), with a median of 5.3 and an interquartile range of 3.6- 6.5. This was as a result of 
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an extensive literature search of all relevant published articles from 1980 to 2007, with 42 
studies selected out of approximately 4,000, representing a total sample of 290,4 71 
persons. Six of the nine studies in the low quartile were located in East Asia, but 
otherwise the authors could not determine the study location, the study method, or the 
time that the study was carried out. It should be noted that the !-year prevalence is a 
hybrid type of prevalence, considered to be between lifetime prevalence and point 
prevalence, and is meant to record the history of the disorder one year prior to assessment 
(Eaton et a l. , 2008). It differs from lifetime prevalence in that it focuses on only I year, 
and it differs from period prevalence in that data for individuals who entered during the 
year of study, but died before the assessment, are not included in the numerator. Since 
there is not a strong relationship between the occurrence of depressive disorders and 
death within 1 year, the 1-year prevalence is considered approximate to the 1-year period 
prevalence (Eaton et al. , 2008). Given depressive disorders typically endure for more 
than one year, the 1-year prevalence is also considered similar to point prevalence. 
According to the Canadian Community Health Survey: Mental Health and Well-
Being (CCHS 1.2), the annual prevalence of major depressive disorders in Canada (age 
15 years and greater) was estimated at 4.0% (95%CT [Confidence Interval]: 3.7%-4.2%), 
the lifetime prevalence was 10.8% (95%CI: 10.3%-11.3%), and the point prevalence was 
1.3% (95%CJ: 1.1 %-1.4%) (Patten et al. , 2006). The CCHS 1.2 was a nationally 
representative mental health survey conducted by Statistics Canada between May 2002 
and December 2002. The target population included persons aged 15 years or over and 
living in private occupied dwellings (98% of the population). According to the Stirling 
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County Study, the overall prevalence of depression remained stable at about 5% across 
three separate samples (1952, 1970 and 1992) in Atlantic Canada (Murphy et al., 2000). 
This study began shortly after the Second World War and provides a 40-year perspective 
for estimating the prevalence and incidence of psychiatric disorders in an adult 
population. It is important to note that the diagnostic criteria of depressive disorders may 
have changed over the last four decades, which in turn might have affected the 
compatibility of rates over time. Starkes et al. (2005) in a cross-sectional study using 
CCHS 1.1 reported 7.3% of people in Atlantic Canada experienced an episode of major 
depression in the previous year, as measured by the Composite International Diagnostic 
Interview Short Form. Patten et al., (2006) in a study conducted in a predominantly rural 
health region in Southern Alberta, reported a weighted 12-month prevalence of I 0.4% 
(95%CI: 7.9%- 13%) for major depressive disorders (Patten et al., 2003). Other studies 
have reported that between 3% and 6% of adults will experience dysthymic disorders 
during their lifetime (Health Canada, 2006; Bland et al., 1988). 
The a1mual incidence of depression has been estimated to be 0. 76% for women and 
0.43% for men, and up to the age of 70 years, the cumulative probability of first-episode 
depression was 45% in women and 27% in men (Akiskal, 2005). In Hungary (a European 
country in which the suicide rate is known to be high), up to the age of 60 years, the 
cumulative probability of a first-episode major depression was 32% for women and 18% 
for men (Akiskal, 2005). The incidence of major depressive disorders was reported 1.6% 
per year (women, 1.9%; men, 1.1% per year). Data from the longitudinal cohort of the 
National Population Health Survey (NPHS - Canada) over a six year period estimated 
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the cumulative incidence of major depressive disorders in 2002/03, 2004/05 and 2006/07 
to be 2.9% (95%Cl: 2.3%-3.4%), 5.7% (95%CI: 4.9%-6.4%) and 7.2% (95%CI: 6.4%-
8.1 %), respectively (Wang et al., 2009). The incidence of major depressive disorders in 
the Patten et al. , (2006) study in southern Alberta (predominantly rural) was estimated at 
3.8% (95%CI 2.0o/o-5.6%). According to the Stirling County Study, the average annual 
incidence of depression was 3.7-4.5 per 1,000 for various cohorts, and the incidence of 
depression was found to be higher among women than men (Murphy et al. , 2000). 
Based on the literature reporting the prevalence and incidence of depressive disorders, 
it is apparent that depressive disorders are common in economically developed nations. 
The prevalence of depression in far eastern countries is lower, probably due to cultural 
differences regarding such areas as psychosocial stressors and alcohol and drug 
consumption. In investigating the differences between ethnic groups- Caucasians, 
African Americans, Hispanics, and Asian Americans- a recent study from the United 
States found that, after adjusting for demographic factors (e.g. , age, gender), Asian 
Americans had the lowest prevalence of both major depressive and dysthymic disorders 
(Akiskal, 2005). This may suggest that the prevalence of major depressive disorders in 
far eastern countries reported by the Cross-National Collaborative Group could, in fact, 
be lower than economically developed countries. However, caution is required in 
interpreting these rates as differences in diagnostic instruments and study design may also 
explain some discrepancies. 
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2.2.2 Risk Factors 
2.2.2.1 Sex 
The most consistent finding across all studies reviewed (Canadian and international) 
on the prevalence and incidence of depressive disorders is that it is approximately 
twofold more common among women than men (Patten et al. , 2009· Akiskal, 2005 ; 
Eaton et al. , 2008; Patten et al. , 2006; Murphy et al. , 2000; Patten et al., 2003 ; Wang et 
al., 2009; Parikh et al. , 200 I ; Parikh et a!.. I 996). This gender difference is thought to 
begin in early adulthood, is most pronounced in people between the ages of 30 and 45, 
and persists into old age. Because there is little evidence (aside from biological- hormonal 
differences) to show that female gender can increase vulnerability for depression, it has 
been suggested that increased stress sensitivity, maladaptive coping strategies, and 
multiple social roles (all of which are frequently seen in women), combined with 
substance use disorders that can mask depressive symptoms (more frequently seen in 
men), may explain the gender difference (Akiskal, 2005). In addition to these 
psychosocial theories, recent studies show that because prior anxiety disorders are more 
common in women, preceding anxiety disorder may also be a significant factor that 
contributes to the higher depressive morbidity in women (Akiskal , 2005). Minor 
depressive disorders and recurrent brief depressive disorders are also more common 
among women, but the difference is not so marked as that with major depressions 
(Akiskal, 2005). Recent population-based epidemiological surveys showed that the 
lifetime prevalence and I -year prevalence of major depression and dysthymia were much 
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higher among people with same-sex sexual behavior, particularly m the case of men 
(Akiskal, 2005). 
2.2.2.2 Age 
There is less consistency among studies regarding age-specific prevalence of 
depressive disorders, but rates do appear higher in young adults than older individuals. 
Most studies have shown that depressive disorders have higher prevalence among people 
younger than 45 years (Akiskal, 2005; Patten et al. , 2006; Wang et al. , 2009; Parikh et al. , 
2001; Parikh et al., 1996; Romans et al. , 2007). The average age of onset of major 
depressive disorder is thought to fall between the ages of 30 and 35 years. Social stressors 
appear to place younger individuals at greater risk for depression than the elderly 
(Akiskal, 2005). On the other hand isolation, loss of interpersonal contacts, medical 
disorders, and disability, play an important role in the development of depression in later 
life (Akiskal, 2005; Wang et al., 2009). Early-onset depression is associated with a higher 
female to male ratio than late-onset (Akiskal, 2005). Because major depressive disorder is 
a frequent and highly recurrent illness, the probabi lity of recurrence does not decrease 
with age. The incidence of major depressive disorder in old age is lower in both sexes, 
but first incidence and prevalence of minor depressive disorder show the opposite trend 
(Akiskal, 2005). Dysthymic disorder typically starts in late adolescence or early 
adulthood. 
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2.2.2.3 Marital Status 
The association between marital status and depressive disorders is complex. For 
instance, being single, divorced, or separated can be either a risk factor for depression, or 
the result of adverse life events generated by depressive psychopathology. Major 
depressive disorder is most frequent among divorced, separated, or widowed individuals 
(Akiskal, 2005; Patten et al., 2006; Wang et al. , 2009). Single women have lower rates of 
depression than married women do, but the opposite is true for men (Akiskal , 2005). 
However, being single as a result of having never married, as a result of the dissolution of 
a difficult marriage, or as a result of widowhood, represent three very different 
conditions. The risk of a major depressive disorder is very high among recently widowed 
individuals of all ages, but is particularly high in the elderly (Charbonneau et al. , 2004). 
Patients with depressive disorders are overrepresented among the divorced, and the rate 
of family breakdown (i .e., separation and divorce) is elevated slightly in dysthymic 
patients, but substantially in major depressive patients (Akiskal , 2005). The presence of 
major depression is a strong predictor for future separation or divorce, which can cause 
serious distress for the patients and for their spouses, and may also generate negative life 
events for their children (Akiskal, 2005 ; Patten et al. , 2006; Wang et al. , 2009). These 
early negative life events (e.g., parental loss before adolescence) are well known 
predisposing risk factors for adult depressive disorders, particularly in the case of family 
loading (i .e. , family hi story of depressive disorders). 
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2.2.2.4 Socioeconomic Factors 
Although the relationship between depressive symptoms and low social class is well 
documented, most studies found only weak (but consistent) correlations between major 
depressive disorders and lower socioeconomic status (Akiskal, 2005; Murphy et a!., 
2000; Wang et a!., 2009; Parikh et a!., 200 I). Individuals with lower socioeconomic 
status also are more likely to have lower levels of education, lower income, and poorer 
living conditions, as well as a higher rate of unemployment. 
2.2.2.5 Residence 
As urban communities can be more stressful than rural communities, most studies 
carried out in economically developed countries concluded that major depression was 
more frequent in urban than rural residents (AkiskaL 2005 ; Patten et a!. , 2006; Patten et 
a!., 2003; Wang et a!., 2009). Parikh et a!., (1996), in examining whether rural Ontario 
differed from urban Ontario in depressive disorder prevalence, found that the prevalence 
of major depression disorder and dysthymia were similar to previous studies, but rural 
prevalence was unexpectedly similar to urban ones. 
2.2.2.6 Comorbidity 
Patients with depressive disorders are at increased risk of having one or more 
comorbidities (Akiskal, 2005; Patten et a!., 2006; Wang et a!., 2009; Himelhoch et a!. , 
2004). Moussavi et al. , (2007) studied approximately a quarter of a million respondents in 
60 countries and found that depressive disorders produced a greater decrement in health 
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than other chronic diseases, including angina, arthritis, asthma, and diabetes. In addition, 
the authors reported that those with angina, arthritis, asthma, or diabetes also had 
increased risks of depressive disorders (Moussavi et al. , 2007). It has been suggested that 
the most frequent disorders associated with depressive disorders are alcohol abuse or 
dependence, panic disorder, obsessive-compulsive disorder, and social anxiety disorder 
(Akiskal , 2005). Conversely, individuals with substance use and anxiety disorders also 
have an elevated risk of lifetime comorbid depressive disorders. Men more frequently 
present with substance use disorders, whereas women more frequently present with 
anxiety and eating disorders (Akiskal, 2005). 
2.2.2.7 Health Services Utilization 
Major depression and dysthymia are associated with increased health service 
utilization (e.g., general medical services or emergency services) for emotional problems 
(Parikh et a!., 2001; Johnson et a!., 1992; Olfson et al. , 1992). It has been reported that 
patients with high health service utilization are more likely to have a high rate of 
untreated depression. Despite advances in both the diagnosis and treatment of depressive 
disorders, they still remain under-diagnosed and undertreated. North American and 
European surveys report that approximately half of those who develop depressive 
disorders seek treatment for them, but only a small proportion (approximately one-third) 
of diagnosed depressive disorders receive appropriate treatment (Akiskal, 2005). An 
increasing rate of health service utilization is related to increasing severity of depression 
and other psychiatric and non-psychiatric co-morbidities. Despite the fact that many 
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patients with depressive disorders seek help in primary care, general practitioners still 
have difficulties diagnosing and treating depression. Most patients who seek care for 
depression are treated in primary care settings, where at least 50% of patients are 
undiagnosed, and 40% to 55% are insufficiently treated (Charbonneau ct al., 2004; Well 
et al. , 1999). The current prevalence of major depression in primary care is approximately 
10%-15% and that of dysthymic disorder is approximately 6%-8% (Akiskal , 2005). 
Because depressive disorders are more common among those with comorbid chronic 
medical disorders, depressions with significant somatic comorbidity may remam 
unrecognized in primary care (J\kiskal , 2005). Women more often seek treatment for 
their depression and are more compliant with the treatment than men, but "male 
depression" is unfortunately Jess frequently recognized (Akiskal , 2005). Concomitant 
depression increases the morbidity and mortality from concurrent medical illness, and 
patients with simultaneous medical disorders and depression are less compliant with 
treatment and take longer to recover than non-depressed medical patients. 
2.3 Economic Burden of Depressive Disorders 
Determining the costs associated with mental illness is challenging, but annual 
treatment costs (direct) in the USA have been estimated at $100 billion with significantly 
more estimated for indirect costs; $193 billion per year is estimated for lost earnings 
alone (Buka, 2008). A recent review by Eaton et al. , (2008) on the burden of mental 
disorders demonstrated that the estimates were variable across disorders, ranging from 
$11 billion per year for simple phobia, to more than $200 billion per year for alcohol and 
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drug use disorders. The direct and indirect costs of major depressive disorders in the USA 
were ranked third ($97.3 billion), following those for drug and alcohol abuse (Eaton et 
al., 2008). 
Health Canada, in its 2002 Economic Burden of Illness in Canada Report (Health 
Canada, 2002), identified a large economic burden of mental illness from the use of direct 
government-funded health care services ($4.7 billion in 1998), and indirect cost of lost 
productivity due to short- and long- term disability and premature mortality ($3.2 billion). 
Lim et al. , (2008) conducted a comprehensive study of the economic burden of mental 
illness in Canada, which incorporated the use of medical resources and productivity 
losses due to disability, as well as reductions in health-related quality of life using the 
Canadian Community Health Survey Cycle 2.1 (2003 ). They concluded that the 
economic burden was $51 billion in 2003 , with over one-half resulting from reductions in 
health-related quality of life. The value of work loss from absenteeism accounted for 
about 35% of the burden, and medical expenses accounting for less than I 0%. 
2.4 Surveillance of Depressive Disorders 
Individuals who manage programs to prevent or control specific diseases need 
reliable information on the status of those diseases in the population. The process that is 
used to collect data, manage, analyze, interpret, and report on a specific disease is called 
surveillance (Buehler, 2008). Surveillance systems are networks of people and activities 
that maintain this process, and because these systems are often operated by public health 
agencies, the term "public health surveillance" is often used. When new public health 
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problems emerge, the rapid implementation of surveillance is crucial to an effective early 
response. Likewise, public health agencies establish surveillance as a first step to inform 
priority setting for new programs. The scope of epidemiologic surveillance has evolved 
from an initial focus on infectious disease monitoring and intervention, to a more 
inclusive scope that includes chronic diseases, injuries, environmental exposures, and 
social factors that influence health status. Elements of a surveillance system include: case 
definition, population under surveillance, cycle of surveillance, confidentiality, and 
incentive to participation. 
Depending on information needed and resources available, a number of methods can 
be employed in conducting surveillance. Administrative databases and surveys are 
commonly used in surveillance. However, these sources have their limitations such as 
concerns about the accuracy of diagnostic information in administrative databases and 
concerns regarding the validity of self-reporting of diagnosis in surveys (Lix et al. , 2008). 
Linkage of surveillance records to other information sources (i.e. , triangulation) can also 
be used to enhance the scope of surveillance data. 
2.4.1 Case Definitions 
Chronic disease case definitions for surveillance systems are constructed by selecting 
specific combinations of several data attributes: source of data, diagnosis or treatment 
codes, number of years of data and number of contacts in administrative records with the 
selected code(s) (Lix et al. , 2008). There is no consensus on the optimal case definition, 
with the choice often dependent on the availability of data. 
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This following section provides a review of relevant literature on studies that have 
employed different types of methodologies for surveillance of mental disorders in 
general, and depressive disorders in particular. 
2.5 Survey as a Method for Surveillance of Depressive Disorders 
Surveys are one of the most common methods for surveillance of health conditions in 
a population. Prevalence and incidence rates obtained from surveys can be used to 
describe the burden of depressive disorders and to plan and evaluate disease prevention, 
treatment and management strategies. However, the validity of surveys depends on many 
factors , such as the sampling strategy, which impacts generalizability, and the accuracy 
of self-reporting (memory). 
In Canada, two national surveys, the CCHS and NPHS, are often used to study the 
burden of disease. The CCHS is funded as part of the Health Information Roadmap 
Initiative (Gravel et al., 2004. Gravel et al. , 2005. Canadian Institute for Health 
Information, 1999). The Health Information Roadmap is a plan to modernize and 
standardize health information across the country. Statistics Canada, the Canadian 
Institute for Health Information, and Health Canada jointly support a series of projects 
that make up the Roadmap Initiative. The CCHS has a 2-year collection cycle comprising 
of 2 surveys: a regional survey in the first year (Cycle 1.1) and a province-level survey in 
the second (Cycle 1.2). Each second year of the cycle is designed to focus in-depth on a 
particular topic. During consultations for the development of the CCHS (Beland et al. , 
2000), mental health was frequently identified as a high-priority topic. Consequently, 
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mental health and well-being was the focus of the provincial component of the first 
CCHS cycle (Cycle 1.2), which took place in 2002. Because information on mental 
disorders in Canada was for the most part incomplete and fragmented, the major 
objectives of the CCHS 1.2 were as follows: I) to determine the prevalence of selected 
mental disorders and to assess their burden of illness; 2) to examine links between mental 
health and social, demographic, geographic, and economic characteristics; 3) to compare 
the use of mental health services with perceived needs, and 4) to assess the disability 
associated with mental health problems in regard to individuals and society. 
The NPHS was initiated by Statistics Canada in 1994/95, targeting household 
residents in all Canadian provinces with certain exclusions (i.e. persons living on Indian 
Reserves and Crown Lands, residents of health institutions, full-time members of the 
Canadian Forces Bases) (Statistics Canada, 2008). The NPHS is a Canadian national 
health survey using multiple-stage, stratified random sampling procedures. The 1994/95 
NPHS participants (n= 17,276) formed a longitudinal cohort that is re-interviewed every 
two years. As of 2008, this cohort has been interviewed 7 times (from 1994/95 through 
2006/07). 
Table 2.2 presents a list of five Canadian studies investigating the burden of mental 
disorders in general, and depressive disorders in particular, using the CCHS and/or the 
NPHS surveys. 
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Table 2.2: Surveys as a Method for Surveillance of Mental Disorders in Canada 
Study Target Data Years of Objective(s) 
populati Source Study 
on 
Patten et a!., 15 years CCHS 2002 Describe the epidemiology of 
(2006) and over major depression in the Canadian 
population 
Wang eta!., 18-65 NPHS 1994/95- Estimating incidence of major 
(2009) years 2006/07 depressive episodes and the 
associations between 
demographic and socioeconomic 
variables and major depressive 
episodes 
Patten & Beck, 15 years NPHS 1994- Assessing mental health care 
(2004) and over 2000 utilization among depressed 
patients 
Vasiliadis et 15 years CCHS 2002 Determining prevalence of health 
a!., (2005) and over care service use for mental health 
reasons, service type, and 
examining determinants of mental 
health service use 
Satyanarayana 15 years CCHS 2002 Determining the prevalence and 
eta!., (2009) and over correlates of chronic depression 
in comparison with non-chronic 
depression 
Surveys are also used as a tool for surveillance of mental disorders in other countries, 
such as the USA and Australia. The National Comorbidity Survey is the first nationally 
representative mental health survey in the USA to use a fully structured research 
diagnostic face-to-face interview as a means to assess the prevalence and correlates of 
mental disorders (Kessler et a!. , 2003). In Australia, the National Survey of Mental 
Health and Wellbeing, conducted first in 1997, has been used as a survey of individuals 
aged 16-85 from 8,841 households across Australia (Whiteford & Groves, 2009). 
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Most national surveys (both Canadian and non-Canadian) use the CIDI (Composite 
International Diagnostic Interview), which is a comprehensive, fully-structured interview 
designed for the assessment of mental disorders according to the definitions and criteria 
of ICD-10 (International Classification of Diseases 1 01h Revision) and DSM-IV. The 
CIDI allows: 1) to measure the prevalence of mental disorders and their severity, 2) to 
determine the burden of these disorders, and 3) to assess service use and the use of 
medications in treating these disorders (CIDI, 2004). The reliability, validity and cross-
national consistency of diagnostic instruments for depressive disorders have not been 
sufficiently established. As stated earlier in Chapter 2, it has been suggested that there is 
a tendency for experts with experience in cross-sectional clinical interviews (e.g. , SCAN) 
to consistently rate lower depression prevalences than those working with non-clinician 
interviews (e.g., CIDI) (Wittchen & Jacobi, 2005). Further, although surveys have been 
used for surveillance of mental disorders (Patten et al. , 2006; Wang et al. , 2009; Patten & 
Beck, 2004; Vasiliadis et al. , 2005; Satyanarayana et al. , 2009), their validity depends on 
many factors, such as the sampling strategy, which impacts generalizability, and the 
accuracy of self-reporting. Further, the periodic nature of surveys and their inability to 
recognize emerging trends in a timely manner may be other limitations of using surveys 
for surveillance purposes. 
2.6 Administrative Data as a Method for Surveillance of Depressive Disorders 
The value of using administrative databases for surveillance of chronic diseases partly 
depends on the process used to identi fy the chronic disease of interest. Several studies 
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have described the processes employed to identify various chronic diseases from 
administrative databases. These processes most always include case definitions and the 
appropriate time frames required to maximize and enhance case identification. Although 
most of the previous studies did not focus on depressive disorders (or mental disorders in 
general), the processes used to identify patients with chronic diseases using 
administrative databases are still relevant for this study. Thus, this following section 
provides an overview of current literature concerning processes for the identification of 
individuals with depressive disorders (or mental disorders in general), as well as other 
chronic diseases. 
Table 2.3 presents various types of case definitions used for the identification of 
individuals with depressive disorders, and other chronic diseases. The studies reviewed 
utilized varying methods to identify chronic diseases from administrative databases. Most 
have used physician claims data (i.e. , billing data or reimbursement data). The most 
common approach for identifying chronic diseases involved counting the number of 
disease-specific physician visits. Some studies listed used a combination of both inpatient 
and outpatient encounters. The most common case definition used is a combination of 
two or more outpatient visits or one or more inpatient visit. However, it has been reported 
that identifying patients with chronic diseases by using one outpatient visit versus two 
outpatient visits resulted in higher sensitivity but lower specificity (Hux et al. , 2002). In 
contrast, other studies did not find any additional benefit of using more than one 
diagnosis to define a case (Robinson et al. , 1997). Further, almost none of the studies 
considered physician specialty in their case definitions. 
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In addition to only usmg physician visits, a combination of physician visits and 
prescription drug use data is common (Fultz et al., 2006). It should be noted that while 
this approach is valuable, some drugs may have multiple indications for different diseases 
which may make it difficult to link a specific drug to a specific disease. 
Table 2.3: Case Definitions Used to Identify Various Chronic Diseases from 
Administrative Databases 
Study Country Chronic Disease(s) Case Definition 
Kisely et Canada (BC, Mental disorders 2: I physician visit or 2: I 
al. , (2009) ON, QC, NS, hosp ita! ization 
AB) 
Damush et USA Depression post stroke (2: I physician visit or 2: I 
al. , (2008) hospitalization) or 
Antidepressant medications 
West et al., Canada (SK) Depression 2: 2 physician visit and 
(2000) Antidepressant medications 
Powell et USA Arthritis 2: I physician visit or 2: I 
al. , (2003) hospitalization 
Scales et Canada (ON) ICU admissions 2: I ICU visit or 2: I procedure 
al. (2006) 
Baldi et Italy Cancer (Breast, Colon, 2: I hospital and 2: I procedure 
al., (2008) Lung) 
Goff et al. , USA Irritable Bowel 2: I physician visit or 2: I 
(2008) Syndrome hospitalization and 2: l 
prescription antispasmodic, 
laxative, antidiarrheal , 5HT3 
receptor agonist, or 5-HT4 
receptor antagonist 
Couris et France Breast Cancer 2: I hospital and 2: I procedure 
al. , (2009) 
Daley et al., USA Children with chronic 2: I visit to a pediatrician 
(2004) medical conditions 
requiring influenza 
vaccination 
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Table 2.3: Case Definitions Used to Identify Various Chronic Diseases from 
Administrative Databases (Cont'd) 
Study Country Chronic Disease(s) Case Definition 
Coffin et Canada Chronic diseases ~ I hospitalization in one year 
a\. , (2005) (Calgary) eligible for 
pneumococcal 
vaccination 
Fultz eta\., USA HIV/AIDS a) ~ I inpatient or outpatient 
(2006) b) HIV prescription drug 
Hux et al., Canada (ON) Diabetes ~ I physician visit or ~ I 
(2002) hospitalization within two years 
James et a\. , Canada (AB, Diabetes ~ I physician visit or ~ I 
(2004) SK, MB) hospitalization within two years 
Solberg et USA Diabetes, Coronary ~ 2 physician visit or ~ I 
a!., (2006) Heart Diseases, hospitalization within 12 months 
Depression 
To eta\., Canada (ON) Asthma ~ I physician visit 
(2006) 
The timeframe required to generate sufficient numbers of healthcare visits is crucial 
for developing a valid case definition. The optimal timeframe needed for the 
identification of patients with chronic diseases varies by the type of disease. A two- to 
three-year timeframe has been suggested as sufficient, particularly for chronic diseases 
with relatively structured visiting behavior such as diabetes and hypertension (Robinson 
et a!. , 1997; Hoogenveen et a!. , 2002). It has been shown that the errors of prevalence 
estimates decreases with increasing follow up time (Robinson et al. , 1997; Hoogenveen et 
al., 2002). For conditions such as asthma which can be challenging to diagnose, a 
timeframe up to five years may be required (Lix et al. , 2008). In other cases, using a 
period longer than two years may not be feasible for ongoing surveillance system (Hux et 
al. , 2002). Other investigators used a shorter timeframe of two years mainly because the 
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purpose of their investigation was to identify cases, rather than to estimate the burden of 
the disease (Coffin et al., 2005). Overall, there is no consensus on the optimal timeframe 
required to identify chronic diseases. The timeframe required to identify individuals with 
chronic diseases from administrative databases depends on the disease of interest, the 
data source(s) available, and the purpose of identification. 
Most administrative health databases have one or more fields dedicated to diagnosis. 
The main diagnosis (versus a secondary diagnosis) may not necessarily be the most 
responsible reason for a specific health care visit. Thus, investigators using administrative 
databases with more than one diagnosis field suggested not considering the order of 
diagnosis in order to enhance and maximize case identification. A Swedish study 
(Wigertz & Westerling, 2001) showed that only 20% of asthma cases were identified 
when only the primary diagnosis is used for identification. In the USA the importance of 
the order of diagnosis depends on the data source and jurisdiction. For instance, in 
Medicaid database (USA) the first diagnosis listed corresponds to the relative importance 
of the diagnosis for a specified visit (Powell eta!., 2003). 
The validity of a case definition, or an identification algorithm, can be defined as the 
degree to which the case definition/identification algorithm identifies a target group from 
administrative databases. There are two types of validity: internal and external. Internal 
validity refers to the accurate identification of a target population from administrative 
databases apart from random error (Rothman et a!., 2008). External validity refers to 
application of study findings beyond the subjects in the study. Internal validity is a 
prerequisite for external validity. The validity of a case definition varies depending on the 
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objective, diseases of interest and jurisdictions. For instance, Canadian databases di ffer 
substantially from those in USA in that historically, financial incentives for recording 
accurate diagnosis have been minimal compared to those of USA (Roos et a!. , 1999). 
Within Canadian provinces the validity of administrative data varies by province and 
diseases (Roos et a!. , 1999). Thus the validi ty of case definitions for identifying chronic 
diseases developed in the USA may not necessarily be applicable to Canada. Even within 
Canada the validity of case definitions derived from one province may not necessari ly be 
applicable to another province. Nevertheless, if the same data sources and years are used, 
the diagnoses might be portable across jurisdictions. 
Little research has been conducted on assessing the reliabi lity or validity of using 
administrative databases to explore mental illness. A recent Canadian study by Kisely e t 
a!., (2009) evaluated the usefulness of administrative data for the surveillance of mental 
illness using databases from British Columbia, Alberta, Ontario, Quebec, and Nova 
Scotia. The primary data sources explored were provincial patient registries, physician 
billings databases and hospital discharge abstract databases . Their case definition 
included any patient with at least one physician v isit, or one discharge from any hospital 
having a diagnosis in the most-responsible diagnosis field using one of the following 
codes: ICD-9 (International Classification of Diseases 91h Revision) from 290 through 
319, inclusive, or their equivalent ICD-1 0 codes. Issues such as ease of data extraction, 
completeness of common data elements and comparability between provinces were 
explored. The prevalence of treated mental disorders across Canada was reported to be 
fa irly consistent ( 15%), with women having a higher prevalence. The authors concluded 
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that provincial and territorial administrative data from hospital morbidity and physician 
billings are useful for the surveillance of treated mental disorders. They also suggested 
that such a surveillance system can provide longitudinal data at relatively little cost for 
health service provision and planning. 
In 2000 West et al., (2000) conducted a study to evaluate the validity of using the 
Saskatchewan Health administrative claims database for conducting research on 
depressed patients who were using antidepressants. The study compared medical record 
abstractions with the Saskatchewan Health outpatient data files (Physician Service File) 
and found there was a 77% agreement (kappa 0.54) for a diagnosis of depression between 
the medical abstraction and the Physician Service File; 71% sensitivity, 85% specificity, 
86% Positive Predictive Value (PPV) and 70% Negative Predictive Value (NPV). This 
study showed a high number of true-positives and true-negatives and shows promise for 
the use of administrative databases in exploring depression. The authors noted that the 
results of this study may not be generalized to other administrative databases. 
Spettell et al., (2003) conducted a study to evaluate two algorithms to identify 
physician-recognized depression using a large USA managed health care organization 
database. The first algorithm was designed to maximize sensitivity and the second to 
decrease false positives. The results showed algorithm l had a sensitivity of 95%, 
specificity of 65%, and a PPV of 49%. Algorithm 2 had a 52% sensitivity, 88% 
specificity, and 60% PPV. Both algorithms had low PPV (falsely classifying patients as 
having depression), highlighting the difficulty in identifying depressed patients from 
administrative data using algorithms based only on diagnostic and pharmacy codes. 
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Rawson et a!., (1997) examined the accuracy and reliability of hospital discharge 
diagnostic codes for schizophrenia and depressive disorder patients using Saskatchewan's 
administrative health care utilization data files. As a measure of external consistency the 
study compared the computerized data files of the Hospital Services Branch with 
patients' medical charts through data abstraction forms. The study found 77.1% 
agreement between primary hospital discharge diagnosis and the chart discharge 
diagnosis for schizophrenia. There was only 58% agreement for patients diagnosed with 
depression, however 93.6% of the identified patients did have some form of depression. 
As a measure of internal consistency a comparison was made between the hospital 
discharge data with physician service claim files and files from the provincial mental 
health branch. For schizophrenia there was 61.8% agreement between hospital data and 
physician service claims, and 83.4% agreement between hospital and mental health 
services data. For depression, there was 66.3% agreement between hospital data and 
physician service claims, but only 37.7% agreement between hospital and mental health 
services data. An examination of the mismatched codes for depressed patients indicated 
that they may have been coded with a depressive disorder, when in fact they had major, 
chronic, or neurotic depression. The study demonstrated that administrative data appears 
to be more reliable when looking at specific mental illnesses, such as schizophrenia, as 
opposed to a more general diagnosis like depression. The findings also highlight the 
difficulty in making an exact depression diagnosis. 
A USA retrospective cohort study was carried out by Damush et al. (2008) to validate 
a case-finding algorithm for post-stroke depression among veteran survivors. The authors 
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assessed the accuracy of patients' post-stroke depression from the administrative 
databases (Veterans Health Administration and Medicare inpatient, outpatient, and 
pharmacy data) through standardized chart reviews. The authors concluded that a case-
finding algorithm using outpatient ICD-9 codes or medication was the most sensitive in 
identifying cases of post-stroke depression. The authors also suggested that the addition 
of antidepressant medications in appropriate doses can improve the accuracy of the case 
finding algorithm for post-stroke depression in administrative data (Veterans Health 
Administration). 
Comparing the PPV for the identification of individuals with chronic disorders from 
one setting to another may be challenging due to the underlying characteristics of 
administrative databases and the prevalence of the disease of interest (Greenland & Lash, 
2008). In one study (Penberthy et al., 2003) data from a certified cancer hospital had a 
higher PPV for identifying cancer cases compared to data from non-certified cancer 
programs. The difference in the PPV may be explained by higher cancer prevalence in 
the certified cancer hospitals than that of a non-certified hospital. 
Hux et al. , (2002) showed that when using two physician claims over two years for a 
diagnosis of diabetes, the sensitivity was higher than when using only one diagnosis of 
diabetes (90% vs. 85%). Increasing the number of claims required for case definitions 
increased the sensitivity but reduced the specificity. In contrast, Robinson et al. ( 1997) 
did not find any meaningful gain in sensitivity by increasing the number of claims while 
holding the timeframe constant. 
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As shown in Table 2.4, the selected examples of case definitions show that the 
specificity of the case definitions in identifying individuals with chronic diseases across 
jurisdictions was generally higher than the sensitivity. This suggests that individuals 
without a chronic disease are less likely to be misclassified by most case definitions (i.e ., 
lower false negative rate), and as well may indicate that there is a higher probability of 
misclassification among those identified with having a chronic disease (i.e. , higher false 
negative rate). 
Overall, most studies have similar case definitions that required one or more 
diagnoses for a particular chronic disease, with or without use of prescription drugs. 
Several studies have examined the validity of case definitions focusing on different types 
of chronic diseases. The outcome of these studies was variable with respect to sensitivity, 
specificity and PPV, depending on the chronic disease studied and the jurisdiction in 
which the study took place. The gold standard used to validate the case definitions has 
mostly been medical charts. It is important to note that using a chart review as the gold 
standard may not always be cost-effective. Further, the lack of availability of clinical 
information in medical charts is the other challenge in using a chart review. 
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Table 2.4: Validity of Various Case Definitions from Previous Studies 
Study Country Chronic Case Definition Gold Validity 
Diseasc(s) Standard 
Damush USA Depression (~ I physician Medical Sensitivi ty=62% 
et al., post stroke visit or ~ I Charts Speciticity=88.9% 
(2008) hospitalization) PPV=67.4% 
or 
Antidepressant 
medications 
West et Canada Depression ~ 2 physician Medical Sensitivity=?! % 
a!., (SK) visits and Charts Speci ticity=85% 
(2000) Antidepressant PPV=86% 
medications NPV=70% 
Scales et Canada ICU ~ I ICU visit or Critical Care Sensitivity=92% 
a!., (ON) admissions ~ I procedure Research Speci ticity=99% 
(2006) Network PPV=84% 
patient NPV= IOO% 
registry 
(CCR-Net) 
Baldi et Ita ly Cancer ~ I hospital and Piedmont Breast 
a!., (Breast, ~ I procedure Cancer (Sens itivi ty=7 6. 7%, 
(2008) Colon, Registry of PPV=92 .6%) 
Lung) Turin Colon 
(PCRT) (Sensitivity=72.4% 
PPY=87.9%) 
Lung 
(Sensitivity=80.8% 
PPV=78.7%) 
Goffet USA Irritable ~ I physician Medical PPV=83% 
a!. , Bowel visit or ~ I Charts 
(2008) Syndrome hospitalization 
and ~ I 
prescription 
antispasmodic, 
laxative, 
antidiarrheal, 
SHT3 receptor 
agonist, or 5-HT4 
receptor 
antagonist 
Couris et France Breast ~ I hospital and Cancer Sensitivity=64. I% 
a!., Cancer ~ I procedure Registry Speciticity=99.9% 
(2009) 
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Table 2.4: Validity of Various Case Definitions from Previous Studies (Cont'd) 
Study Country Chronic Case Definition Gold Validity 
Disease(s) Standard 
Daley et USA Children ~ I visit to a Medical Sensitivity=72% 
al., with chronic pediatrician Charts Specifi city=95% 
(2004) medical 
conditions 
requiring 
influenza 
vaccination 
Coffin et Canada Chronic ~ I Sensitivi ty=83% 
al. , (Calgary) diseases hospitalization in Specificity=78% 
(2005) eligible for one year PPY=87% 
pneumococc NPV=72% 
al 
vaccination 
Hux et Canada Diabetes ~ I physician a) a) Sensitivity for I 
al., (ON) visit or ~ I Prescription claim=94%, for 2 
(2002) hospitalization Drug Data claims=91 % 
within two years b) NPHS b) Sensitivity for I 
c) Medical claim=90%, for 2 
Charts claims=85%; PPY 
for I claim=44%, 
for 2 claims=64% 
c) Sensitivity for I 
claim=93 .4%, for 2 
claims=97. 1 %; PPY 
for I claim=61.3%, 
for 2 claims=79.8% 
Penberthy USA Cancer ~ I Virginia PPY=84%-98% 
et al., hospitalization Cancer 
(2003) Registry 
Solberg et USA Diabetes, ~ 2 physician Medical PPY 
al., Coronary visit or ~ I Charts Diabetes=0.97-I 
(2006) Heart hospitalization Coronary Heart 
Diseases, within 12 months Diseases=0.95 
Depression Depression=0.65-
0.99 
To et al., Canada Asthma ~ I physician Medical Sensitivity=91.4% 
(2006) (ON) visit Charts 
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2. 7 Summary of the Literature Review 
Depressive disorder is a global public health problem which is associated with 
substantial social and economic burden. Administrative databases provide a promising 
tool that can enhance existing methods of surveillance of depressive disorders which in 
turn can aid in planning and evaluating necessary epidemiologic and preventive 
programs. 
There is limited evidence on how administrative databases can optimally be used for 
the purpose of population-based surveillance of depressive disorders. Most studies that 
used administrative data were not population-based, and validation of the case definitions 
have mainly used chart reviews, which are timely and expensive. The majority of studies 
reviewed used two or more outpatient diagnoses, or one or more inpatient diagnosis to 
define various chronic diseases. Of note, case definitions that have used physician visits 
have rarely taken into consideration the physicians' specialty. 
Considering the limitations of administrative databases and a lack of a coordinated 
and efficient system to identify populations with depressive disorders in Canada, we may 
be missing an opportunity to better measure the effectiveness of policies and programs 
directed at mental health. 
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CHAPTER THREE: MATERIALS AND METHODS 
This chapter outlines the methodology used to address the research questions, as well 
as a description of the study design, analysis, study populations, data sources, and case 
definitions. 
3.1 Study Design 
This is a cross-sectional study auditing electronic patient charts at three family 
practice clinics equipped with an Electronic Medical Records (EMR) system in St. 
John's, Newfoundland and Labrador. A sample of patients from each clinic were 
classified into one oftwo cohorts; those diagnosed with a depressive disorder (cases) and 
those not diagnosed with a depressive disorder (controls). The classification of patients 
selected from the EMRs in each of the three clinics served as the "gold standard" in the 
study. The gold standard was then compared with several case definitions based on 
hospital separation and physician claims databases. 
3.2 Study Setting 
The study was carried out at three family practice clinics located in St. John's (Family 
Practice Unit- Health Sciences Centre, Shea Heights Community Health Center, and the 
Ross Family Medicine Centre). These clinics are all affiliated with the Discipline of 
Family Medicine, Memorial University of Newfoundland, where staff practitioners are 
either academic physicians or residents. The three clinics have been using the EMR 
system developed by the Wolf Medical Software (Wolf Medical Systems, 2007) since 
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December 2006. Prior to 2006, the clinics used hard copy charts to document patient 
care. Upon implementation of EMRs in these clinics, all patient information was captured 
electronically. 
Of note, the three clinics provided the Newfoundland and Labrador Medical Care 
Plan (MCP) registry with demographic (e.g., age, sex, date of birth, MCP etc.) and 
clinical information (e.g., diagnosis code, fee code, etc.) via a shadow billing process 
until June 30, 2007. The Medical Care Plan registry, maintained at the Ministry of 
Health, is the insurance system for fee-for-service physicians and its primary role is 
payment for physician services. The shadow billing process was only considered for 
sharing demographic and limited clinical information, not for billing purposes. It is 
important to note that there is no effect on the data integrity between shadow and actual 
billing in the clinics under study. Physicians practicing in these clinics are university-
based employees and do not require to bill MCP for providing patient care. Because the 
physician claims database was one of the administrative data sources used in this study, 
only those patients who had a visit at one the three clinics between December 2006 (date 
of implementation of EMR) and June 2007 (end date of shadow billing process) were 
considered for inclusion in the study. 
3.3 Study populations 
3.3.1 Depressive Disorders Cohort (Cases) 
Using the Wolf EMR Practice Search capability in each clinic, all patients aged 18 
years or older who had a diagnosis or a co-diagnosis (e.g. , past medical history or present 
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illness section of the electronic patient encounters) for any depressive disorders were 
identified for full electronic chart audit. It should be noted that the classification coding 
system used in the EMR system was the ICD-9 system. Upon consultation with the 
clinics staff physicians, it was determined that the ICD-9 diagnosis code of 3 II was used 
for coding depressive disorders, thus code 311 was used to search and subsequently flag 
patients with depressive disorders in the EMR. Each patient chart (including all 
encounters) identified was then reviewed by a physician (i.e., the author of this 
dissertation who is also a general practitioner) to identify patients with true depressive 
disorders. The DSM-IV-TR criteria were used wherever possible to make a clinical 
judgment. It should be noted that clinicians may not always document all relevant clinical 
symptoms mentioned in the DSM-TV-TR criteria in the patient charts. The exclusion 
criteria were: 1) age less than 18 years, 2) non-depressive disorders diagnoses (e.g. either 
psychiatric or non-psychiatric conditions such as generalized anxiety disorder, 
schizophrenia, bipolar disorder, etc.), 3) depressive disorder encounter not within the 
study time frame (December 2006 to June 30, 2007), and 4) lack of clinical information 
in chart for diagnosis of depressive disorder. All excluded cases at this stage were 
independently reviewed by an experienced psychiatrist not involved in the study to 
maximize objectivity. A data collection form (Appendix B) was developed to collect 
demographic and clinical information such as age, gender, diagnosis, associated co-
morbidities, and drug history including antidepressant medications (e.g. selective 
serotonin reuptake inhibitors- SSRis, tricyclic antidepressants- TeAs, and monamine-
oxidase inhibitors- MAO Is). Considering that low doses of some antidepressants such as 
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TCAs are used for analgesia and sedation rather than as antidepressants, those patients 
who received low doses antidepressants were excluded from the analysis. It should be 
noted that through auditing the charts, co-morbid anxiety was captured, while those 
patients with primary diagnosis of anxiety disorders were excluded. As part of the 
validation process and prior to use, the data collection form was reviewed by a family 
physician and a psychiatrist. 
3.3.2 Non-Depressive Disorders Cohort (Controls) 
The control patients were identified using the EMR Practice Search function in each 
family practice clinic. At the beginning those meeting the following criteria were 
excluded: I) age less than 18 years, and 2) any psychiatric diagnoses including depressive 
disorders at any given time (not only limited to the study time frame). Excluded controls 
due to psychiatric disorders were independently reviewed by an experienced psychiatrist 
not involved in the study. Once the exclusions had been made, a random sample of 
remaining records equal in number to the depressed cohort previously flagged was drawn 
from each clinic population. Controls were matched to cases by age and gender (using a 
stratified random sampling approach). Charts selected underwent a full chart review. The 
data collection form used for the cases (Appendix B) was also used to collect 
demographic and clinical information on the controls. The data collection form was 
initially piloted on 20 electronic patient charts ( 10 for depressed patients and 10 for non-
depressed patients). 
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3.4 Administrative Data Sources/Data Linkage 
In this study, data obtained on depressed and non-depressed patients through the 
EMR system in the three clinics served as the "gold standard". These data were then 
compared to various case definitions using data from both the provincial hospital and 
physician claims databases for these same patients. 
3.4.1 Provincial Hospital Separation Database 
The provincial hospital separation database is maintained by the Newfoundland and 
Labrador Centre for Health Information (NLCHI). The hospital database captures 
demographic, clinical, and interventional information for patients admitted to all acute 
health care facilities and surgical day cares in the province. The database includes 
Newfoundland and Labrador residents and out-of-province patients receiving care in 
provincial acute care institutions. NLCHI currently has data from 1995/96 to 2007/08 
(fiscal year). Of note, the coding classification system in the hospital database changed 
from ICD-9 to ICD-1 0-CA (International Classification of Diseases I 01h Revision -
Canadian Enhancement) in April 200 I. 
3.4.2 Provincial Fee-for-Service Physician Claims Database 
The Newfoundland and Labrador Medical Care Plan (MCP) was established in 1969 
with the primary function of processing payments for fee-for-service physicians in the 
province. The MCP is a comprehensive plan of medical care insurance designed to cover 
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the cost of physician services for eligible residents of the provmce. Each resident of 
Newfoundland and Labrador is provided a lifetime unique MCP number, whereas non-
eligible individuals for MCP coverage (e.g. , visitors, armed forces, etc.) are assigned a 
temporary MCP number by the hospital where they receive care. This temporary number 
is used for the current episode of care only and is not linkable to any previous or future 
episodes of care the individual may have. The physician claims database captures 
information on age and sex, as well as codes with information on service billed for, 
diagnosis, and physician involved. NLCHI currently has data from 1995 to 2007 
(calendar year). The coding classification system in the physician MCP claims database 
has been ICD-9 since 1995. 
3.4.3 Reliability and Validity of Administrative Databases 
The reliability and validity of administrative health databases has been extensively 
documented. A summary of studies on the quality of health care administrative databases 
in Canada reported that demographic information on patient age, sex and residence is 
complete and reliable (Williams & Young, 1996). They found high levels of agreement 
on surgical procedure codes in hospital discharge data and physician claims. As for the 
diagnoses coding, hospital data on the most responsible diagnosis may vary in 
completeness and accuracy. Diagnoses such as acute myocardial infarction or fracture are 
reasonably reliable. Diagnostic data for conditions such as stroke are substantially less 
reliable, and the greatest disagreement with expert criteria-based reviews occurred with 
diagnoses such as rheumatoid arthritis where clinicians themselves may disagree. Limited 
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information is avai lable regarding the accuracy of psychiatric diagnoses in both hospital 
and physician claim databases. 
3.4.4 lCD Codes 
As mentioned in Section 3.3.1, the classification coding system used in the clinics 
EMR system was ICD-9, and that the lCD code 311 was used to initially identify patients 
with depressive disorders. Thus the ICD-9 code 31 1 was considered to identify 
depressive disorders in administrative databases. There are other ICD-9 codes that are 
also used for depressive disorders such as 296.2 (major depression, single episode), 296.3 
(major depression, recurrent episode) and 300.4 (dysthymia), but were not used in this 
study because the provincial fee-for-service physician claims database only captures the 
first three digits of JCD-9 codes. The physician claims database uses only JCD-9 while 
the hospital database switched from ICD-9 to I CD-I 0-CA in 200 I. lCD-I 0-CA is an 
enhanced version ofiCD-1 0 developed by the Canadian Institute for Health Information 
(CIHI) for morbidity classification in Canada. Table 3 .I presents a list of ICD-9 and lCD-
I 0-CA codes used to identify patients with depressive disorders. 
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Table 3.1: ICD-9 and ICD-1 0-CA codes used to identify patients with depressive 
disorders 
ICD-9 Code Description 
311 Depressive disorder, not elsewhere classified 
ICD-10-CA Codes 
F32.0 Mild Depressive episode 
F32.1 Moderate depressive episode 
F32.2 Severe depressive episode without psychotic symptoms 
F32.3 Severe depressive episode with psychotic symptoms 
F32.8 Other depressive episodes 
F32.9 Depressive episode, unspecified 
F33.0 Recurrent depressive disorder, current episode mild 
F33.1 Recurrent depressive disorder, current episode moderate 
F33 .2 Recurrent depressive disorder, current episode severe without 
psychotic symptoms 
F33.3 Recurrent depressive disorder, current episode severe with 
psychotic symptoms 
F33.4 Recurrent depressive disorder, currently in remission 
F33.8 Other recurrent depressive disorders 
F34.1 Dysthymia 
3.4.5 Data Linkage 
Variables of interest were extracted from the hospital database and the physician 
claims database. The following data were extracted from the provincial hospital database: 
MCP numbers (for data linkage purpose), admission date, diagnosis code (ICD-9 and 
lCD-I 0-CA), diagnosis type, and care episode identification and care episode type (acute 
care or surgical day care). A care episode is a unique hospitalization for an individual 
patient and contains diagnostic, service and demographic information associated with that 
specific hospitalization. Each care episode was given a unique code (a care episode ID) to 
represent that hospitalization. This approach was necessary given that an individual may 
46 
have multiple hospitalizations in the same reporting year. Diagnosis type is related to the 
relevance of the diagnosis code within an episode of care and was categorized as one of 
the following: most responsible diagnosis (i.e., the diagnosis most responsible for the 
patient's hospital stay); pre-admission co-morbidity (i.e. , a condition that existed before 
admission that significantly influenced the patient's hospitalization); or post-admission 
co-morbidity (i.e., a condition that arose during a patient's hospitalization). It should be 
noted that all coding is performed by the hospital health record staff through extraction of 
information from the clinical notes. For the provincial fee-for-service physician claims, 
data on MCP numbers (for data linkage purposes), date of service, diagnosis code (ICD-
9), provider type (e.g., general practitioner, psychiatrist) and procedure code (e.g., 
psychotherapy) were collected. Given that data in the hospital database is collected on a 
fiscal year basis, and on a calendar year in the physician claims database, to be consistent 
the data was extracted for the period Apri l 1, 1995 and March 31 , 2008 from both 
databases. 
Given the nature of depressive disorders with long latency or chronic course, the 
patients captured in EMRs were linked to all 13 years of available hospital and physician 
data (April 1, 1995 to March 31, 2008). A 2-step linkage approach was used to link data 
from the EMRs to the hospital and physician databases (Figure 3. 1 ). The EMR records of 
patients with and without depressive disorders were linked to the hospital database (via 
MCP number) to identify those patients having at least one hospital separation due to any 
condition between 1995/96 and 2007/08. In the second step these records were linked to 
the physician claims database (via MCP number) to capture data on physician utilization 
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between 1995/96 and 2007/08. Considering that the nature and the severity of depressive 
disorders range from mild depression to those requiring hospitalization, a number of 
potential case definitions were developed and compared to the results of the EMR review 
(i.e., gold standard). 
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Figure 3.1: Data I inkage approach 
'' EMR Clinical Data 
(Depressed and Non-depressed 
Cohorts) 
Final Depressive/Non-
Depressive Disorders Clinical 
Database 
3.5 Case Definitions 
Step l 
Linkage of Hospital Data 
Step 2 
Linkage of Physician Data 
Defining a case is a fundamental element of a surveillance system and requires an 
assessment of the objectives and logistics of such a system. Due to the need for 
simplic ity, surveillance case definitions are typically brief and balance competing needs 
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for sensitivity, specificity and feasibility (Buehler, 2008). Ideally, surveillance case 
definitions should both inform and reflect clinical practice, particularly for diseases with 
long latency or a chronic course such as depressive disorders (Buehler, 2008). In Canada, 
the National Diabetes Surveillance System (NDSS) is one of the surveillance systems 
developed to provide data about diabetes using hospital and physician administrative 
databases (National Diabetes Surveillance System, 2008). Considering the NDSS model 
and its case definitions which uses data sources similar to those employed in this study, a 
large number of potential case definitions were developed to be examined (Appendix C). 
Variables used in the development of the case definitions were depressive disorders 
diagnoses (either in hospital or physician claims data), date of diagnosis, and service 
providers type (general practitioners vs. psychiatrists). These case definitions were 
developed based on the fact that the severity of depressive disorders ranges from mild 
depression to debilitating levels requiring professional help, medication and even 
hospitalization. Further, depressive episodes usually run a fluctuating course and some 
people recover within a few years. For others, the symptoms persist for a protracted 
period, in which case the depression is classified as a chronic disease. 
3.6 Statistical Analysis 
Data obtained using the EMR review were compared to the results of linking the 
hospital and physician claim databases and using various case definitions. The following 
measures were investigated: 
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• Sensitivity: the percentage of individuals who are diagnosed as having a 
depressive disorder according to the administrative databases among patients who 
truly have a depressive disorder according to their EMR. 
• Specificity: the percentage of individuals for whom there is no depressive 
disorder diagnosis on the administrative databases among patients who truly do 
not have a depressive disorder according to their EMR. 
• Positive predictive value: the percentage of patients with depressive disorder 
according to their EMR among those who are classified as having depressive 
disorder according to the administrative databases. 
• Negative predictive value: the percentage of patients not having depressive 
disorder (i .e ., no depressive disorder diagnosis in their EMR) among those who 
are classified as having non-depressive disorder according to the administrative 
databases. 
Percent agreement was calculated by summing the true-positives and true-negatives 
and dividing by the total study population. Cohen's kappa coefficient was used to 
quantify agreement between various case definitions and the gold standard. Kappa 
statistics and 95% confidence limits were also calculated to determine the percent 
agreement attributed to chance. Kappa is a commonly adopted measure given it corrects 
the agreement between two sources by taking account of the proportion of agreement 
expected by chance. The magnitude of agreement was assessed as follows: poor 
agreement: kappa < 0.20; fair agreement: 0.20 S kappa < 0.40; moderate agreement: 0.40 
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S kappa< 0.60; good agreement: 0.60 S kappa< 0.80; and very good agreement: kappa 
~ 0.80. 
In this study we hypothesized that certain conditions such as chronic pain, insomnia, 
anxiety and antidepressant medications could be associated with depressive disorders 
diagnoses. For this, multivariate logistic regression analyses were used to assess the 
relationship between each case definition and the various conditions. A step-wise 
selection strategy was used to identify parsimonious models with significant predictor 
variables (p < 0.05). Akaike's information criteria and likelihood-ratio statistics were 
computed to assess the overall goodness of fit for each model. Analyses were performed 
using the Statistical Package for the Social Sciences (SPSS) version 15.0 (SPSS, 2006) 
and Statistical Analysis Software (SAS®) version 9.2 (SAS, 2008). 
3. 7 Ethical Considerations 
The Human Investigation Committee (HIC) of Memorial University of 
Newfoundland (Appendix D) and the NLCHI Secondary Use Advisory Committee 
approved the research protocol. A number of ethical principles guided the research study. 
First, only an employee of the Centre for Health Information (statistician) who was not a 
member of the research team and had signed an Oath of Confidentiality as a condition of 
his employment had access to all study data. A physician (the author of this di ssertation) 
reviewed the electronic medical charts and extracted/accessed the EMR clinical data. 
Following linkage of the hospital separation data and physician data to the data obtained 
from the clinics (EMR), the records were de-identified and key-coded by the Centre for 
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Health Information ' s statistician. The clinics from which data was obtained were the 
custodians of the study keys. The study keys were kept to allow for data quality processes 
- no identifiable data was retained at the Centre for Health Information for this study. 
Upon receiving approvals from the NLCHI Secondary Use Advisory Committee and 
HIC, the author of this dissertation obtained a de-identified copy of the database for 
analysis purposes. 
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CHAPTER FOUR: RESULTS 
This chapter presents a summary of: 1) descriptive statistics, including demographic 
and clinical characteristics of both the depressed and non-depressed patients (e.g., age, 
sex, and clinics distribution, as well as co-morbidities and medication use patterns), and 
2) inferential statistics, including binary classification tests (e.g., sensitivity, specificity, 
positive predictive value and negative predictive value, percent agreement, and kappa 
statistics), as well as multivariate logistic regression analyses used to assess the 
relationship between the various case definitions and selected medical conditions. 
4.1 Descriptive Statistics 
A total of 420 patients (all three clinics), found to have a diagnosis code for a 
depressive disorder (ICD-9 code of 311) through searching the EMRs, were identified 
and their charts reviewed. Table 4.1 presents the distribution of the 420 patients by age, 
sex and clinic. Of these 420 patients, 253 were found to be truly depressed (depressed 
cohort). Table 4.2 presents the distribution by age, sex and clinic of the depressed cohort. 
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Table 4.1: Distribution of Patients with a Diagnosis Code For Depressive Disorder 
(N=420) 
Age (yr) 
< 18 
18 - 29 
30 - 39 
40 - 49 
50 - 59 
60 - 69 
70 - 79 
80 + 
Total 
M: Male 
F: Female 
Health Sciences 
Centre 
M F Total 
---* --- ---
--- --- II 
--- --- 23 
12 38 50 
II 32 43 
9 24 33 
8 14 22 
--- --- 9 
48 144 192 
M 
0 
---
---
8 
II 
10 
10 
5 
50 
LA Miller Shea Heights 
Centre Centre 
F Total M F Total 
--- --- 0 --- ---
--- 7 --- --- 13 
--- 17 5 14 19 
19 27 7 18 25 
II 22 8 13 21 
15 25 2 6 8 
II 21 0 --- ---
13 18 0 0 0 
88 138 25 65 90 
* Suppressed due to policies specific to patient privacy. 
All Clinics 
M F Total 
0 5 5 
8 23 31 
12 47 59 
27 75 102 
30 56 86 
21 45 66 
18 26 44 
7 20 27 
123 297 420 
Table 4.2: Distribution of Truly Depressed Patients (n=253) 
Age (yr) 
18 - 29 
30 - 39 
40 - 49 
50 - 59 
60 - 69 
70 - 79 
80 + 
Total 
M: Male 
F: Female 
Health Sciences 
Centre 
M F Total M 
---* --- 7 ---
--- --- 18 ---
7 23 30 ---
--- --- 22 ---
5 18 23 6 
--- --- II ---
--- --- --- ---
23 92 115 25 
LA Miller Shea Heights 
Centre Centre 
F Total M F Total 
--- 6 --- --- 10 
--- 13 --- --- 17 
--- 9 6 14 20 
--- 9 6 9 15 
8 14 --- --- 6 
--- 6 0 --- ---
8 12 0 0 0 
44 69 21 48 69 
* Suppressed due to policies specific to patient privacy. 
All Clinics 
M F Total 
6 17 23 
II 37 48 
17 42 59 
12 34 46 
13 30 43 
5 13 18 
5 II 16 
69 184 253 
Using a stratified random sampling technique, 318 patients who did not have a 
diagnosis code for depressive disorder in their electronic chart were selected for chart 
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review, of which 257 were identified as truly non-depressed (non-depressed cohort). Note 
that no tables summarizing the distribution of the non-depressed cohort is presented given 
it would mirror the distribution of the depressed cohort presented in Tables 4.1 and 4.2. 
Using the exclusion criteria described in the Method section, all 738 patients' charts 
were reviewed with 228 excluded prior to assignment of patients to the final groups of 
the depressed and the non-depressed cohorts. Table 4.3 presents reasons for exclusion of 
these patients in each cohort. 
Table 4.3: Reasons for Exclusion of Patients from the Study During the Chart Review 
(n=228) 
Reasons for exclusion Depressed 
Non-Depressed Total 
Cohort Cohort 
Did not meet clinical criteria 39 58 97 
Patient' s encounter was not in the study 
92 0 92 
time frame (December 2006 to June 2007) 
Lack of clinical information in the chart 36 3 39 
Total 167 61 228 
Table 4.4 presents demographics, co-morbidities and medication pattern for the 
depressed and non-depressed patients. The depressed cohort had a higher proportion of 
patients with anxiety, insomnia, fatigue, and chronic pain than the non-depressed cohort 
(P < 0.05). Further, the depressed cohort appeared to have a higher proportion of 
narcotics, anticonvulsant, gastro-intestinal , and respiratory prescriptions than the non-
depressed cohort (P < 0.05). No significant differences were found between the 
demographic information of the two cohorts. 
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Table 4.4: Demographic and Clinical Characteristics of the Depressed and Non-
Depressed Cohorts 
Factors 
Depressed Non-Depressed 
(n=253) (n=257) P-value 
Number % Number % 
Sex (male) 69 27.3% 70 27.2% 0.993 
Age mean (±SD) 50.6 (± 16.5) 50.9 (± 16.6) 0.808 
Co-morbidities 
Cancer 19 7.5% 13 5.1 % 0.254 
Endocrinological 55 21.7% 55 21.4% 0.926 
disorders 
Mental disorders 
61 24.1% 1.9% 0.000 
excluding depression 
5 
Cardiovascular disorders 115 45 .5% 109 42.4% 0.489 
Respiratory disorders 58 22.9% 46 17.9% 0.159 
Gastrointestinal 
78 30.8% 69 26.8% 0.321 disorders 
Neurologic disorders 45 17.8% 33 12.8% 0.121 
Musculoskeletal 54 21.3% 83 32.3% 0.005 
disorders 
Other medical 
conditions 
Insomnia 57 22.5% 10 3.9% 0.000 
Chronic pain 67 26.5% 45 17.5% 0.014 
Fatigue 29 11.5% 12 4.7% 0.005 
Anxiety 113 44.7% 28 10.9% 0.000 
Medication Use 
No history of 
0 0.0% 29 11.3% 0.000 
medication use 
Selective serotonin 
reuptake inhibitors 161 63.6% 0 0.0% 0.000 
(SSRis) 
Serotonin-
norepinephrine reuptake 57 22.5% 1 0.4% 0.000 
inhibitors (SNRis) 
Monamine-oxidase 
0.4% 0 0.0% 0.313 
inhibitors (MAOis) 1 
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Table 4.4: Demographic and Clinical Characteristics of the Depressed and Non-
Depressed Cohorts (Cont'd) 
Factors 
Depressed 
(n=253) 
Tricyclic antidepressants 
27 10.7% (TCAs)* 
Other antidepressants** 229 90.5% 
Benzodiazepines 91 36.0% 
Anti psychotics 7 2.8% 
Other psychiatric 
59 23.3% 
medication 
Narcotics 22 8.7% 
Nonsteroidal Anti-
inflammatory Drugs 48 19.0% 
(NSAIDs) 
Anticonvulsive 17 6.7% 
Cardiovascular 
90 35.6% 
medications 
Hormonal 
47 18.6% 
medications*** 
Hematologic 
1 0.4% 
medications 
GI medications 81 32.0% 
Respiratory medications 60 23.7% 
Antimicrobial agents 4 1.6% 
* TCAs with a dose greater than 75 mg/day. 
** Includes zopiclone, bupropion, and mirtazapine. 
*** Includes insu lin, metformin, levothyroxine, etc. 
Non-Depressed 
P-value (n=257) 
2 0.8% 0.000 
3 1.2% 0.000 
18 7.0% 0.000 
0 0.0% 0.007 
1 I 4.3% 0.000 
8 3. 1% 0.007 
64 24.9% 0.106 
3 1.2% 0.001 
100 38.9% 0.436 
47 18.3% 0.933 
0 0.0% 0.313 
55 21.4% 0.007 
40 15.6% 0.020 
2 1 8.2% 0.001 
Table 4.5 presents findings of the data linkage between the depressed and non-
depressed patients to the provincial hospital separation database and the provincial fee-
for-service physician claims database over a 13-year time period (April 1, 1995 to March 
31, 2008). All patients who had a hospitalization with a depressive disorder were 
identified in the depressed cohort (22 of 253), whereas none of the non-depressed cohort 
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patients were found to have a hospitalization as a result of a depressive disorder. Five of 
the 253 patients in the depressed cohort did not have a record in the physician claims 
database for any physician visits (for any reason). These could be individuals who do not 
have a valid MCP number, and would include visitors/tourists, armed-forces personnel 
etc. Conversely, 14 of 257 of non-depressed patients were found not to have any 
physician visits in the physician database. 
Table 4.5: Linkage of the Depressed and the Non-Depressed Cohorts to the Hospital And 
Physician Databases 
Depressed Non-Depressed 
Cohort Cohort 
(No. of patients) (No. of patients) 
Hospital Linkage 
Patients who had at least one 
190 174 hospitalization due to any diseases 
Patients who had at least one 
hospitalization due to depressive 22 0 
disorders 
Patients who did not have any 
hospitalizations due to depressive 231 257 
disorders 
Patients who did not have any 
63 83 hospitalization 
Physician Claims Linkage 
Patients who had at least one physician 
248 243 
visit due to any conditions 
Patients who had at least one physician 
226 45 
visit due to depressive disorders 
Patients who did not have any physician 
27 212 
visit due to depressive disorders 
Patients who did not have any physician 
5 14 
visit 
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Table 4.6 presents descriptive statistics on health service utilization (both hospital and 
physician visits) due to depressive disorders among the depressed and non-depressed 
cohorts. The depressed patients utilized physician services more than the non-depressed 
patients during the study period. 
Table 4.6: Descriptive Statistics of Health Service Utilization during the Study Period 
Depressed Non-Depressed 
Service Cohort Cohort 
Hospitalizations 
Number of patients 22 0 
Mean (±SO) number of hospitalizations 3.9 (±9.1) -
Median number of hospitalizations 1 -
Mode number of hospitalizations 1 -
Maximum number of hospitalizations 1-43 -
Physician visits 
Number of patients 226 45 
Mean (±SD) number of visits 23 .2 (±38.3) 8.2 (±19.6) 
Median number of visits 10 1 
Mode number of visits 3 I 
Maximum number of visits 399 110 
Number of visits 
1 to 4 visits 62 32 
5 to 8 visits 43 7 
9 to 12 visits 28 I 
More than 13 visits 93 5 
4.2 Inferential Statistics 
In this study 120 case definitions (Appendix C) were developed and compared to the 
gold standard (i .e., EMR) to identify the most valid case definition(s) for surveillance of 
depressive disorders. Of the 120 case definitions investigated, 26 were found to have a 
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kappa statistic greater than 0.6 (interpreted as substantial agreement). For ease of 
presentation, only these 26 case definitions are presented in Table 4. 7. The remaining of 
94 definitions, including their binary classification tests are provided in Appendix E. 
Table 4.7: 26 Definitions with Kappa Statistics Greater than 0.6 
CDI 
2: I hospitalizations due to depressive disorders any time OR 2: l physician visit due 
to depressive disorders any time 
C02 
2: I hospitalizations due to depressive disorders any time OR 2: 2 physician visits 
due to depressive disorders any time 
CD3 
2: I hospitalizations due to depressive disorders any time OR 2: 3 physician visits 
due to depressive disorders any time 
CD4 
2: I hospitalizations due to depressive disorders any time OR 2: 4 physician visi ts 
due to depressive disorders any time 
CDS 
2: I hospitalizations due to depressive disorders any time OR 2: 5 physician visits 
due to depressive disorders any time 
CD6 
2: I hospitalizations due to depressive disorders any time OR 2: I physician visit due 
to depressive disorders within the first year of diagnosis 
CD7 
2: I hospitalizations due to depressive disorders any time OR 2: 2 physician visits 
due to depressive disorders within the first year of diagnosis 
CDS 2: I hospitalizations due to depressive disorders any time OR 2: I physician visit due 
to depressive disorders within the first 2 years of diagnosis 
CD9 
2: I hospitalizations due to depressive disorders any time OR 2: 2 physician visits 
due to depressive disorders within the first 2 years of diagnosis 
CDIO 2: I hospitalizations due to depressive disorders any time OR 2: I physician visit due 
to depressive disorders within the first 3 years of diagnosis 
CDII 2: I hospitalizations due to depressive disorders any time OR 2: 2 physician visits due to depressive disorders within the first 3 years of diagnosis 
CDI2 2: I hospitalizations due to depressive disorders any time OR 2: 3 physician visits due to depressive disorders within the first 3 years of diagnosis 
CDI3 2: I hospitalizations due to depressive disorders any time OR 2: I physician visit due 
to depressive disorders within the first 4 years of diagnosis 
CDI4 
2: I hospitalizations due to depressive disorders any time OR 2: 2 physician visits 
due to depressive disorders within the first 4 years of diagnosis 
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Table 4.7: 26 Definitions with Kappa Statistics Greater than 0.6 (Cont'd) 
CDIS 
:::_ I hospitalizations due to depressive disorders any time OR :::_ 3 physician visits 
due to depressive disorders within the first 4 years of diagnosis 
CDI6 
(:::, I hospita lizations OR ~ I psychiatrist visit due to depressive disorders any time) 
OR ~ I GP visits due to depress ive disorders within the first I year of diagnosis 
CDI 7 (~ I hospita lizations OR~ I psychiatrist visit due to depressive disorders any time) OR ~ 2 GP visits due to depressive disorders within the fi rst I year of diagnosis 
CDI8 (:::. I hospitalizations OR~ I psychiatrist visit due to depressive disorders any time) OR :::_ I GP visits due to depressive disorders within the first 2 years of diagnosis 
CDI 9 (:::, I hospitalizations OR ~ I psychiatrist visit due to depressive disorders any time) OR :::. 2 GP visits due to depressive disorders within the first 2 years of diagnosis 
CD20 (:::, I hospita lizations OR ~ I psychiatrist visit due to depressive disorders any time) OR :::. 3 GP visits due to depressive disorders within the fi rst 2 years of diagnosis 
C0 2 I (:::, 1 hospita lizations OR ~ I psychiatrist visit due to depressive disorders any time) OR :::_ I GP visits due to depressive disorders within the first 3 years of diagnosis 
CD22 (:::, I hospitalizations OR ~ I psychiatrist visit due to depress ive disorders any time) OR :::. 2 GP visits due to depressive disorders within the first 3 years of diagnosis 
CD23 (:::, I hospitalizations OR ~ I psychiatrist visit due to depress ive disorders any time) OR :::_ 3 GP visits due to depress ive disorders within the fi rst 3 years of diagnosis 
CD24 (~ I hospita lizations OR ~ I psychiatrist visit due to depressive disorders any time) OR :::_ I GP visits due to depressive disorders within the first 4 years of diagnosis 
CD25 (:::, l hospitalizations OR ~ I psychiatrist visit due to depressive disorders any time) OR ~ 2 GP visits due to depressive disorders within the fi rst 4 years of diagnosis 
CD26 (~ l hospitalizations OR ~ I psychiatrist visit due to depressive disorders any time) OR :::_ 3 GP visits due to depressive disorders within the fi rst 4 years of diagnosis 
Table 4.8 presents the sensitivity, specificity, false positive rate, false negative rate, 
positive predictive value, negative predictive value, percent agreement, kappa and its 
95% CI for each of the 26 selected case definitions. 
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Table 4.8: Inferential Statistics for 26 Definitions with Kappa Statistics Greater than 0.6 
2:1 hospital OR 2:1 2:1 hospital OR 2:2 2:1 hospital OR 2:3 2:1 hospital OR 2:4 
physician anytime physician anytime physician anytime physician anytime 
(CD #1) (CD #2) (CD #3) (CD #4) 
Sensitivity 89.3 Sensitivity 82.6 Sensitivity 77.1 Sensitivity 69.6 
Specificity 82.5 Specificity 91.4 Specificity 93.0 Specificity 93.8 
FP rate 17.5 FP rate 8.6 FP rate 7.0 FP rate 6.2 
FNL rate 10.7 FN rate 17.4 FN rate 22.9 FN rate 30.4 
ppyj 83.4 ppy 90.5 PPY 91.5 PPY 9 1.7 
NPY4 88.7 NPY 84.2 NPY 80.5 NPY 75.8 
Percent 85.9 Percent 87.1 Percent 85.1 Percent 81.8 
agreement agreement agreement agreement 
Kappa 0.718 Kappa 0.741 Kappa 0.702 Kappa 0.635 
Kappa 0.66- Kappa 0.68-0.80 Kappa 0.64- Kappa 0.57-
95%CI 0.78 95%C1 95%CI 0.76 95%CI 0.70 
2:1 hospital OR 2:5 2:1 hospital OR 2:1 2:1 hospital OR 2:2 2:1 hospital OR 2:1 
physician anytime physician within 1 yr physician within I physician within 2 
(CD #5) (CD #6) yr yr 
(CD #7) (CD #8) 
Sensitivity 65.6 Sensitivity 89.3 Sensitivity 70.0 Sensitivity 89.3 
Specificity 94.9 Specificity 82.5 Specificity 93.8 Specificity 82.5 
FP rate 5.1 FP rate 17.5 FP rate 6.2 FP rate 17.5 
FN rate 34.4 FN rate 10.7 FN rate 30.0 FN rate 10.7 
PPY 92.7 ppy 83.4 PPY 91.7 ppy 83.4 
NPV 73.7 NPY 88.7 NPY 76.0 NPY 88.7 
Percent 80.4 Percent 85.9 Percent 82.0 Percent 85 .9 
agreement agreement agreement agreement 
Kappa 0.607 Kappa 0.718 Kappa 0.639 Kappa 0.718 
Kappa 0.54- Kappa 0.66-0.78 Kappa 0.57- Kappa 0.66-
95%CI 0.67 95%CI 95%CI 0.70 95%CI 0.78 
2:1 hospital OR 2:2 2:1 hospital OR 2:1 2:1 hospital OR 2:2 2:1 hospital OR 2:3 
physician within 2 physician within 3 yr physician within 3 physician within 3 
yr (CD #10) yr yr 
(CD #9) (CD #11) (CD #12) 
Sensitivity 75 .1 Sensitivity 89.3 Sensitivity 77.9 Sensitivity 68.0 
Specificity 93.0 Specificity 82.5 Specifi city 92.6 Specifi city 94.2 
FP rate 7.0 FP rate 17.5 FP rate 7.4 FP rate 5.8 
FN rate 24.9 FN rate 10.7 FN rate 22.1 FN rate 32.0 
PPV 91.3 ppy 83.4 PPY 91.2 PPY 92.0 
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Table 4.8: Inferential Statistics for 26 Definitions with Kappa Statistics Greater than 0.6 
(Coot' d) 
~1 hospital OR ~2 ~1 hospital OR ~1 ~1 hospital OR ~2 ~1 hospital OR ~3 
physician within 2 physician within 3 yr physician within 3 physician within 3 
yr (CD #10) yr yr 
(CD #9) (CD #11) (CD #12) 
NPV 79.1 NPV 88.7 NPV 81.0 NPV 74.9 
Percent 84.1 Percent 85.9 Percent 85.3 Percent 81.2 
agreement agreement agreement agreement 
Kappa 0.682 Kappa 0.718 Kappa 0.706 Kappa 0.623 
Kappa 0.62- Kappa 0.66-0.78 Kappa 0.64- Kappa 0.56-
95%CI 0.74 95%CI 95%CI 0.77 95%CI 0.69 
~1 hospital OR ~1 ~1 hospital OR ~2 ~1 hospital OR ~3 (~1 hospital OR ~1 
physician within 4 physician within 4 yr physician within 4 PSY~) OR ~1 GP6 
yr (CD #14) yr within 1 yr (CD 
(CD #13) (CD #15) #16) 
Sensitivity 89.3 Sensitivity 80.6 Sensitivity 71.1 Sensitivity 89.3 
Specificity 82.5 Specificity 91.4 Specificity 93.4 Specificity 82.5 
FP rate 17.5 FP rate 8.6 FP rate 6.6 FP rate 17.5 
FN rate 10.7 FN rate 19.4 FN rate 28.9 FN rate 10.7 
ppy 83.4 ppy 90.3 PPV 91.4 PPV 83.4 
NPV 88.7 NPV 82.7 NPV 76.7 NPV 88.7 
Percent 85.9 Percent 86.1 Percent 82.4 Percent 85.9 
agreement agreement agreement agreement 
Kappa 0.718 Kappa 0.72 1 Kappa 0.646 Kappa 0.7 18 
Kappa 0.66- Kappa 0.66-0.78 Kappa 0.58- Kappa 0.66-
95%CI 0.78 95%Cl 95%CI 0.71 95%CI 0.78 
(~1 hospital OR ~1 (~1 hospital OR ~1 (~1 hospital OR ~1 (~l hospital OR ~1 
PSY) OR~2 GP PSY) OR~1 GP PSY) OR ~2 GP PSY) OR ~3 GP 
within 1 yr (CD within 2 yr (CD #18) within 2 yr (CD within 2 yr (CD 
#17) #19) #20) 
Sensitivity 73.1 Sensitivity 89.3 Sensitivity 77.5 Sensitivity 67.6 
Specificity 93.4 Specificity 82.5 Specificity 93.0 Specificity 93.8 
FP rate 6.6 FP rate 17.5 FP rate 7.0 FP rate 6.2 
FN rate 26.9 FN rate 10.7 FN rate 22.5 FN rate 32.4 
PPV 91.6 PPV 83.4 PPV 91.6 ppy 91.4 
NPV 77.9 NPV 88.7 NPV 80.7 NPV 74.6 
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Table 4.8: Inferential Statistics for 26 Definitions with Kappa Statistics Greater than 0.6 
(Coot' d) 
(~1 hospital OR ~1 (~1 hospital OR ~1 (~1 hospital OR ~1 (~1 hospital OR ~1 
PSY) OR~2 GP PSY) OR~1 GP PSY) OR~2 GP PSY) OR ~3 GP 
within 1 yr (CD within 2 yr (CD #18) within 2 yr (CD within 2 yr (CD 
#17) #19) #20) 
Percent 83.3 Percent 85.9 Percent 85.3 Percent 80.8 
agreement agreement agreement agreement 
Kappa 0.666 Kappa 0.718 Kappa 0.706 Kappa 0.615 
Kappa 0.60- Kappa 0.66-0.78 Kappa 0.64- Kappa 0.55-
95%C1 0.73 95%CI 95%CI 0.77 95%CI 0.68 
(~1 hospital OR ~1 (~1 hospital OR ~1 (~1 hospital OR~~ (~1 hospital OR ~1 
PSY) OR ~1 GP PSY) OR ~2 GP PSY) OR~3 GP PSY) OR ~l GP 
within 3 yr (CD within 3 yr (CD #22) within 3 yr (CD within 4 yr (CD 
#21) #23) #24) 
Sensitivity 79.1 Sensitivity 79. 1 Sensitivity 69.6 Sensitivity 89.3 
Specificity 92.6 Specificity 92.6 Specificity 93.4 Specificity 82.5 
FP rate 7.4 FP rate 7.4 FP rate 6.6 FP rate 17.5 
FN rate 20.9 FN rate 20.9 FN rate 30.4 FN rate 10.7 
ppy 91.3 PPV 91.3 ppy 91.2 ppy 83.4 
NPV 81.8 NPV 81.8 NPV 75.7 NPV 88.7 
Percent 85.9 Percent 85.9 Percent 81.6 Percent 85.9 
agreement agreement agreement agreement 
Kappa 0.717 Kappa 0.717 Kappa 0.631 Kappa 0.718 
Kappa 0.66- Kappa 0.66-0.78 Kappa 0.57- Kappa 0.66-
95%C1 0.78 95%CI 95%CI 0.70 95%CI 0.78 
(~1 hospital OR ~1 (~1 hospital OR ~1 
PSY) OR ~2 GP PSY) OR ~3 GP 
within 4 yr (CD within 4 yr (CD #26) 
#25) 
Sensitivity 81.4 Sensitivity 72.7 
Specificity 91.4 Specificity 92.6 
FP rate 8.6 FP rate 7.4 
FN rate 18.6 FN rate 27.3 
PPV 90.4 ppy 90.6 
NPV 83.3 NPV 77.5 
Percent 86.5 Percent 82.7 
agreement agreement 
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I. 
Table 4.8: Inferential Statistics for 26 Definitions with Kappa Statistics Greater than 0.6 
(Coot' d) 
(~I hospital OR ~1 (~I hospital OR ~1 
PSY) OR~2 GP PSY) OR~3 GP 
within 4 yr (CD within 4 yr (CD #26) 
#25) 
Kappa 0.729 
Kappa 0.67-
95%CI 0.79 
I ~ .. False posJtJve rate 
2 False negative rate 
Kappa 
Kappa 
95%CI 
3 Positive predictive value 
4 Negative predictive value 
5 Psychiatrist visit 
6 General practitioner visit 
0.654 
0.59-0.72 
Considering the clinical characteristics of the different types of depressive disorders, 
as well as the severity and chronicity (which may sustain over a period of weeks to 
months even years) and a sensitivity threshold of greater than 70% (with kappa more than 
0.6), five of 26 selected case definitions were considered the most appropriate for 
surveillance of depressive disorders (Table 4.9). Specificity and false positive rate for 
these five definitions were similar (93% for specificity, 6.2-7.0 for false positive rate). Of 
the five definitions, a false negative rate was found to be lowest for case definition # 19 
([2: 1 hospitalizations OR 2: 1 psychiatrist visit due to depressive disorders any time] OR 
2: 2 GP visits due to depressive disorders within the first 2 years of diagnosis). 
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CD#7 
CD#9 
CD#l7 
CD#l9 
CD #23 
Table 4.9-A: Five Most Appropriate Case Definitions 
2: I hospitalizations due to depressive disorders any time OR 2: 2 physician visits 
due to depressive disorders within the first year of diagnosis 
2: I hospitalizations due to depressive disorders any time OR 2: 2 physician visits 
due to depressive disorders within the first 2 years of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive disorders any time) 
OR 2: 2 GP visits due to depressive disorders within the first I year of diagnosis 
(2: I hospita lizations OR 2: I psychiatrist visit due to depressive disorders any time) 
OR 2: 2 GP visits due to depressive disorders within the first 2 years of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive disorders any time) 
OR 2: 3 GP visits due to depress ive disorders within the first 3 years of diagnosis 
Table 4.9-B: Inferential Statistics for Five Most Appropriate Case Definitions 
~ I hospital OR ~ I hospital OR (~ I hospital OR (~ I hospital OR {~ I hospital OR 
~2 physician ~2 physician ~ I PSY5) OR ~2 ~ I PSY) OR ~2 ~ I PSY) OR ~3 
within 1 yr (CD within 2 yr (CD GP6 within 1 yr GP within 2 yr GP within 3 y r 
#7) #9) (CD #17) (CD #19) (CD #23) 
Sensitivity 70.0 Sensitivity 75.1 Sensitivity 73 .1 Sensitivity 77.5 Sensiti vity 69.6 
Specificity 93.8 Specificity 93.0 Specificity 93.4 Specificity 93.0 Specificity 93.4 
FP 1 rate 6.2 FP rate 7.0 FP rate 6.6 FP rate 7.0 FP rate 6.6 
FN• rate 30.0 FN rate 24.9 FN rate 26.9 FN rate 22.5 FN rate 30.4 
ppyJ 91.7 ppy 91.3 ppy 91.6 ppy 91.6 ppy 91.2 
NPY4 76.0 NPY 79.1 NPV 77.9 NPV 80.7 NPV 75.7 
Percent 82.0 Percent 84.1 Percent 83.3 Percent 85.3 Percent 81.6 
agreement agreement agreement agreement agreement 
Kappa 0.639 Kappa 0.682 Kappa 0.666 Kappa 0.706 Kappa 0.631 
Kappa 0.57- Kappa 0.62- Kappa 0.60- Kappa 0.64- Kappa 0.57-
95%CI 0.70 95%CI 0.74 95%CI 0.73 95%CI 0.77 95%CI 0.70 
I . . False pos1t1ve rate 
2 False negative rate 
3 Positive predictive value 
4 Negative predictive value 
5 Psychiatrist visit 
6 General pract itioner visit 
Figure 4.1 shows Receiver Operating Characteristic (ROC) Curves for the five most 
appropriate case definitions. 
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Figure 4.1: Receiver Operating Characteristic (ROC) Curves for the five most 
appropriate case definitions 
As noted in the Materials and Methods Section, information on medication utilization 
ts not currently captured in the hospital or physician databases; therefore, it was not 
possible to consider information on drugs in the development of potential case definitions 
for depressive disorders. The research team examined the impact of including medication 
information (via the EMR) on sensitivity and specificity for the 26 selected case 
definitions. The medication information specific to antidepressants were combined with 
the case definitions either as 'AND' or ' OR' . Appendix F presents sensitivity, specificity, 
false positive rate, false negative rate, positive predictive value, negative predictive value 
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percent agreement, kappa and its 95% CI measures for each case definition. Table 4.10 
presents the impact of including anti-depressant medication information on the selected 
five most appropriate case definitions. Addition of medication data to the five case 
definitions increased either the specificity or the sensitivity level to 100%. 
Table 4.10: Inferential Statistics for Five Most Appropriate Case Definitions with the 
Addition of Anti-Depressant Medication Information 
~1 hospital OR ~I hospital OR (~I hospital OR (~1 hospital OR (~1 hospital OR 
~2 physician ~2 physician ~ 1 PSY5) OR ~2 ~ 1 PSY) OR ~2 ~I PSY) OR ~3 
within I yr AND within 2 yr AND GP6 within I yr GP within 2 yr GP within 3 yr 
Anti-Depressant Anti-Depressant AND Anti- AND Anti- AND Anti-
Medication Medication Depressant Depressant Depressant 
Medication Medication Medication 
Sensitivity 62.1 Sensitivity 66.8 Sensitivity 64.8 Sensitivity 68.8 Sensitivity 61.3 
Specificity 100.0 Specificity 100.0 Specificity 100.0 Specificity 100.0 Specificity 100.0 
FP rate 0.0 FP rate 0.0 FP rate 0 .0 FP rate 0 .0 FP rate 0 .0 
FN" rate 37.9 FN rate 33.2 FN rate 35.2 FN rate 31.2 FN rate 38.7 
ppyJ 100.0 PPV 100.0 PPV 100.0 PPV 100.0 PPV 100.0 
NPV" 72.8 NPV 75.4 NPV 74.3 NPV 76.5 NPV 72.4 
Percent 81.2 Percent 83.5 Percent 82.5 Percent 84.5 Percent 80.8 
agreement agreement agreement agreement agreement 
Kappa 0.622 Kappa 0.670 Kappa 0.650 Kappa 0.689 Kappa 0.615 
Kappa 0.56- Kappa 0.61- Kappa 0.59- Kappa 0.63- Kappa 0.55-
95%CI 0.69 95%CI 0.73 95%CI 0.7 1 95%CI 0.75 95%CI 0.68 
~1 hospital OR ~1 hospital OR (~1 hospital OR (~ I hospital OR (~ I hospital OR 
~2 physician ~2 physician ~1 PSY) OR ~2 ~ I PSY) OR ~2 ~ I PSY) OR ~3 
within I yr OR within 2 yr OR GP within I yr GP within 2 yr GP within 3 yr 
Anti-Depressant Anti-Depressant OR Anti- OR Anti- OR Anti-
Medication Medication Depressant Depressant Depressant 
Medication Medication Medication 
Sensitivity 100.0 Sensitivity 100.0 Sensitivity 100.0 Sensitivity 100.0 Sensitivity 100.0 
Specificity 92.7 Spec ific ity 91.9 Specificity 92.3 Specificity 91.9 Specificity 92.3 
FP rate 7.3 FP rate 8.1 FP rate 7.7 FP rate 8.1 FP rate 7.7 
FN rate 0 .0 FN rate 0 .0 FN rate 0 .0 FN rate 0.0 FN rate 0.0 
PPV 92 .9 PPV 92.3 PPV 92.6 PPV 92.3 PPV 92.6 
NPV 100.0 NPV 100.0 NPV 100.0 NPV 100.0 NPV 100.0 
Percent 96.3 Percent 95.9 Percent 96.1 Percent 95.9 Percent 96.1 
agreement agreement agreement agreement agreement 
Kappa 0.926 Kappa 0.9 18 Kappa 0.922 Kappa 0.9 18 Kappa 0.922 
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Table 4.10: Inferential Statistics for Five Most Appropriate Case Definitions with the 
Addition of Anti-Depressant Medication Information (Cont'd) 
~1 hospital OR 
~2 physician 
within 1 yr OR 
Anti-Depressant 
Medication 
Kappa I 0.89-
95%CI 0.96 
I 0 0 False pos1t1ve rate 
2 False negative rate 
~1 hospital OR 
~2 physician 
within 2 yr OR 
Anti-Depressant 
Medication 
Kappa I 0.88-
95%CI 0.95 
3 Positive predictive value 
4 Negative predictive value 
5 Psychiatrist visit 
6 General practitioner visit 
(~I hospital OR (~1 hospital OR (~ I hospital OR 
~1 PSY) OR ~2 ~I PSY) OR ~2 ~~ PSY) OR ~3 
GP within 1 yr GP within 2 yr GP within 3 yr 
OR Anti- OR Anti- OR Anti-
Depressant Depressant Depressant 
Medication Medication Medication 
Kappa I 0.89- Kappa I 0.88- Kappa I 0.89-
95%CI 0.96 95%CI 0.95 95%CI 0.96 
Table 4.11 presents the results of step-wise multiple regression models found to have 
significant variables (p < 0.05). Consistently across all the models, the depressed cohort 
were 4-5 times more likely to have been prescribed antidepressant medications than the 
controls. This was also true for antipsychotic and other psychiatric medications which 
were significantly associated with a diagnosis of depression in all the models, but the 
degree of association varied. Similarly, the depressed cohort appeared to have 4-5 times 
higher odds of having received psychotherapy (either by general practitioners or 
psychiatrists) than those in the control cohort. Further, fee-for-service physician visits 
were found to be significantly higher for the depressed cohort in all five regression 
models. Cardiovascular, musculoskeletal disorders, history of no medication use, and 
anxiety were less likely to be noted in the depressed cohort. 
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Table 4.11: Step-Wise Logistic Multiple Regression Models 
Model .l - Odds Ratio Estimates ~1 hospital OR ~2 physician within 1 yr 
(CD #7) 
Effect 
Point 95% Wald 
Estimate Confidence Limits 
Anxiety 0.520 0.329 0.823 
Cardiovascular disorder 0.497 0.330 0.747 
Musculoskeletal disorder 0.546 0.341 0.874 
No medication 0.177 0.038 0.814 
Antidepressant medication 4.446 2.931 6.743 
·-
Antipsychotic medication 5.513 1.231 24.682 
- -
Other psychiatric medication 2.020 1.139 3.582 
Psychotherapy 4.364 2.938 6.482 
Number of Fee-for-Service physician visits 7.0 4.7 11.8 
Model 2 - Odds Ratio Estimates ~1 hospital OR ~2 physician within 2 yr 
(CD #9) 
Effect 
Point 95% Wald 
Estimate Confidence Limits 
Anxiety 0.579 0.354 0.945 
Cardiovascular disorder 0.516 0.333 0.801 
Musculoskeletal disorder 0.599 0.367 0.977 
Endocrinologic disorder 0.549 0.325 0.927 
No medication 0.214 0.057 0.804 
Antidepressant medication 5.076 3.250 7.928 
Antipsychotic medication 5.050 1.017 25.069 
Other psychiatric medication 2.434 1.31 2 4.514 
NSAIDs 0.601 0.369 0.977 
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-- ----- ·----------------------- --------
Model 2 - Odds Ratio Estimates ~1 hospital OR~ physician within 2 yr 
(CD #9) 
Effect 
Point 95% Wald 
Estimate Confidence Limits 
Antimicrobial agents 0.289 0.102 0.823 
Psychotherapy 5.574 3.712 8.368 
Number of Fee-for-Service physician visits 8.5 5.3 15.4 
Model3- Odds Ratio Estimates (~1 hospital OR ~1 PSY) OR ~2 GP 
within 1 yr (CD # 17) 
Effect 
Point 95% Wald 
Estimate Confidence Limits 
Anxiety 0.545 0.341 0.870 
Cardiovascular disorder 0.520 0.344 0.785 
Musculoskeletal disorder 0.555 0.346 0.891 
Antidepressant medication 5.335 3.492 8.151 
Antipsychotic medication 5.272 1.153 24.117 
Other psychiatric medication 1.982 1.104 3.558 
Psychotherapy 4.653 3.141 6.893 
Number of Fee-for-Service physician visits 7.4 4.9 12.8 
Model4 - Odds Ratio Estimates (~1 hospital OR ~1 PSY) OR ~2 GP within 
2 yr(CD #19) 
Effect Point 95% Wald 
Estimate Confidence Limits 
Anxiety 0.568 0.347 0.928 
Cardiovascular disorder 0.490 0.318 0.753 
Musculoskeletal disorder 0.526 0.324 0.855 
No medication 0.221 0.059 0.833 
'-
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Model 4 - Odds Ratio Estimates (2:1 hospital OR 2:1 PSY) OR 2:2 GP within 
2 yr(CD #19) 
Effect 
Point 95% Wald 
Estimate Confidence Limits 
Antidepressant medication 5.562 3.546 8.723 
Other psychiatric medication 2.581 1.384 4.8 14 
- 1----
Antimicrobial agents 0.269 0.094 0.77 1 
Psychotherapy 5.675 3.804 8.467 
Number of Fee-for-Service physician visits 8.2 5.2 14.7 
Model 5 - Odds Ratio Estimates (2:1 hospital OR 2:1 PSY) OR 2:3 GP within 
3 yr (CD #23) 
Effect 
Point 95% Wald 
Estimate Confidence Limits 
Anxiety 0.568 0.354 0.9 11 
Chronic pain 0.478 0.292 0.782 
Mental disorder excluding depression 1.980 1.1 63 3.370 
Cardiovascular disorder 0.491 0.323 0.748 
No medication 0.252 0.067 0.944 
-
Antidepressant medication 3.877 2.5 10 5.988 
Hormonal medication 0.564 0.327 0.97 1 
Other psychiatric medication 2.448 1.354 4.424 
Antimicrobial agents 0.232 0.078 0.694 
Psychotherapy 5.442 3.625 8.1 70 
Number of Fee-for-Service physician visits 7.6 4.9 13.3 
,_ 
'- -
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CHAPTER FIVE: DISCUSSION 
The objectives of this chapter are: 1) to discuss pertinent findings of the study within 
the context of previous research, 2) to discuss the strengths and limitations of this study, 
3) to discuss suggestions for future studies, and 4) to provide conclusions. 
5.1 Discussion of Study Findings 
The focus of this study was to examine the usefulness and validity of using provincial 
administrative databases for carrying out surveillance of depressive disorders. Depressive 
disorders studied included major depressive disorder, dysthymic disorder, and depressive 
disorders not otherwise specified (e.g., minor depressive disorders, recurrent brief 
depressive disorders). At the national level, the challenges in developing a mental illness 
surveillance system has been discussed (Patel , 2004) with several challenges identified, 
including: establishing the goals of the surveillance system; getting agreement on key 
data elements for the system; creating indicators and case definitions; identifying data 
sources; specifying data collection, analysis, and dissemination procedures; ensuring use 
of the system; and the need to evaluate the system (Health Canada, 2002). The Public 
Health Agency of Canada, with the mandate to strengthen Canada's capacity to protect 
and improve the health of Canadians, plans to develop a national picture of mental 
disorders using a valid and feasible methodology. This methodology will be similar to 
that of the National Diabetes Surveillance System, whereby provinces and territories 
share aggregate data based on a common case definition for select chronic diseases. This 
current study has shown that using administrative databases for the surveillance of 
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depressive disorders and research is both a valid and feasible approach. A recent study by 
Kisely et al. (2009) evaluated the usefulness of administrative data in the surveillance of 
mental illness in Canada using a population-based record-linkage analysis. Kisely et al. 
(2009) utilized data from physician billings, hospital discharge abstracts, and community-
based clinics obtained from the following five provinces: British Columbia, Ontario, 
Quebec, Nova Scotia, and Alberta. The case definition used in the Kisely's study 
included two or more physician visits, or one hospitalization due to any mental disorders 
(ICD-9 codes 290-319) at any point of time. The authors concluded that using 
administrative data to measure the prevalence of mental health disorders that are being 
treated is feasible. The authors also suggest that despite suspected variations in data 
coding, their results showed acceptable uniformity of data across the five provinces. 
This study validated the use of administrative databases versus surveys as a method 
for surveillance of depressive disorders. Administrative databases are increasingly being 
used for many types of research in economically developed countries, given their 
advantage of having larger sample size, lower costs, and increased generalizability 
(Harpe, 2009). They also can include a wide variety of data fields through linkage to 
other disparate health care information at the individual level, and frequently include 
large numbers of patients spanning many years. While they are considered a valuable 
source for many types of research, administrative databases have not been widely used 
for public health surveillance (Harpe, 2009). And although surveys have been used for 
surveillance of mental disorders (Patten et al. , 2006; Wang et al. , 2009: Patten & Beck, 
2004; Vasiliadis et al.. 2005 ; Satyanarayana et al. , 2009), their validity depends on many 
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factors, such as the sampling strategy which impacts generalizability, and the accuracy of 
self-reporting. Lix et a!. (2008) found that agreement between administrative databases 
and population surveys was highest for diabetes and hypertension, and lowest for 
arthritis. Okura et a!. (2004) suggested that although diabetes and hypertension are not 
usually characterized by distinct and dramatic clinical presentations, they are chronic and 
require ongoing repeated health services utilizations which increases their likelihood of 
identification in administrative data. For arthritis, the selection of non-specific diagnostic 
codes by physicians, potentially inaccurate diagnoses by non-specialized practitioners, 
and the low probability that this condition will contribute to a hospital stay, may all be 
factors contributing to the lack of concordance between the two data sources (Lix et a!. , 
2008). 
Our findings showed that of all the depressed patients who were hospitalized (due to 
psychiatric or non-psychiatric reasons), only a small proportion (11.6%, 22/190) had 
hospitalizations as a result of a depressive disorder. The large discrepancy between the 
hospital records and gold standard in this study may be due in part to patients being 
hospitalized for reasons other than depression, yet subsequently receiving a co-morbid 
diagnosis of depression while hospitalized. Nonetheless, all patients who had a 
hospitalization due to depressive disorders were identified in the depressed cohort, 
whereas none of the non-depressed cohort patients were found to have a hospitalization 
as a result of a depressive disorder. This suggests high specificity of the hospital data in 
capturing patients with a depressive disorder diagnosis. It is worth noting that depressions 
requiring hospitalizations are often severe and protracted, with potential multiple 
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outpatient treatment failures. Identifying and diagnosing such patients may not be as 
challenging as those who have mild depression, who often are treated in an outpatient 
setting. 
Of all those patients found by chart review with a depressive disorder, 89.3% 
(226/253) were identified in the provincial fee-for-service physician claims database as 
having an outpatient visit with an associated code of depressive disorder. The 
discrepancy between the charts and the physician claims database could partially be 
explained by individuals who do not have a valid MCP (health insurance) number (e.g., 
non-residents, armed-forces personnel, etc.) and as such would not be included in the 
physician claims database. In this study, we could not identify the severity of the disease 
(mild versus severe) due of lack of clinical information in the medical charts. It is also 
important to note that patients with mild depressive disorders may not easily be 
diagnosed in the clinic. Further, it was challenging to be able to identify the severity of 
depression using administrative databases. Although it is arguable that those patients who 
had a hospitalization or psychiatric visit may have had severe depression, not all patients 
with depressive disorders require hospital admissions or psychiatric visits. 
Despite the fact that many patients with depressive disorders seek help in primary 
care, general practitioners still have difficulties diagnosing and treating depression 
(Charbonneau eta!., 2004; Wells eta!., 1999). Additionally, because depressive disorders 
are more common among those with comorbid chronic medical disorders, depressions 
with significant somatic comorbidity may remain unrecognized in primary care (Akiskal , 
2005). Moreover, studies using administrative databases for conducting research on 
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depression often identify patients by ICD codes (West et al. , 2000). Basing analyses on 
diagnostic codes such as the ICD classification must be done with caution because mental 
illnesses, due to their potential for stigma, may not be fully reported on insurance claims. 
Rawson et al. (1997) evaluated the reliability of schizophrenia and depression 
diagnoses in several Saskatchewan health care databases. The study focused on patients 
who were hospitalized for these conditions, and sought confirmation of the diagnosis in 
both the patient charts and the Physician Services file (containing information on 
outpatient visits to Saskatchewan clinicians). Following a review of the hospital charts, 
agreement was found to be 94% for schizophrenia and 58% for depression. Agreement 
with the Physician Services file was lower for schizophrenia (60%) than for depression 
(73%). In Saskatchewan, West et al. (2000) reported similar results to that of Rawson and 
colleagues (1997) for a depression diagnosis according to the Physician Services file 
(77% vs. 73%). 
In this study, considering previously developed chronic disease models and their case 
definitions (e.g., the National Diabetes Surveillance System model), a large number of 
potential case definitions for depressive disorders were developed. These case definitions 
were developed with the understanding that the severity of depressive disorders range 
from mild depression to debilitating levels requiring professional help, medication and 
even hospitalization. Further, depressive episodes usually run a fluctuating course with 
some people recovering within a few years, while for others the symptoms persist for a 
protracted period and become chronic. Unlike most previous studies (Kisely et al., 2009; 
Damush et al. , 2008; West et al. , 2000; Fultz et al. , 2006; Hux et al. , 2002; James et al. , 
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2004; Solberg et al. , 2006; To et al. , 2006), the case definitions used in this study 
incorporated the physician specialty (general practitioners vs. psychiatrists) when 
counting the number of physician visits. Surveillance case definitions must balance 
competing needs for sensitivity, specificity, and feasibility. Because of the need for 
simplicity, surveillance case definitions are typically brief (Buehler, 2008). For disease 
with long latency or chronic course (e.g. , depressive disorders), developing a case 
definition depends on decisions regarding which phase to monitor: asymptomatic, early 
disease, late disease, or death. Ideally, surveillance case definitions should both inform 
and reflect clinical practices (Buehler, 2008). In this study, incorporating physician 
specialty (e.g., general practitioner vs. psychiatrist) enabled us to capture the range of 
depression from mild depressive not requiring hospitalizations or psychiatric visits, to 
major depression which may have required either hospitalizations or psychiatric visits. 
We believe this component of our study added another degree of validity with respect to 
the diagnosis of the patient. 
Overall, none of the case definitions developed for this study resulted in exceptional 
performance with respect to sensitivity and specificity (e.g. > 85%). Nonetheless, five 
case definitions based on inpatient and outpatient ICD codes and physician specialty data 
were found to perform best. 
This study found that valid case definitions for identifying patients with depressive 
disorders require at least one hospitalization and at least two fee-for-service physician 
visits. With respect to duration, a minimum of 2-3 years of retrospective data is required 
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to have hospitalizations and fee-for-service physician visits identify the majority of the 
cases. 
The timeframe required to generate sufficient numbers of healthcare visits is crucial 
for developing a valid case definition. The optimal timeframe needed for the 
identification of patients with chronic diseases varies by type of disease. A two- to three-
year timeframe has been suggested as sufficient, particularly for chronic diseases with 
relatively structured visiting behavior such as diabetes and hypertension (Robinson et al., 
1997; Hoogenveen et al. , 2002). Using a two-year time frame for our case definition was 
appropriate, given depressive symptoms often persist over a protracted time. This time 
frame is also consistent with other established chronic diseases such as diabetes in the 
National Diabetes Surveillance System model case definition. Previous research has 
shown that the errors of prevalence estimates decreases with increasing follow up time 
(Robinson et al., 1997; Hoogenveen et al., 2002). For conditions that may be challenging 
to diagnose such as asthma, a timeframe up to five years may be required (Lix et al., 
2008). In other cases, using a period longer than two years may not be feasible for 
ongoing surveillance system (Hux et a!., 2002). Other investigators used a shorter 
timeframe of two years mainly because the purpose of their investigation was to identify 
cases rather than to estimate the burden of the disease (Coffin et al.. 2005). 
Of the five case definitions found to perform best, the case definition, (~ 1 
hospitalization OR ~ I psychiatrist visit due to depressive disorders any time) OR ~ 2 
GP visits due to depressive disorders within the first 2 years of diagnosis, appears to be 
the most appropriate, having high sensitivity (77.5%), specificity (93%), and PPV 
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(91.6%), with a kappa statistics of 0.706. We put forward this case definition as the most 
appropriate for studies of depressive disorders using hospital and physician 
administrative databases, given: 1) there is congruence between the administrative 
databases and medical charts in identifying cases, 2) has high sensitivity and specificity, 
3) incorporates physician specialty (general practitioners vs. psychiatrists) in the case 
definition, and 4) considers a minimum of 2 years of retrospective data. 
In our study, the addition of drug use data from the electronic charts (EMR) 
(antidepressant medications) enhanced the accuracy of all five of our case definitions by 
improving the sensitivity level to 100% and the kappa statistics to over 90%, while the 
false negative rate reduced to zero. This finding could have important implications in the 
development of future case definitions by considering data from population-based 
Pharmacy Networks. The Newfoundland and Labrador Pharmacy Network will connect 
pharmacists, physicians, and other authorized health professionals to comprehensive drug 
data of their patients. It will contain drug information and an interactive database that will 
assist in identifying potential adverse drug events. Using the Pharmacy Network, health 
professionals will have access to complete patient-medication profiles at the point of 
distribution and prescribers will be able to enter and transmit medication orders online. 
The Newfoundland and Labrador Pharmacy Network is expected to begin a phased-in 
implementation across the province's community pharmacies in December 2009. 
Damush et al. (2008) showed that when antidepressant medications were included in 
the case definition, the ability to identify post-stroke depression patients using 
administrative data improved. In Manitoba, Lix et a!. (2008) investigated the congruence 
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between administrative databases and surveys in studying chronic disease by examining 
multiple case definitions for arthritis, asthma, diabetes, heart disease, hypertension and 
stroke. The authors reported that using prescription drug data, in addition to hospital and 
physician databases, had mixed effects on agreement in ascertaining disease state 
between administrative databases and surveys. While case ascertainment for asthma 
benefited from the use of both diagnostic and prescription drug information when the 
definition was based on one or two years of administrative data, improvements in 
agreement were less substantial for diabetes. For hypertension, there was also some 
improvement in agreement associated with using both diagnosis and prescription drug 
data for case ascertainment, but not for other diseases. It is important to note that a 
specific set of prescription drugs are used to treat asthma and diabetes; for other chronic 
diseases such as hypertension or arthritis, the drugs prescribed for an individual may be 
used to treat more than one chronic disease, and therefore may not be helpful for 
identifying cases. In our study, drug use data with medications' names and classes (e.g., 
SSRls, TCA), dosages and durations were available from the electronic charts (EMR). 
We believe that for the purpose of surveillance of depressive disorders, the classes of 
antidepressant medications (as opposed to the name of each individual medication) along 
with the dosages should be included in the case definitions. The duration of treatment can 
be obtained via the dispensed dates. Provincial pharmacy networks, such as the one soon 
to be implemented in Newfoundland and Labrador, will provide an opportunity to include 
administrative medication information at a population level in the development of case 
definitions in the surveillance of many types of diseases. 
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The depressed cohort in this study had a higher proportion of patients with anxiety, 
insomnia, fatigue, and chronic pain than that of the non-depressed cohort. This is to be 
expected, as such symptoms are frequently associated with a diagnosis of depressive 
disorders. Further, the depressed cohort appeared to have a higher proportion of 
narcotics, anticonvulsant, gastro-intestinal, and respiratory prescriptions prescribed, than 
that of the non-depressed cohort. The depressed patients were also more likely to be more 
frequent users of physician services than that of the non-depressed patients. It has been 
reported that patients with depressive disorders are at increased risk of having one or 
more comorbidities (Akiskal, 2005; Patten et al.. 2006; Wang et al. , 2009; Himelhoch et 
a!., 2004). Moussavi et a!. (2007) studied approximately 250,000 respondents in 60 
countries, and found that depressive disorders produced a greater decrement in health 
than other chronic diseases, including angina, arthritis, asthma, and diabetes. In addition, 
the authors reported that those with angina, arthritis, asthma, or diabetes also had 
increased risks of depressive disorders (Moussavi eta!. , 2007). 
This study also examined factors associated with depressive disorder diagnoses, 
based on selected case definitions. Results of our inferential statistics (multiple regression 
analyses) consistently showed that, across all the models the depressed cohort was 4-5 
times more likely to have been prescribed antidepressant medications than that of the 
controls. Similarly, the depressed cohort appeared to have 4-5 times higher odds of 
having received psychotherapy (either by general practitioners or psychiatrists) than those 
in the control cohort. It should be noted that pharmacotherapy (e.g., antidepressant 
medications), with or without psychotherapy, are the most important and most common 
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treatment choices available to depressed patients (Rush, 2005). Further, the frequency of 
fee-for-service physician visits was found to be significantly higher for the depressed 
cohort in all five regression models. It has been shown that depressi ve disorders are 
associated with increased health service utilization (e.g., general medical services or 
emergency services) for emotional problems (Parikh et al. , 2001; Johnson et al., 1992; 
Olfson et al., 1992). Patients with high health service utilization are more likely to have a 
high rate of untreated depression (Akiskal, 2005). Despite the fact that many patients 
with depressive disorders seek help in primary care, general practitioners still have 
difficulties diagnosing and treating depression . Most patients who seek care for 
depression are treated in primary care settings, where at least 50% of depressed patients 
are undiagnosed, and 40% to 55% of those that are diagnosed are insufficiently treated 
(Charbonneau et al. , 2004; Wells et al. , 1999). North American and European surveys 
report that approximately half of those who develop depressive disorders seek treatment 
for them, but only a small proportion (approximately one-third) receive appropriate 
treatment (Akiskal , 2005). An increasing rate of health service utilization is related to 
increasing severity of depression and other psychiatric and non-psychiatric co-
morbidities (Akiskal, 2005). 
Multiple regression analyses m this study showed that cardiovascular and 
musculoskeletal disorders identified in the medical chart were less likely to be associated 
with the depressed cohort than the non-depressed cohort. This study does not fully 
explain this pattern. We used a random matching sampling technique by age and gender 
for selecting controls, however, we did not match by co-morbidities which may partially 
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explain this pattern. Further, cardiovascular and musculoskeletal disorders are not 
uncommon diseases in age groups 50 years and greater, and the mean age in both the 
depressed and non-depressed cohort in our study was slightly more than 50 years. 
5.2 Strengths 
First, in this study a medical chart review (EMR) was considered the gold standard, 
which may have decreased potential bias in identifying patients with true depressive 
disorders. Further, all excluded cases in this study were independently reviewed by an 
experienced psychjatrist not involved in the study to maximize objectivity. Other similar 
studies used various sources such as surveys and registries (e.g. Prescription Drug Data, 
NPHS, and Cancer Registry) . Secondly, unlike most previous studies, the case definitions 
used in this study incorporated the physician specialty (general practitioners vs. 
psychiatrists). This approach is unique in that physician specialty (e.g., general 
practitioner vs. psychiatrist) added another level of confidence to the case definitions. 
Lastly, we included three large family practice clinics in the study which may have 
decreased potential selection bias. 
5.3 Limitations 
A major limitation of this study is that the results may not be generalizable to the non-
university based practices. The study setting included only university-based clinics where 
most staff are either academic physicians or rotating residents. The majority of family 
practice clinics in the province are operated either by fee-for-service or salaried 
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physicians, which may have different patterns of claims submission practices compared 
to that of academic settings. It is also important to note that rural areas were not included 
in this study, which also would contribute to the generalizability issue in this study. We 
believe that the definitions proposed in this study need to be validated in settings other 
than the university practices. Secondly, the provincial fee-for-service physician claims 
database does not capture all patients with depressive disorders, such as those who do not 
have a valid MCP number (e.g., non-Newfoundland residents, armed-forces personnel 
etc.), or those that visit a salaried physician. There is approximately one third of the 
population in the province (mainly in rural areas) on whom no physician data is currently 
available because it is not collected (data for salaried physicians are not captured in the 
provincial fee-for-service physician claims database). This may have negatively impacted 
our estimation on the agreement between the gold standard (i .e ., electronic medical chart) 
and administrative databases. Thirdly, the ICD-9 and ICD-1 0-CA codes were used in the 
administrative databases to identify patients with depressive disorders. The potential for 
misclassification of diagnostic codes by the medical record technicians needs to be 
considered. Fourthly, the coding classification system in the hospital database changed 
from ICD-9 to lCD-I 0-CA in April 2001. Given the mapping issue that exist for 
diagnosis codes in these two classification systems, potential discrepancies in identifying 
patients with depressive disorders between ICD-9 to lCD-I 0-CA is possible. It should be 
noted that there may not be a perfect one to one match for depressive disorders between 
the ICD-9 to ICD-1 0-CA codes. Fifthly, the time period available for reviewing the 
medical charts in the three family practice clinics was approximately six months, due to 
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the shadow billing issue (see Materials and Method, section 3.2). This rather short time 
period may have impacted the assessment of medical chart reviews in each clinic, 
particularly when a chronic disease such as depression often fluctuates over time. Sixthly, 
considering the timeframe (of within certain number of years of diagnosis) used in the 
case definitions, there is a potential bias for older patients to have a greater potential time 
at risk than younger patients with respect to being captured in administrative databases. 
Lastly, the lack of prescription drug data at the provincial level presently available in 
Newfoundland and Labrador limited our ability to study definitions for depressive 
disorders using population-based prescription drug data. 
5.4 Suggestions for Future Studies 
Future studies should examine the implications of the limitations stated, in pru1icular 
the issue of academic versus non-academic clinics. Secondly, prescription drug data at 
the population level should be included in the further development of case definitions in 
an effort to enhance the ascertainment of cases with depressive disorders. Finally, the 
continuity of care in primary care settings should be considered as it is associated with 
better problem recognition, improved preventive care, improved patient satisfaction and 
treatment adherence, reduced hospitalization and emergency room visits, and lower 
health care costs (Knight et al. , 2009). Further, considering that different training and 
cultural backgrounds of the physicians in the province might potentially impact on 
identifying and diagnosing depressive disorders, more research in this area is warTanted. 
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5.5 Conclusions 
This study found that provincial administrative databases are useful for undertaking 
surveillance on depressive disorders among the adult population. The approach used in 
developing case definitions for depressive disorders was simple and practical and resulted 
in high sensitivity, specificity, and PPV; the comparison between the chart review and the 
administrative databases indicated strong agreement. Although this study focused on 
depressive disorders among the adult population, its methodology can be adopted for 
other mental disorders, as well as other cohorts such as the pediatric population. 
This study advanced the methodology for identifying patients with depressive 
disorders from administrative databases in several ways. First, the case definitions were 
constructed by incorporating the specialty of the physician, which added a degree of 
accuracy to the identification of patients. Secondly, the study examined the addition of 
pharmacy data (antidepressant medications) to case definitions which maximized the 
accuracy of the five most appropriate case definitions (in some cases improving the 
sensitivity level to 100% and kappa statistics to over 90% with 0% false negative rate). 
Lastly, the study provided five valid case definitions, which can be considered as valid 
case definitions for the purpose of surveillance of depressive disorders among the adult 
population. 
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APPENDICES 
Appendix A. DSM-IV-TR Diagnostic Criteria for various depressive disorders 
Appendix A-J. DSM-IV-TR Diagnostic Criteria for Major Depressive Disorder 
A. Presence of a single major depressive episode. 
B. The major depressive episode is not better accounted lor by schizoaffecti vc disorder and is not superimposed on 
schizophrenia, schi zophreniform disorder, delusional disorder. or psychotic disorder not otherwise speci fied. 
C. There has never been a manic episode, a mixed episode. or a hypomanic episode. 
Note: This exclusion does not apply if all of the manic-like. mixed-like, or hypomanic-like episodes are substance 
or treatment induced or are due to the direct physiological effects of a general medical condition. 
If the full criteria are currently met tor a major depressive episode, spec(fj' its current clinical status or features, or both: 
Mild, moderate, severe without psychotic features, or severe with psychotic features 
Chronic 
With catatonic features 
With melancholic features 
With atypical features 
With postpartum onset 
If the full criteria are not current ly met for a major depn:ssive episode. specifY the current cl inical status of' the major 
depressive disorder or features of the most recent episode: 
In panial remission, in full remission 
Chronic 
With catatonic features 
With melancholic features 
With atypical features 
With postpartum onset 
Appendix A-2. DSM-IV-TR Diagnostic Criteria for Dysthymic Disorder 
A. Depressed mood for most of the day. lor more days than not. as indicated by subjective account or observation by 
others, for atlcast 2 years. Note: In children and adolescents. mood can be irritable. and durat ion mu. t be at least I 
year. 
B. Presence, while depressed, of two (or more) of the !allowing: 
( I) Poor appetite or overeating 
(2) Insomnia or hypersomn ia 
(3) Low energy or fatigue 
( 4) Low set f-esteem 
(5) Poor concentration or difficulty making decisions 
(6) Feelings of hopelessness 
C. During the 2-year period (I year for children or adolescents) of the disturbance. the person has never been without 
the symptoms in Criteria A and B for more than 2 months at a time. 
D. No major depressive episode has been present during the lirst 2 years of the disturbance (I year for children and 
adolescents): that is, the disturbance is not better accounted for by chronic major depressive disorder or major 
depressive disorder. in panial remission. 
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Note: There may have been a previous major depres ive episode, provided that there was a full remission (no 
significant signs or symptoms for 2 months) before development of the dysthymic disorder. In addition. after the initial 
2 years (I year in children or adolescents) or dysthymic disorder, there may be superimposed episodes of major 
depressive disorder, in which case both diagnoses may be given when the criteria are met for a major depressive 
episode. 
E. There has never been a manic episode. a mixed episode, or a hypomanic episode, and criteria have never been met 
for cyclothymic disorder. 
F. The disturbance does not occur exclusively during the course of a chronic psychotic disorder, such as sch izophren ia 
or delusional disorder. 
G. The symptoms are not due to the direct physiological effects of a substance (e.g. , a drug of abuse. a medication) or a 
general medical condition (e.g., hypothyroidism). 
H. The symptoms cause clinically significant distress or impairment in social. occupational. or other important areas of 
functioning. 
Specify if: 
Early onset: if onset is before 21 years or age 
Late onset: if onset is at 21 years of age or older. 
Specify i f (for most recent 2 years of dysthymic disorder) : 
With atypical features. 
Appendix A-3. DSM-IV-TR Diagnostic Criteria for Depressive Disorder Not 
Otherwise Specified 
The depressive di order not otherwise specilied category includes disorders with depressive features that do not meet 
the criteria for major depressive disorder, dysthymic disorder, adjustment disorder with depressed mood, or adjustment 
disorder with mixed anxiety and depressed mood. Sometimes depressive symptoms can present as part of an anxiety 
disorder not otherwise speci tied. Examples of depre. si ve disorder not otherwise speci lied include: 
I . Premenstrual dysphoric disorder: In most menstrual cycles during the past year. symptoms (e.g .. markedly 
depressed mood, marked anxiety. marked affective lability. and decreased interest in activities) regularly 
occurred during the last week ofthe luteal phase (and remitted within a few days of the on. et of menses). These 
symptoms must be severe enough to markedly interfere with work. school, or usual nctivities and must be 
entirely absent for at least I week postmenses. 
2. Min or depressive di sorder: episodes of at least 2 weeks of depressive symptoms but with fewer than the five 
items required for major depressive disorder. 
3. Recurrent brief depressive disorder: depressive episodes lasting from 2 days to as long as 2 weeks, occurring 
at least once a month for 12 months (not associated with the menstrual cycle). 
4. Postpsychotic depressive disorder of' schizophrenia: a maj or depressive episode that occurs during the 
residual phase of schizophrenia. 
5. A major depressive episode superimposed on delusional disorder, psychotic disorder not otherwise specilied, 
or the active phase of' schizophrenia. 
Situations in which the clinician has concluded that a depressive disorder is prt:scnt but is unable to determine whether 
it is primary, due to a general medical condition. or substance induced. 
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Appendix A-4. DSM-IY-TR Research Criteria for Minor Depressive Disorder 
A. A mood disturbance, defined as fo llows: 
( I ) At least two (but less than five) of the following symptoms have been present during the same 2-week period and 
represent a change fi·om previous functioning; at least one of the symptoms is (a) or (b): 
(a) Depressed mood most of the day, nearly every day, as indicated by subjective report (e.g., feels sad or empty) or 
observation made by other (e.g .. appears tearful ). ote: In children and adolescents, can be irritable mood. 
(b) M arkedly diminished interest or pleasure in all, or almost all. activities most of the day. nearly every day (as 
indicated by subjective account or observation made by others). 
(c) Significant weight loss when not dieting or weight gain (e.g .. a change of more than 5 percent of body weight in 
a month) or decrease or increase in appetite nearly every day. Note: In ch ildren, consider failure to make expected 
weight gains. 
(d) Insomnia or hypersomnia nearly every day. 
(e) Psychomotor agi tation or retardation nearly every day (observable by others. not merely subject ive feelings of 
restlessness or being slowed down). 
(f) Fatigue or loss of energy nearly every day. 
(g) Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not 
merely self-reproach or guilt about being sick). 
(h) Diminished ability to think or to concentrate or indecisiveness. nearly every day (by subj ecti ve account or as 
observed by others). 
(i) Recurrent thoughts of death (not just fear of dying). rc<.:urrent suicidal ideation wi thout a specific plan. or a 
suicide attempt or a specific plan for committing suicide. 
(2) The symptoms cause clinically signilicant distress or impairment in soc ial , o<.:cupational. or other impo11ant areas 
of functioning. 
(3) The symptoms are not due to the direct physiological effects of a substance (e.g., a drug of abuse or a medication) 
or a general medical condition (e.g., hypothyroidism). 
(4) The symptoms arc not better accounted for by bereavement (i.e .. a normal reaction to the death or a loved one). 
B. There has never been a major depressive episode, and criteria are not met for dysthymic disorder. 
C. There has never been a manic episode, a mixed episode, or a hypomanic episode, and criteria arc not met for 
cyclothymic disorder. 
Note: This exclusion does not apply if all of the manic-like, mixed-like, or hypomanic- like episodes are substance 
or treatment induced. 
D. The mood disturbance docs not occur exclusively during schizophren ia. schizophreni form disorder. schizoaffect ive 
disorder, delusional disorder. or psychotic disorder not otherwise specified. 
Appendix A-5. DSM-IY-TR Research Criteria for Recurrent Brief Depressive 
Disorder 
A. Criteria. except lor duration, are met for a major depressive episode. 
13. The depressive periods in Criterion A last at least 2 days but less than 2 weeks. 
C. The depressive periods occur at least once a month for 12 consecuti ve months and arc not associated with the 
menstrual cycle. 
D. The periods of depressed mood cause cl inically significant distress or impairment in social, occupational, or other 
important areas of functioning. 
E. The symptoms are not due to the direct physiological effects of a substance (e.g., a drug of ahuse or a medication) or 
a genera l medical condition (e.g., hypothyroidism). 
F. There has never been a major depressive episode, and criter ia are not met lor dysthymic disorder. 
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G. There has never been a manic episode, a mixed episode, or a hypomanic episode, and criteria are not met for 
cyclothymic disorder. 
Note: This exclusion does not apply if all of the manic-like, mixed-li ke. or hypomanic- like episodes are substance 
or treatment induced. 
H. The mood disturbance does not occur exclusively during schizophrenia. schizophreni form disorder. schizoaiTcct i v~: 
disorder, delusional disorder. or psychotic disorder not otherwise spec ified. 
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Appendix B. Data Collection Form 
/ ' · Study Code: ,2. List #: ,3. Clinic: 
4 . MCP: 5. Sex: Male Female 6. Date of Birth (DD/MM/YY): 
7. Has a depress ive di sorder diagnos is been confirmed? Yes No 
8. Does the patient have any of the followi ng co-d iagnoses/condi ti ons? Check all that apply, specify 
disease 
-~ ~~r ( ) ~--------------------------------------------------~ 
_ 2 Endocrinologica l d isorders ('---------------------------------------___J) 
_ 3 Menta I disorder exc lud ing depress ion ('---------------------------------__/) 
_ 4 C i rcu Ia tory disorders ('----------------------------------------------') 
_ 5 Respiratory di sorders <~------------------------------------------') 
_ 6 G I di sorders ('-----------------------------------------------__J) 
_ 7 Neurologica l disorders ('---------------------------------------------') 
_ 8 Musculoskeleta l/Connective di sorders ( ) ~----------------------------~ 
9 Insomn ia _ 10 Chronic pain _ II Fatigue _ 12 Anxiety 
13 Other ( ) ~----------------------------------------------------~ 
9. Does the pati ent currently take any medications? Check a// that apply 
--
I None __ 8 Other psychiatric __ 15 Gastro intesti na l drugs 
--
2 SS RI 
--
9 Narcotics __ 16 Respiratory agents 
--
3 SNRis 
--
10 NSAIDS __ 17 Ant imicrobia l agents 
4 MAOis II Anticonvulsants 18 Other 
-- -- --
--
5 TCA __ 12 Cardiovascular agents 
__ 6 Benzodiazepines __ 13 Hormone agents 
__ 7 Antipsychotic __ 14 Hematologic agents 
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Appendix C. Potential case definitions examined in the study. 
Case Definition # 1 ~ I hospitalizations due to depressive disorders any time OR ~ 1 physician visit due to depressive disorders any time 
Case Definition #2 ~ 1 hospitalizations due to depressive disorders any time OR ~ 2 physician visits due to depressive disorders any time 
Case Definition #3 ~ 1 hospitalizations due to depressive disorders any time OR ~ 3 physician visits due to depressive disorders any time 
Case Definition #4 ~ 1 hospitalizations due to depressive disorders any time OR ~ 4 physician visits due to depressive disorders any time 
Case Definition #5 ~ 1 hospitalizations due to depressive disorders any time OR ~ 5 physician visits due to depressive disorders any time 
Case Definition #6 ~ 1 hospitalizations due to depressive disorders any time OR ~ 6 physician visits due to depressive disorders any time 
Case Definition #7 ;::-: I hospitalizations due to depressive disorders any time OR ~ 7 physician visits due to depressive disorders any time 
Case Definition #8 ~ I hospitalizations due to depressive disorders any time OR ~ 8 physician visits due to depressive disorders any time 
~ I hospitalizations due to depressive disorders any time OR ~ 
Case Definition #9 I physician visit due to depressive disorders within the first year 
of diagnosis 
~ I hospitalizations due to depressive disorders any time OR ~ 
Case Definition #I 0 2 physician visits due to depressive disorders within the first 
year of diagnosis 
~ I hospitalizations due to depressive disorders any time OR ~ 
Case Definition #II 3 physician visits due to depressive disorders within the first 
year of diagnosis 
~ 1 hospitalizations due to depressive disorders any time OR ~ 
Case Definition# 12 4 physician visits due to depressive disorders within the first 
year of diagnosis 
~ I hospitalizations due to depressive disorders any time OR ~ 
Case Definition # 13 5 physician visits due to depressive disorders within the first 
year of diagnosis 
;::-: I hospitalizations due to depressive disorders any time OR ~ 
Case Definition# 14 6 physician visits due to depressive disorders within the first 
year of diagnosis 
~ I hospitalizations due to depressive disorders any time OR ~ 
Case Definition # 15 7 physician visits due to depressive disorders within the first 
year of diagnosis 
~ I hospitalizations due to depressive disorders any time OR ~ 
Case Definition # 16 8 physician visits due to depressive disorders within the first 
year of diagnosis 
~ I hospitalizations due to depressive disorders any time OR ~ 
Case Definition # 17 I physician visit due to depressive disorders within the first 2 
years of diagnosis 
Case Definition # 18 ~ 1 hospitalizations due to depressive disorders any time OR ~ 
107 
2 physician visits due to depress ive disorde rs within the fi rst 2 
years of diagnos is 
~ I hospita lizatio ns due to depress ive disorders any time OR ~ 
Case De finition # 19 3 phys ician visits due to depress ive disorde rs within the first 2 
years of diagnos is 
~ I hospita lizations due to depress ive disorders any time OR ~ 
Case De finition #20 4 physician v isits due to depress ive disorders with in the fi rst 2 
years of diagnos is 
~ I hospita lizations due to depress ive disorders any time OR ~ 
Case De finition #2 1 5 phys ician v isits due to depressive disorders w ithin the fi rst 2 
years of diagnos is 
~ I hospita lizations due to depressive disorders any time OR ~ 
Case Definition #22 6 physician visits due to depress ive disorders within the first 2 
years of diagnos is 
~ I hospitalizations due to depressive disorders any time OR ~ 
Case Definitio n #23 7 physician visits due to depress ive disorde rs w ithin the first 2 
years of diagnosis 
~ I hospita lizatio ns due to depressive disorders any time OR ~ 
Case Definition #24 8 physician visits due to depress ive disorde rs within the first 2 
years of diagnosis 
~ I hospita li zatio ns due to depressive disorders any time OR ~ 
Case Definition #25 I physic ian visit due to depressive disorders w ithin the first 3 
years of diagnosis 
~ 1 hospita lizatio ns due to depressive disorders any time OR ~ 
Case Definition #26 2 physician visits due to depress ive disorde rs with in the first 3 
years of diagnos is 
~ I hospita lizatio ns due to depressive disorders any time OR ~ 
Case Definition #27 3 phys ic ian visits due to depress ive disorde rs w ith in the first 3 
years of diagnos is 
~ I hospita lizatio ns due to depressive disorders any time OR ~ 
Case Definition #28 4 phys ic ian visits due to depress ive disorde rs with in the fi rst 3 
years of diagnosis 
~ I hospita lizatio ns due to depressive disorders any time OR ~ 
Case Definition #29 5 phys ic ian visits due to depress ive d isorders w ith in the first 3 
years of diagnosis 
~ I hospitalizatio ns due to depressive disorders any time OR ~ 
Case Definition #30 6 phys ic ian visits due to depress ive disorders within the first 3 
years of diagnosis 
~ 1 hospita lizatio ns due to depressive disorder any time OR ~ 
Case Definition #3 I 7 phys ic ian visits due to depress ive disorders within the first 3 
years of diagnosis 
~ I hospita lizations due to depressive disorders any time OR ~ 
Case Definition #32 8 phys ic ian visits due to depress ive disorders with in the fi rst 3 
years of diagnosis 
Case Defi nition #33 > I hospita lizations due to depressive disorders any time OR > 
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1 physician visit due to depressive disorders within the first 4 
years of diagnosis 
=:: I hospitalizations due to depressive disorders any time OR =:: 
Case Definition #34 2 physician visits due to depressive disorders within the first 4 
y_ears of diagnosis 
=:: I hospitalizations due to depressive disorders any time OR =:: 
Case Definition #35 3 physician visits due to depressive disorders within the first 4 
years of diagnosis 
=:: I hospitalizations due to depressive disorders any time OR =:: 
Case Definition #36 4 physician visits due to depressive disorders within the first 4 
years of diagnosis 
=:: I hospitalizations due to depressive disorders any time OR =:: 
Case Definition #37 5 physician visits due to depressive disorders within the first 4 
years of diagnosis 
=:: I hospitalizations due to depressive disorders any time OR =:: 
Case Definition #38 6 physician visits due to depressive disorders within the first 4 
years of diagnosis 
=:: I hospitalizations due to depressive disorders any time OR =:: 
Case Definition #39 7 physician visits due to depressive disorders within the first 4 
years of diagnosis 
=:: I hospitalizations due to depressive disorders any time OR =:: 
Case Definition #40 8 physician visits due to depressive disorders within the first 4 
years of diagnosis 
(=:: I hospitalizations OR=:: I psychiatrist visit due to depressive 
Case Definition #41 disorders any time) AND =:: I GP visit due to depressive 
disorders any time 
(=:: I hospitalizations OR=:: I psychiatrist visit due to depressive 
Case Definition #42 disorders any time) AND =:: 2 GP visits due to depressive 
disorders any time 
(=:: I hospitalizations OR=:: I psychiatrist visit due to depressive 
Case Definition #43 disorders any time) AND =:: 3 GP visits due to depressive 
disorders any time 
(=:: I hospitalizations OR=:: I psychiatrist visit due to depressive 
Case Definition #44 disorders any time) AND =:: 4 GP visits due to depressive 
disorders any time 
(=:: I hospitalizations OR=:: I psychiatrist visit due to depressive 
Case Definition #45 disorders any time) AND =:: 5 GP visits due to depressive 
disorders any time 
(=:: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #46 disorders any time) AND =:: 6 GP visits due to depressive 
disorders any time 
(=:: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #47 disorders any time) AND =:: 7 GP visits due to depressive 
disorders any time 
Case Definition #48 (=:: I hospitalizations OR 2: I psychiatrist visit due to depressive disorders any time) AND =:: 8 GP visits due to depressive 
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disorders any time 
(~ 1 hospitalizations OR~ I psychiatrist visit due to depressive 
Case Definition #49 disorders any time) AND ~ I GP visit due to depressive 
disorders within the first I year of diagnosis 
(~ 1 hospitalizations OR~ I psychiatrist visit due to depressive 
Case Definition #50 disorders any time) AND ~ 2 GP visits due to depressive 
disorders within the first I year of diagnosis 
(~ 1 hospitalizations OR~ I psychiatrist visit due to depressive 
Case Definition #5 1 disorders any time) AND ~ 3 GP visits due to depressive 
disorders within the first I year of diagnosis 
(~ I hospitalizations OR ~ I psychiatrist visit due to depressive 
Case Definition #52 disorders any time) AND ~ 4 GP visits due to depressive 
disorders within the first I year of diagnosis 
(~ I hospitalizations OR ~ I psychiatrist visit due to depressive 
Case Definition #53 disorders any time) AND ~ 5 GP visits due to depressive 
disorders within the first I year of diagnosis 
(~ I hospitalizations OR ~ I psychiatrist visit due to depressive 
Case Definition #54 disorders any time) AND ~ 6 GP visits due to depressive 
disorders within the first I year of diagnosis 
(~ I hospitalizations OR ~ I psychiatrist vis it due to depressive 
Case Definition #55 disorders any time) AND ~ 7 GP visits due to depressive 
disorders within the first I year of diagnosis 
(~ I hospitalizations OR~ I psychiatrist visit due to depressive 
Case Definition #56 disorders any time) AND ~ 8 GP visits due to depressive 
disorders within the first I year of diagnosis 
(~ 1 hospitalizations OR ~ I psychiatrist visit due to depressive 
Case Definition #57 disorders any time) AND ~ I GP visits due to depressive 
disorders within the first 2 years of diagnosis 
(~ I hospitalizations OR ~ I psychiatrist visit due to depressive 
Case Definition #58 disorders any time) AND ~ 2 GP visits due to depressive 
disorders within the first 2 years of diagnosis 
(~ 1 hospitalizations OR ~ I psychiatrist visit due to depressive 
Case Definition #59 disorders any time) AND ~ 3 GP visits due to depressive 
disorders within the first 2 years of diagnosis 
(~ I hospitalizations OR ~ I psychiatrist visit due to depressive 
Case Definition #60 disorders any time) AND ~ 4 GP visits due to depressive 
disorders within the first 2 years of diagnosis 
(~ 1 hospitalizations OR ~ I psychiatrist visit due to depressive 
Case Definition #61 disorders any time) AND ~ 5 GP visits due to depressive 
disorders within the first 2 years of diagnosis 
(~ 1 hospitalizations OR ~ I psychiatrist visit due to depressive 
Case Definition #62 disorders any time) AND ~ 6 GP visits due to depressive 
disorders within the first 2 years of diagnosis 
Case Definition #63 (~ I hospitalizations OR ~ I psychiatrist visit due to depressive disorders any time) AND ~ 7 GP visits due to depressive 
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disorders within the first 2 years of diagnosis 
(~ 1 hospitalizations OR ~ I psychiatrist visit due to depressive 
Case Definition #64 disorders any time) AND ~ 8 GP visits due to depressive 
disorders within the first 2 years of diagnosis 
(~ 1 hospita lizations OR ~ I psychiatrist visit due to depressive 
Case Definiti on #65 disorders any time) AND ~ I GP visits due to depressive 
disorders within the first 3 years of diagnosis 
(~ 1 hospita lizations OR ~ I psychiatrist visit due to depressive 
Case Definition #66 disorders any time) AND ~ 2 GP visits due to depressive 
disorders within the fi rst 3 years of diagnosis 
(~ 1 hospitalizations OR 2:: I psychiatrist visit due to depressive 
Case Defini tion #67 disorders any time) AND ~ 3 GP visits due to depressive 
disorders within the first 3 years of diagnosis 
(~ 1 hospitalizations OR 2:: I psychiatrist visit due to depressive 
Case Definition #68 disorders any time) AND ~ 4 GP visits due to depressive 
disorders within the first 3 years of diagnosis 
(~ I hospitalizations OR 2:: I psychiatrist visit due to depressive 
Case Definition #69 disorders any time) AND ~ 5 GP visits due to depress ive 
disorders within the first 3 years of diagnosis 
(~ I hospita lizations OR 2:: I psychiatrist visit due to depressive 
Case Defini tion #70 disorders any time) AND ~ 6 GP visits due to depressive 
disorders within the first 3 years of diagnosis 
(~ I hospitalizations OR 2:: I psychiatrist visit due to depressive 
Case Definition #7 I disorders any time) AND ~ 7 GP visits due to depressive 
disorders within the fi rst 3 years of diagnosis 
(~ I hospita lizations OR 2:: I psychiatrist visit due to depressive 
Case Definition #72 disorders any time) AND ~ 8 GP visits due to depressive 
disorders within the first 3 years of diagnosis 
(~ I hospita lizations OR 2:: I psychiatrist visit due to depress ive 
Case Definition #73 disorders any time) AND ~ I GP visits due to depressive 
disorders within the first 4 years of diagnosis 
(~ I hospita lizations OR 2:: I psychiatrist visit due to depress ive 
Case Definition #74 disorders any time) AND ~ 2 GP visits due to depressive 
disorders within the fi rst 4 years of diagnosis 
(~ 1 hospitalizations OR 2:: I psychiatrist visit due to depress ive 
Case Definition #75 disorders any time) AND ~ 3 GP visits due to depressive 
disorders within the first 4 years of diagnosis 
(~ 1 hospitalizations OR 2:: I psychiatrist visit due to depressive 
Case Definition #76 disorders any time) AND 2:: 4 GP visits due to depressive 
disorders within the first 4 years of diagnosis 
(~ I hospitalizations OR 2:: I psychiatrist visit due to depressive 
Case Definition #77 disorders any time) AND ~ 5 GP visits due to depressive 
disorders within the fi rst 4years of diagnosis 
Case Definition #78 (~ I hospita lizations OR 2:: I psychiatrist visit due to depress ive disorders any time) AND ~ 6 GP visits due to depress ive 
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disorders within the first 4 years of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #79 disorders any time) AND 2: 7 GP visits due to depressive 
disorders within the first 4 years of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #80 disorders any time) AND 2: 8 GP visits due to depressive 
disorders within the first 4 years of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #81 disorders any time) OR 2: I GP visits due to depressive 
disorders any time 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #82 disorders any time) OR 2: 2 GP visits due to depressive 
disorders any time 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #83 disorders any time) OR 2: 3 GP visits due to depressive 
disorders anytime 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #84 disorders any time) OR 2:4 GP visits due to depressive 
disorders any time 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #85 disorders any time) OR 2: 5 GP visits due to depressive 
disorders any time 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #86 disorders any time) OR 2: 6 GP visits due to depressive 
disorders any time 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #87 disorders any time) OR 2: 7 GP visits due to depressive 
disorders any time 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #88 disorders any time) OR 2: 8 GP visits due to depressive 
disorders any time 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #89 disorders any time) OR 2: I GP visits due to depressive 
disorders within the first I year of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #90 disorders any time) OR :::._ 2 GP visits due to depressive 
disorders within the first I year of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #91 disorders any time) OR 2: 3 GP visits due to depressive 
disorders within the first I year of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #92 disorders any time) OR 2: 4 GP visits due to depressive 
disorders within the first I year of diagnosis 
Case Definition #93 (2: I hospitalizations OR 2: I psychiatrist visit due to depressive disorders any time) OR 2: 5 GP visits due to depressive 
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disorders within the first I year of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #94 disorders any time) OR 2: 6 GP visits due to depressive 
disorders within the first I year of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #95 disorders any time) OR 2: 7 GP visits due to depressive 
disorders within the first I year of diagnosis 
(2: I hospita lizations OR 2: I psychiatrist visit due to depressive 
Case Definition #96 disorders any time) OR 2: 8 GP visits due to depressive 
disorders within the first I year of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #97 disorders any time) OR 2: I GP visits due to depressive 
disorders within the first 2 years of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #98 disorders any time) OR 2: 2 GP visits due to depressive 
disorders within the first 2 years of diagnosis 
(2: I hospital izations OR 2: I psychiatrist visit due to depressive 
Case Definition #99 disorders any time) OR 2: 3 GP vis its due to depressive 
disorders within the first 2 years of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition # I 00 disorders any time) OR 2: 4 GP visits due to depressive 
disorders within the first 2 years of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition # I 0 I disorders any time) OR 2: 5 GP visits due to depressive 
disorders within the first 2 years of diagnosis 
(2: 1 hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition #102 disorders any time) OR 2: 6 GP visits due to depressive 
disorders within the first 2 years of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition # I 03 disorders any time) OR 2: 7 GP visits due to depressive 
disorders within the first 2 years of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition # I 04 disorders any time) OR 2: 8 GP vis its due to depressive 
disorders within the first 2 years of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition # I 05 disorders any time) OR 2: I GP visits due to depressive 
disorders within the first 3 years of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition # I 06 disorders any time) OR 2: 2 GP visits due to depressive 
disorders within the first 3 years of diagnosis 
(2: I hospitalizations OR 2: I psychiatrist visit due to depressive 
Case Definition # I 07 disorders any time) OR 2: 3 GP visits due to depressive 
disorders within the first 3 years of diagnosis 
Case Definition # 108 (2: 1 hospitalizations OR 2: I psychiatrist vis it due to depressive disorders any time) OR 2: 4 GP visits due to depressive 
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disorders within the first 3 years of diagnosis 
(~ I hospitalizations OR~ I psychiatrist visit due to depressive 
Case Definition# I 09 disorders any time) OR ~ 5 GP visits due to depressive 
disorders within the first 3 years of diagnosis 
(~ 1 hospitalizations OR~ I psychiatrist visit due to depressive 
Case Definition # II 0 disorders any time) OR ~ 6 GP visits due to depressive 
disorders within the first 3 years of diagnosis 
(~ 1 hospitalizations OR~ I psychiatrist visit due to depressive 
Case Definition # II I disorders any time) OR ~ 7 GP visits due to depressive 
disorders within the first 3 years of diagnosis 
(~ I hospitalizations OR ~ I psychiatrist visit due to depressive 
Case Definition # I 12 disorders any time) OR ~ 8 GP visits due to depressive 
disorders within the first 3 years of diagnosis 
(~ I hospitalizations OR ~ I psychiatrist visit due to depressive 
Case Definition # 113 disorders any time) OR ~ I GP visits due to depressive 
disorders within the first 4 years of diagnosis 
(~ I hospitalizations OR~ I psychiatrist visit due to depressive 
Case Definition # 114 disorders any time) OR ~ 2 GP visits due to depressive 
disorders within the first 4 years of diagnosis 
(~ I hospitalizations OR~ I psychiatrist visit due to depressive 
Case Definition # 115 disorders any time) OR ~ 3 GP visits due to depressive 
disorders within the first 4 years of diagnosis 
(~ I hospitalizations OR~ 1 psychiatrist visit due to depressive 
Case Definition # 116 disorders any time) OR ~ 4 GP visits due to depressive 
disorders within the first 4 years of diagnosis 
(~ I hospitalizations OR ~ I psychiatrist visit due to depressive 
Case Definition # 11 7 disorders any time) OR ~ 5 GP visits due to depressive 
disorders within the first 4 years of diagnosis 
(~ 1 hospitalizations OR ~ I psychiatrist vis it due to depressive 
Case Definition # I I 8 disorders any time) OR ~ 6 GP visits due to depressive 
disorders within the first 4 years of diagnosis 
(~ I hospitalizations OR~ I psychiatrist visit due to depressive 
Case Definition # 119 disorders any time) OR ~ 7 GP visits due to depressive 
disorders within the first 4 years of diagnosis 
(~ l hospitalizations OR ~ I psychiatrist visit due to depressive 
Case Definition # 120 disorders any time) OR ~ 8 GP visits due to depressive 
disorders within the first 4 years of diagnosis 
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Appendix D. Ethics Approval Letters 
UNIVERSITY 
Faculty of Mt•didnc 
llunwn l m..:slil!.at inn Commitk ..: 
2"d 1:1oor. ht>l ~ rn l 'rusl llldg. 
95 BnnaH'nlu t'c' 1\\<:nu..: 
St. .J ohn ·,_ Nl Canada ;\ lll 2X5 
T.: l : 709 777 6'17-1 Fa' : 7()lJ 777 '/1.77(> 
hic"l(ntun.c;t \\\\\\ .nt..:d .muru:aihic 
November 27, 2008 
Reference #08.189 
Dr. Reza Alaghehbandan 
28 Pippy Place 
StJohn's, NL 
AlB 3X4 
Dear Dr. Alaghehbandan: 
RE: Assessing administrative databases for surveillance of depressive disorders in 
Newfoundland and Labrador 
Your application received an expedited review by the Human Investigation Committee. Full 
approval was granted for one year effective November 27, 2008. 
This approval will lapse on November 27, 2009. It is your responsibility to ensure that the Ethics 
Renewal form is forwarded to the H IC office prior to the renewal date. The information provided 
in this form must be current to the time of submission and submitted to HIC not less than 30 
nor more than 45 days of the anniversary of your approval date . The Ethics Renewal form can 
be downloaded from the HIC website 
http://www.med.mun.ca/hic/downloads/ Annuai%20Update%20Fonn.doc 
The Human Investigation Committee advises THAT IF YOU DO NOT return the completed 
Ethics Renewal form prior to date of renewal: 
Your ethics approval will lapse 
You will be required to stop research activity immediately 
You may not be permitted to restart the study until you reapply for and receive approval to 
undertake the study again 
Lapse in ethics approval may result in interruption or termination of funding 
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For a hospital-based study, it is your responsibility to seek the necessary approval from 
Eastern Health and/or other hospital boards as appropriate. 
Modifications of the protocol/consent are not permitted without prior approval from the Human 
Investigation Committee. Implementing changes in the protocol/consent without HIC approval 
may result in the approval of your research study being revoked, necessitating cessation of all 
related research activity. Request for modification to the protocol/consent must be outlined on an 
amendment form (available on the HJC website) and submitted to the HIC for review. 
This research ethics board (the HlC) has reviewed and approved the research protocol and 
documentation as noted above for the study which is to be conducted by you as the qualified 
investigator named above at the specified site. This approval and the views of this Research 
Ethics Board have been documented in writing. In addition, please be advised that the Human 
Investigation Committee currently operates according to Tr i-( 'ouncil Poliq ,)'!ulell ll! ll/ : F.!liical 
Conduct j(Jr Resear ch fm·ol ving Humons and applicable laws and regulations. The membership 
of this research ethics board is constituted in compliance with the membership requirements for 
research ethics boards as per these guidelines. 
Notwithstanding the approval of the HIC, the primary responsibility for the ethical conduct of the 
investigation remains with you. 
We wish you every success with your study. 
Sincerely, 
Fern Brunger, PhD 
Co-Chair 
Human Investigation Committee 
Richard S. Neuman, PhD 
Co-Chair 
Human Investigation Committee 
CC Dr. C. Loomis, c/o Office ofResearch, MUN 
Mr. W. Miller, c/o Patient Research Centre, Eastern Health 
HIC meeting date: December 4, 2008 
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hiC:a mun.c•t \1'\\'\l'.lllt:d.mun.c tlhic 
July 15,2009 
Reference #08. 189 
Dr. Reza Alaghehbandan 
28 Pippy Place 
StJohn's, NL 
AlB 3X4 
Dear Dr. Alaghehbandan: 
This will acknowledge receipt of your amendment form dated July 10,2009, wherein you request 
to access and use de-identifYing data for your research study entitled "Assessing 
administrative databases for surveillance of depressive disorders in Newfoundland 
and Labrador". 
The Co-Chairs ofthe Human Investigation Committee reviewed your amendment and granted 
approval as submitted. 
This Research Ethics Board (the HI C) has reviewed the amendment for the study which is to be 
conducted by you as the qualified investigator named above at the specified study site. This 
approval and the views of this Research Ethics Board have been documented in writing. In 
addition, please be advised that the Human Investigation Committee currently operates according 
to the Tri-Council Policy Statement and applicable laws and regulations. 
Sincerely, 
Fern Brunger, PhD 
Co-Chair 
Human Investigation Committee 
John Harnett, MD, FRCPC 
Co-Chair 
Human Investigati on Committee 
C Dr. C. Loomis, Office of Research , MUN 
Mr. W. Miller, Patient Research Centre 
Meeting date: July 23, 2009 
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Appendix E: 94 case definitions with their binary classification tests 
>=1 hospital OR at >= 1 hospital OR >=1 hospital OR at >= 1 hospital OR at least 
least 6 physician at least 7 least 8 physician 3 physician within first 
over 12 years physician over over 12 years 1 year 
12 years 
Sensitivity 60.5 Sensitivity 56.9 Sensitivity 51.8 Sensitivity 43 .5 
Specificity 96.1 Specificity 96.9 Specificity 96.9 Specific ity 95.3 
FP 1 rate 3.9 FP rate 3.1 FP rate 3.1 FP rate 4.7 
FN' rate 39.5 FN rate 43.1 FN rate 48.2 FN rate 56.5 
ppyJ 93 .9 PPV 94.7 PPV 94.2 PPV 91.9 
NPV" 71.2 NPV 69.6 NPV 67. 1 NPV 58.1 
Percent 78.4 Percent 77.1 Percent 74.5 Percent 66.8 
agreement agreement agreement agreement 
Kappa 0.567 Kappa 0.54 Kappa 0.488 Kappa 0.367 
Kappa 0.50- Kappa 0.47- Kappa 0.42- Kappa 95%C I 0.30-
95%CI 0.63 95%CI 0.61 95%CI 0.56 0.43 
>= 1 hospital OR at >=1 hospital OR >=1 hospital OR at >=1 hospital OR at least 
least 4 physician at least 5 least 6 physician 7 physician within first 
within first 1 year physician within within first 1 year 1 year 
first 1 year 
Sensitivity 40.7 Sensitivity 35.6 Sensitivity 28.5 Sensitivity 23.7 
Specific ity 95.7 Specificity 96.5 Specificity 97.3 Specific ity 98.4 
FP rate 4.3 FP rate 3.5 FP rate 2.7 FP rate 1.6 
FN rate 59.3 FN rate 64.4 FN rate 7 1.5 FN rate 76.3 
PPV 90.4 PPV 90.9 PPV 91.1 PPV 93.8 
NPV 62. 1 NPV 60.3 NPV 58.0 NPV 56.7 
Percent 68.4 Percent 66.3 Percent 63 . 1 Percent 61.4 
agreement agreement agreement agreement 
Kappa 0.366 Kappa 0.322 Kappa 0.259 Kappa 0.223 
Kappa 0.30- Kappa 0.26- Kappa 0.20- Kappa 95%CI 0 .17-
95%CJ 0.43 95%CI 0.39 95%CI 0.32 0.28 
>=1 hospital OR at >= I hospital OR >=I hospital OR at >= 1 hospital OR at least 
least 8 physician at least 3 least 4 physician 5 physician within first 
within first 1 year physician within within the first 2 2 years 
first 2 years years 
Sensitivity 21.3 Sensitivity 64.8 Sensitivity 51.8 Sensitivi ty 44.7 
Specificity 98.8 Specificity 94.6 Specificity 95.3 Specificity 96.1 
FP rate 1.2 FP rate 5.4 FP rate 4.7 FP rate 3.9 
FN rate 78.7 FN rate 35.2 FN rate 48.2 FN rate 55.3 
PPV 94.7 PPV 92.1 PPV 91.6 PPV 9 1.9 
NPV 56.1 NPV 73.2 NPV 66.8 NPV 63.8 
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Percent 60.4 Percent 79.8 Percent 73.7 Percent 70.6 
agreement agreement agreement agreement 
Kappa 0.203 Kappa 0.595 Kappa 0.473 Kappa 0.409 
Kappa 0.15- Kappa 0.53- Kappa 0.40- Kappa 95%Cl 0.34-
95%CI 0.26 95%CI 0.66 95%Cl 0.54 0.48 
>=1 hospital OR at >=1 hospital OR >=1 hospital OR at >=1 hospital OR at least 
least 6 physician at least 7 least 8 physician 4 physician within first 
within first 2 years physician within within first 2 years 3 years 
first 2 years 
Sensitivity 37.9 Sensitivity 34.4 Sensitivity 31.2 Sensitivity 58.1 
Specificity 96.5 Specificity 98.1 Specificity 98.1 Specificity 94.6 
FP rate 3.5 FP rate 1.9 FP rate 1.9 FP rate 5.4 
FN rate 62.1 FN rate 65.6 FN rate 68.8 FN rate 41.9 
ppy 91.4 PPV 94.6 PPV 94.0 PPV 91.3 
NPV 61.2 NPV 60.3 NPV 59.2 NPV 69.6 
Percent 67.5 Percent 66.5 Percent 64.9 Percent 76.5 
agreement agreement agreement agreement 
Kappa 0.346 Kappa 0.326 Kappa 0.294 Kappa 0.528 
Kappa 0.28- Kappa 0.26- Kappa 0.23- Kappa 95%CI 0.46-
95%CI 0.41 95%CI 0.39 95%CI 0.36 0.60 
>=1 hospital OR at >=1 hospital OR >=1 hospital OR at >=1 hospital OR at least 
least 5 physician at least 6 least 7 physician 8 physician within first 
within first 3 years physician within within first 3 years 3 years 
first 3 years 
Sensitivity 50.6 Sensitivity 44.3 Sensitivity 41.9 Sensitivity 39.1 
Specificity 95.7 Specificity 96.1 Specificity 97.3 Specificity 97.7 
FP rate 4.3 FP rate 3.9 FP rate 2.7 FP rate 2.3 
FN rate 49.4 FN rate 55.7 FN rate 58.1 FN rate 60.9 
ppy 92.1 ppy 91.8 PPV 93.8 PPV 94.3 
NPV 66.3 NPV 63.7 NPV 63.0 NPV 62.0 
Percent 73.3 Percent 70.4 Percent 69.8 Percent 68.6 
agreement agreement agreement agreement 
Kappa 0.465 Kappa 0.405 Kappa 0.393 Kappa 0.37 
Kappa 0.40- Kappa 0.34- Kappa 0.33- Kappa 95%C l 0.30-
95%CI 0.53 95%CI 0.47 95%CI 0.46 0.44 
>=1 hospital OR at >=1 hospital OR >=1 hospital OR at >=1 hospital OR at least 
least 4 physician at least 5 le~tst 6 physician 7 physician within first 
within first 4 years physician within within first 4 years 4 years 
first 4 years 
Sensitivity 62.5 Sensitivity 55.3 Sensitivity 47.8 Sensitivity 45.5 
Specificity 94.2 Specificity 95.7 Specificity 96.1 Specificity 97.3 
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FP rate 5.8 FP rate 4.3 FP rate 3.9 FP rate 2.7 
FN rate 37.5 FN rate 44.7 FN rate 52.2 FN rate 54.5 
PPV 91.3 ppy 92.7 ppy 92.4 ppy 94.3 
NPV 71.8 NPV 68.5 NPV 65.2 NPV 64.4 
Percent 78.4 Percent 75.7 Percent 72.2 Percent 7 1.6 
agreement agreement agreement agreement 
Kappa 0.568 Kappa 0.51 2 Kappa 0.441 Kappa 0.429 
Kappa 0.50- Kappa 0.44- Kappa 0.37- Kappa 9S%Cl 0.36-
95%CI 0.64 95%CI 0.58 95%CI 0.51 0.50 
>=1 hospital OR at (>=1 hos~ital OR (>=1 hospital OR (>= 1 hospita l OR >=1 
least 8 physician >=1 PSY) AND >=1 PSY) AND at PSY) AND at least 3 GP 
within first 4 years at least 1 GP6 least 2 GP visit for visit for 311 over 12 
visit for 311 over 311 over 12 years years 
12 years 
Sensitivity 40.3 Sensitivity 14.2 Sens itivity 14.2 Sensitivity 14.2 
Specific ity 97.3 Specificity 99.2 Specific ity 99.2 Specifi city 99.2 
FP rate 2.7 FP rate 0.8 FP rate 0.8 FP rate 0.8 
FN rate 59.7 FN rate 85.8 FN rate 85.8 FN rate 85 .8 
PPV 93 .6 PPV 94.7 ppy 94.7 ppy 94.7 
NPV 62.3 NPV 54.0 NPV 54.0 NPV 54.0 
Percent 69.0 Percent 57. 1 Percent 57.1 Percent 57.1 
agreement agreement agreement agreement 
Kappa 0.378 Kappa 0.135 Kappa 0. 135 Kappa 0.1 35 
Kappa 0.3 1- Kappa 0.09- Kappa 0.09- Kappa 95%C I 0.09-
95%CI 0.44 95%CI 0.1 8 95%CI 0. 18 0. 18 
(>=1 hospital OR (>=1 hospital OR (>=1 hospital OR (>=1 hospital OR >= 1 
>=1 PSY) AND at >=1 PSY) AND a t >=1 PSY) AND at PSY) AND at least 7 GP 
least 4 GP visit for least 5 GP visit least 6 GP visit for visit for 311 over 12 
311 over 12 years for 311 over 12 311 over 12 years years 
years 
Sensitivity 14.2 Sensitivity 14.2 Sensitivity 14.2 Sensitiv ity 14.2 
Specificity 99.2 Specificity 99.2 Specificity 99.2 Specifi c ity 99.2 
FP rate 0.8 FP rate 0.8 FP rate 0.8 FP rate 0.8 
FN rate 85.8 FN rate 85 .8 FN rate 85.8 FN rate 85.8 
PPV 94.7 ppy 94.7 PPV 94.7 PPY 94.7 
NPV 54.0 NPV 54.0 NPV 54.0 NPV 54.0 
Percent 57.1 Percent 57.1 Percent 57.1 Percent 57.1 
agreement agreement agreement agreement 
Kappa 0.135 Kappa 0.135 Kappa 0. 135 Kappa 0.135 
Kappa 0.09- Kappa 0.09- Kappa 0.09- Kappa 95%C1 0.09-
95%CI 0.18 95%CI 0.18 95%CI 0.18 0.18 
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(>=1 hospital OR (>=1 hospital OR (>=1 hospital OR (>=1 hospital OR >=1 
>=1 PSY) AND at >=1 PSY) AND at >=1 PSY) AND at PSY) AND at least 3 GP 
least 8 GP visit for least 1 GP visit least 2 GP visit for visit for 311 within first 
311 over 12 years for 311 within 311 within first 1 1 year 
first 1 year year 
Sensitivity 14.2 Sensitivity 23.3 Sensitivity 19.8 Sensitivity 17.4 
Specificity 99.2 Specificity 98.1 Specificity 98.8 Specificity 98.8 
FP rate 0.8 FP rate 1.9 FP rate 1.2 FP rate 1.2 
FN rate 85.8 FN rate 76.7 FN rate 80.2 FN rate 82.6 
PPV 94.7 PPV 92.2 PPV 94.3 PPV 93.6 
NPV 54.0 NPV 56.5 NPV 55.6 NPV 54.9 
Percent 57.1 Percent 61.0 Percent 59.6 Percent 58.4 
agreement agreement agreement agreement 
Kappa 0.135 Kappa 0.215 Kappa 0.187 Kappa 0.163 
Kappa 0.09- Kappa 0.16- Kappa 0.13- Kappa 95%C1 0.11-
95%CI 0.18 95%CI 0.27 95%CI 0.24 0.2 1 
(>=1 hospital OR (>=1 hospital OR (>=1 hospital OR (>=1 hospital OR >=1 
>=1 PSY) AND at >=1 PSY) AND at >=1 PSY) AND at PSY) AND at least 7 GP 
least 4 GP visit for least 5 GP visit least 6 GP visit for visit for 311 within first 
311 within first 1 for 311 within 311 within first 1 1 year 
year first 1 year year 
Sensitivity 15.8 Sensitivity 15.0 Sens itivity 14.6 Sensitivity 14.2 
Specificity 98.8 Specificity 99.2 Specificity 99.2 Specificity 99.2 
FP rate 1.2 FP rate 0.8 FP rate 0.8 FP rate 0.8 
FN rate 84.2 FN rate 85.0 FN rate 85.4 FN rate 85.8 
PPV 93.0 PPV 95.0 PPV 94.9 PPV 94.7 
NPV 54.4 NPV 54.3 NPV 54.1 NPV 54.0 
Percent 57.6 Percent 57.5 Percent 57.3 Percent 57. 1 
agreement agreement agreement agreement 
Kappa 0.147 Kappa 0.143 Kappa 0.139 Kappa 0.135 
Kappa 0.10- Kappa 0.10- Kappa 0.09- Kappa 95%Cl 0.09-
95%Cl 0.20 95%Cl 0.19 95%CI 0.19 0.18 
(>=1 hospital OR (>=1 hospital OR (>=1 hospital OR (>=1 hospital OR >=1 
>=1 PSY) AND at >=1 PSY) AND at >=1 PSY) AND at PSY) AND at least 3 GP 
least 8 GP visit for least 1 GP visit least 2 GP visit for visit for 311 within first 
311 within first 1 for 311 within 311 within first 2 2 years 
year first 2 years years 
Sensitivity 14.2 Sensitivity 23 .3 Sensitivity 21.3 Sensitivity 18.6 
Specificity 99.2 Specificity 98.1 Specificity 98.4 Specificity 98.8 
FP rate 0.8 FP rate 1.9 FP rate 1.6 FP rate 1.2 
FN rate 85.8 FN rate 76.7 FN rate 78.7 FN rate 81 .4 
PPV 94.7 ppy 92.2 ppy 93.1 ppy 94.0 
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NPV 54.0 NPV 56.5 NPV 56.0 NPV 55.2 
Percent 57.1 Percent 61.0 Percent 60.2 Percent 59.0 
agreement agreement agreement agreement 
Kappa 0.135 Kappa 0.215 Kappa 0.199 Kappa 0.1 75 
Kappa 0.09- Kappa 0. 16- Kappa 0.14- Kappa 95%CI 0.1 2-
95%CI 0.18 95%CI 0.27 95%CI 0.25 0.23 
(>=1 hospital OR (>=1 hospital OR (>=1 hospital OR (>=1 hospital OR >=1 
>=1 PSY) AND at >=1 PSY) AND at >=1 PSY) AND at PSY) AND at least 7 GP 
least 4 GP visit for least 5 GP visit least 6 GP visit for visit for 311 within first 
311 within first 2 for 311 within 311 within first 2 2 years 
years first 2 years years 
Sensitivity 17.0 Sensitivity 15.4 Sensitivity 14.6 Sensitivity 14.2 
Specificity 98.8 Specificity 98.8 Specificity 99.2 Specificity 99.2 
FP rate 1.2 FP rate 1.2 FP rate 0.8 FP rate 0.8 
FN rate 83.0 FN rate 84.6 FN rate 85.4 FN rate 85.8 
ppy 93.5 ppy 92.9 ppy 94.9 PPV 94.7 
NPV 54.7 NPV 54.3 NPV 54.1 NPV 54.0 
Percent 58.2 Percent 57.5 Percent 57.3 Percent 57.1 
agreement agreement agreement agreement 
Kappa 0.159 Kappa 0.143 Kappa 0.139 Kappa 0. 135 
Kappa 0.11- Kappa 0.10- Kappa 0.09- Kappa 95%Cl 0.09-
95%CI 0.21 95%CI 0.19 95%Cl 0.19 0.18 
(>=1 hospital OR (>=1 hospital OR (>= l hospital OR (>=1 hospital OR >=l 
>=1 PSY) AND at >=1 PSY) AND at >=1 PSY) AND at PSY) AND at least 3 GP 
least 8 GP visit for least 1 GP visit least 2 GP visit for visit for 311 within first 
311 within first 2 for 311 within 311 within first 3 3 years 
years first 3 years years 
Sensitivity 14.2 Sensitivity 22.9 Sensitivity 22.9 Sensitivity 20.6 
Specificity 99.2 Specificity 98.4 Specificity 98.4 Specificity 98.8 
FP rate 0.8 FP rate 1.6 FP rate 1.6 FP rate 1.2 
FN rate 85.8 FN rate 77.1 FN rate 77.1 FN rate 79.4 
PPV 94.7 PPY 93.5 ppy 93.5 ppy 94.5 
NPV 54.0 NPV 56.5 NPV 56.5 NPV 55.8 
Percent 57.1 Percent 61.0 Percent 61.0 Percent 60.0 
agreement agreement agreement agreement 
Kappa 0.135 Kappa 0.2 15 Kappa 0.215 Kappa 0.195 
Kappa 0.09- Kappa 0.16- Kappa 0.16- Kappa 95%CI 0.14-
95%CI 0.18 95%CI 0.27 95%CI 0.27 0.25 
(>=1 hospital OR (>=1 hospital OR (>=1 hospital OR (>=1 hospital OR >=1 
>=1 PSY) AND at >=1 PSY) AND at >=1 PSY) AND at PSY) AND at least 7 GP 
least 4 GP visit for least 5 GP visit least 6 GP visit for visit for 311 within first 
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311 within first 3 for 311 within 311 within first 3 3 yea rs 
years first 3 years years 
Sensitivity 17.0 Sensitivity 15.4 Sensitivity 14.6 Sensitivity 14.2 
Specificity 98.8 Specificity 98.8 Specificity 99.2 Specificity 99.2 
FP rate 1.2 FP rate 1.2 FP rate 0.8 FP rate 0.8 
FN rate 83.0 FN rate 84.6 FN rate 85.4 FN rate 85.8 
PPV 93.5 PPV 92.9 PPV 94.9 PPV 94.7 
NPV 54.7 NPV 54.3 NPV 54.1 NPV 54.0 
Percent 58.2 Percent 57.5 Percent 57.3 Percent 57. I 
agreement agreement agreement agreement 
Kappa 0.159 Kappa 0.143 Kappa 0.139 Kappa 0.135 
Kappa 0.11- Kappa 0.10- Kappa 0.09- Kappa 95%CI 0.09-
95%CI 0.21 95%CI 0.19 95%CI 0.19 0.18 
(>=1 hospital OR (>=1 hospital OR (>=1 hospital OR (>=1 hospital OR >=1 
>=1 PSY) AND at >=1 PSY) AND at >=1 PSY) AND at PSY) AND at least 3 GP 
least 8 GP visit for least 1 GP visit least 2 GP visit for visit for 311 within first 
311 within first 3 for 311 within 311 within first 4 4 years 
years first 4 years years 
Sensitivity 14.2 Sensitivity 26.1 Sensitivity 23.7 Sensitivity 21.7 
Specificity 99.2 Specificity 98.1 Specificity 98.4 Specificity 98.8 
FP rate 0.8 FP rate 1.9 FP rate 1.6 FP rate 1.2 
FN rate 85.8 FN rate 73 .9 FN rate 76.3 FN rate 78.3 
PPV 94.7 PPV 93.0 PPV 93.8 PPV 94.8 
NPV 54.0 NPV 57.4 NPV 56.7 NPV 56.2 
Percent 57.1 Percent 62.4 Percent 61.4 Percent 60.6 
agreement agreement agreement agreement 
Kappa 0.135 Kappa 0.243 Kappa 0.223 Kappa 0.207 
Kappa 0.09- Kappa 0.18- Kappa 0.17- Kappa95%CI 0.15-
95%CI 0.18 95%CI 0.30 95%CI 0.28 0.26 
(>=1 hospital OR (>=1 hospital OR (>=1 hospital OR (>=1 hospital OR >=1 
>=1 PSY) AND at >=1 PSY) AND at >=1 PSY) AND at PSY) AND at least 7 GP 
least 4 GP visit for least 5 GP visit least 6 GP visit for visit for 311 within first 
311 within first 4 for 311 within 311 within first 4 4 years 
years first 4 years years 
Sensitivity 18.6 Sensitivity 18.2 Sensitivity 16.2 Sensitivity 14.2 
Specificity 98.8 Specificity 98.8 Specificity 99.2 Specificity 99.2 
FP rate 1.2 FP rate 1.2 FP rate 0.8 FP rate 0.8 
FN rate 81.4 FN rate 81.8 FN rate 83.8 FN rate 85.8 
PPV 94.0 PPV 93.9 PPV 95.3 PPV 94.7 
NPV 55.2 NPV 55. 1 NPV 54.6 NPV 54.0 
Percent 59.0 Percent 58.8 Percent 58.0 Percent 57. I 
agreement agreement agreement agreement 
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Kappa 0.175 Kappa 0. 171 Kappa 0.155 Kappa 0.135 
Kappa 0.12- Kappa 0.1 2- Kappa 0.11- Kappa 95%CI 0.09-
95%CI 0.23 95%CI 0.22 95%CI 0.20 0. 18 
(>=1 hospital OR (>=1 hospital OR (>= 1 hospital OR {>=1 hospital OR >=1 
>=1 PSY) AND at >=1 PSY) OR at >=1 PSY) OR at PSY) OR at least 3 GP 
least 8 GP visit for least 1 GP visit least 2 GP visit for visit for 311 over 12 
311 within first 4 for 311 over 12 311 over 12 years years 
years years 
Sensitivity 14.2 Sensitivity 29.6 Sensitivity 29.6 Sensitivity 29.6 
Specificity 99.2 Specificity 96.5 Specificity 96.5 Specificity 96.5 
FP rate 0.8 FP rate 3.5 FP rate 3.5 FP rate 3.5 
FN rate 85.8 FN rate 70.4 FN rate 70.4 FN rate 70.4 
ppy 94.7 ppy 89.3 ppy 89.3 PPV 89.3 
NPV 54.0 NPV 58.2 NPV 58.2 NPV 58.2 
Percent 57.1 Percent 63.3 Percent 63.3 Percent 63.3 
agreement agreement agreement agreement 
Kappa 0.135 Kappa 0.263 Kappa 0.263 Kappa 0.263 
Kappa 0.09- Kappa 0.20- Kappa 0.20- Kappa 95%CI 0.20-
95%Cl 0.18 95%CI 0.33 95%Cl 0.33 0.33 
(>=1 hospital OR (>=1 hospital OR (>=1 hospital OR (>=1 hospital OR >=1 
>=1 PSY) OR at >=1 PSY) OR at >=1 PSY) OR at PSY) OR at least 7 GP 
least 4 GP visit for least 5 GP visit least 6 GP visit for visit for 311 over 12 
311 over 12 yea rs for 311 over 12 311 over 12 yea rs yea rs 
years 
Sensitivity 29.6 Sensitivity 29.6 Sensitivity 29.6 Sensitivity 29.6 
Specificity 96.5 Specificity 96.5 Specific ity 96.5 Specificity 96.5 
FP rate 3.5 FP rate 3.5 FP rate 3.5 FP rate 3.5 
FN rate 70.4 FN rate 70.4 FN rate 70.4 FN rate 70.4 
PPV 89.3 PPV 89.3 PPV 89.3 PPV 89.3 
NPV 58.2 NPY 58.2 NPY 58.2 NPV 58.2 
Percent 63.3 Percent 63.3 Percent 63.3 Percent 63.3 
agreement agreement agreement agreement 
Kappa 0.263 Kappa 0.263 Kappa 0.263 Kappa 0.263 
Kappa 0.20- Kappa 0.20- Kappa 0.20- Kappa 95%Cl 0.20-
95%CI 0.33 95%CI 0.33 95%CI 0.33 0.33 
{>=1 hospital OR (>=1 hospital OR {>=1 hospital OR (>= l hospital OR >=1 
>=1 PSY) OR at >=1 PSY) OR at >=1 PSY) OR at PSY) OR at least 5 GP 
least 8 GP visit for least 3 GP visits least 4 GP visits for visits for 311 within 
311 over 12 years for 311 within 311 within first 1 first 1 year 
first 1 year year 
Sensitivity 29.6 Sensitivity 57.7 Sensitivity 48.6 Sensitivity 45 .1 
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---------- ---------- - - --------
Specificity 96.5 Specificity 94.2 Specificity 94.6 Specificity 95.7 
FP rate 3.5 FP rate 5.8 FP rate 5.4 FP rate 4.3 
FN rate 70.4 FN rate 42.3 FN rate 51.4 FN rate 54.9 
PPV 89.3 PPV 90.7 PPV 89.8 PPV 91.2 
NPV 58.2 NPV 69.3 NPV 65.1 NPV 63.9 
Percent 63.3 Percent 76.1 Percent 71.8 Percent 70.6 
agreement agreement agreement agreement 
Kappa 0.263 Kappa 0.520 Kappa 0.433 Kappa 0.409 
Kappa 0.20- Kappa 0.45- Kappa 0.36- Kappa 95%C1 0.34-
95%CI 0.33 95%CI 0.59 95%CI 0.50 0.48 
(>=1 hospital OR (>=1 hospital OR (>=1 hospital OR (>=1 hospital OR >=1 
>=1 PSY) OR at >=1 PSY) OR at >=1 PSY) OR at PSY) OR at least 4 GP 
least 6 GP visits least 7 GP visits least 8 GP visits for visit for 311 within first 
for 311 within first for 311 within 311 within first 1 2 years 
1 year first 1 years years 
Sensitivity 39.9 Sensitivity 37.2 Sensitivity 35.2 Sensitivity 56.5 
Specificity 95.7 Specificity 96.1 Specificity 96.5 Specificity 94.6 
FP rate 4.3 FP rate 3.9 FP rate 3.5 FP rate 5.4 
FN rate 60.1 FN rate 62.8 FN rate 64.8 FN rate 43.5 
PPV 90.2 PPV 90.4 PPV 90.8 PPV 91.1 
NPV 61.8 NPV 60.8 NPV 60.2 NPV 68.8 
Percent 68.0 Percent 66.9 Percent 66.1 Percent 75.7 
agreement agreement agreement agreement 
Kappa 0.358 Kappa 0.334 Kappa 0.318 Kappa 0.512 
Kappa 0.29- Kappa 0.27- Kappa 0.25- Kappa 95%Cl 0.44-
95%Cl 0.43 95%CI 0.40 95%CI 0.38 0.58 
(>=1 hospital OR (>=1 hospital OR (>=1 hospital OR (>=1 hospital OR >=1 
>=1 PSY) OR at >=1 PSY) OR at >=1 PSY) OR at PSY) OR at least 8 GP 
least 5 GP visit for least 6 GP visit least 7 GP visit for visit for 311 within first 
311 within first 2 for 311 within 311 within first 2 2 years 
years first 2 years years 
Sensitivity 50.2 Sensitivity 45.8 Sensitivity 43 .1 Sensitivity 40.7 
Specificity 95.7 Specificity 95.7 Specificity 96.1 Specificity 96.1 
FP rate 4.3 FP rate 4.3 FP rate 3.9 FP rate 3.9 
FN rate 49.8 FN rate 54.2 FN rate 56.9 FN rate 59.3 
PPV 92.0 PPV 91.3 PPV 91.6 PPV 91.2 
NPV 66.1 NPV 64.2 NPV 63.2 NPV 62.2 
Percent 73.1 Percent 71.0 Percent 69.8 Percent 68.6 
agreement agreement agreement agreement 
Kappa 0.461 Kappa 0.417 Kappa 0.394 Kappa 0.370 
Kappa 0.39- Kappa 0.35- Kappa 0.33- Kappa 95%Cl 0.30-
95%CI 0.53 95%CI 0.49 95%CI 0.46 0.44 
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(>= 1 hospital OR (>= 1 hospital OR (>= 1 hospital OR (>= 1 hospital OR >=1 
>=1 PSY) OR at >=1 PSY) OR at >=1 PSY) OR at PSY) OR at least 7 GP 
least 4 GP visit for least 5 GP visit least 6 GP visit for visit for 311 within first 
311 within first 3 for 311 within 311 within first 3 3 years 
years first 3 years years 
Sensitivity 61.3 Sensitivity 53.8 Sensitivity 49.0 Sensitivity 47.0 
Specificity 93.8 Specificity 95.3 Specificity 95.3 Specificity 95.7 
FP rate 6.2 FP rate 4.7 FP rate 4.7 FP rate 4.3 
FN rate 38.7 FN rate 46.2 FN rate 51.0 FN rate 53.0 
PPV 90.6 PPV 91.9 PPV 91.2 PPV 91.5 
NPV4 71.1 NPV 67.7 NPV 65.5 NPV 64.7 
Percent 77.6 Percent 74.7 Percent 72.4 Percent 71.6 
agreement agreement agreement agreement 
Kappa 0.552 Kappa 0.492 Kappa 0.445 Kappa 0.429 
Kappa 0.48- Kappa 0.42- Kappa 0.38- Kappa 95%Cl 0.36-
95%CI 0.62 95%CI 0.56 95%CI 0.51 0.50 
(>= 1 hospital OR (>=1 hospital OR (>=1 hospital OR (>=1 hospital OR >=1 
>=1 PSY) OR at >=1 PSY) OR at >=1 PSY) OR at PSY) OR at least 6 GP 
least 8 GP visit for least 4 GP visit least 5 GP visit for visit for 311 within first 
311 within first 3 for 311 within 311 within first 4 4 years 
years first 4 years years 
Sensitivity 44.7 Sensitivity 64.4 Sensitivity 57.3 Sensitivity 51.0 
Specificity 96.1 Specificity 93.4 Specificity 95.3 Specificity 95.3 
FP rate 3.9 FP rate 6.6 FP rate 4.7 FP rate 4.7 
FN rate 55.3 FN rate 35.6 FN rate 42.7 FN rate 49.0 
PPV 91.9 PPV 90.6 PPV 92.4 PPV 91.5 
NPV 63.8 NPV 72.7 NPV 69.4 NPV 66.4 
Percent 70.6 Percent 79.0 Percent 76.5 Percent 73.3 
agreement agreement agreement agreement 
Kappa 0.409 Kappa 0.579 Kappa 0.528 Kappa 0.465 
Kappa 0.34- Kappa 0.51- Kappa 0.46- Kappa 95%Cl 0.40-
95%CI 0.48 95%Cl 0.65 95%CI 0.60 0.53 
(>=1 hospital OR (>=1 hospital OR 
>=1 PSY) OR at >=1 PSY) OR at 
least 7 GP visit for least 8 GP visit 
311 within first 4 for 311 within 
years first 4 years 
Sensitivity 48.6 Sensitivity 45.5 
Specificity 95.7 Specificity 95.7 
FP rate 4.3 FP rate 4.3 
FN rate 51.4 FN rate 54.5 
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PPV 91.8 PPV 
NPV 65.4 NPV 
Percent 72.4 Percent 
agreement agreement 
Kappa 0.445 Kappa 
Kappa 0.38- Kappa 
95%CI 0.51 95%CI 
I .. False postttve rate 
2 False negative rate 
3 Positive predictive value 
4 Negative predictive value 
5 Psychiatrist visit 
6 General practitioner visit 
91.3 
64.1 
70.8 
0.413 
0.34-
0.48 
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Appendix F: 26 selected cases with the addition of anti-depressant medication 
information (either as 'AND' or 'OR') with their binary classification tests 
>= 1 hospital OR >= 1 hospital OR >= 1 hospital OR >= 1 hospital OR 
At least 1 At least 2 At least 3 At least 4 
physician AND physician AND physician AND physician AND 
Anti-depressant Anti-depressant Anti-depressant Anti-depressant 
meds over 12 meds over 12 meds over 12 meds over 12 
years years years vears 
Sensitivity 80.6 Sensitivity 73.9 Sensitivity 68.4 Sensitivity 61.3 
Specificity 100.0 Specificity 100.0 Specificity 100.0 Specificity 100.0 
FP 1 rate 0.0 FP rate 0.0 FP rate 0.0 FP rate 0.0 
FNL rate 19.4 FN rate 26.1 FN rate 31.6 FN rate 38.7 
ppyJ 100.0 ppy 100.0 ppy 100.0 ppy 100.0 
NPY4 84.0 NPV 79.6 NPV 76.3 NPV 72.4 
Percent 90.4 Percent 87.1 Percent 84.3 Percent 80.8 
agreement agreement agreement agreement 
Kappa 0.808 Kappa 0.741 Kappa 0.685 Kappa 0.615 
Kappa 0.76- Kappa 0.68- Kappa 0.63- Kappa 0.55-
95%CI 86 95%CI 0.80 95%CI 0.75 95%CI 0.68 
>= 1 hospital OR >= 1 hospital OR >= 1 hospital OR >= 1 hospital OR 
At least 5 At least 1 At least 2 At least 1 
physician AND physician AND physician AND physician AND 
Anti-depressant Anti-depressant Anti-depressant Anti-depressant 
meds over 12 meds within first meds within first meds AND Anti-
years 1 year 1 year depressant meds 
within first 2 
years 
Sensitivity 57.7 Sensitivity 80.6 Sensitivity 62.1 Sensitivity 80.6 
Specificity 100.0 Specificity 100.0 Specificity 100.0 Specificity 100.0 
FP rate 0.0 FP rate 0.0 FP rate 0.0 FP rate 0.0 
FN rate 42.3 FN rate 19.4 FN rate 37.9 FN rate 19.4 
ppy 100.0 ppy 100.0 ppy 100.0 PPV 100.0 
NPV 70.6 NPV 84.0 NPV 72.8 NPV 84.0 
Percent 79.0 Percent 90.4 Percent 81.2 Percent 90.4 
agreement agreement agreement agreement 
Kappa 0.579 Kappa 0.808 Kappa 0.622 Kappa 0.808 
Kappa 0.51- Kappa 0.76- Kappa 0.56- Kappa 0.76-
95%CI 0.64 95%CI 0.86 95%CI 0.69 95%CI 0.86 
>= 1 hospital OR >= 1 hospital OR >= 1 hospital OR >= 1 hospital OR 
At least 2 At least 1 At least 2 At least 3 
physician AND physician AND physician AND physician AND 
Anti-depressant Anti-depressant Anti-depressant Anti-depressant 
meds AND Anti- meds AND Anti- meds AND Anti- meds AND Anti-
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depressant meds depressant meds depressant meds depressant meds 
within first 2 within first 3 within first 3 within first 3 
years years years years 
Sensitivity 66.8 Sensitivity 80.6 Sensitivity 69.2 Sensitivity 59.7 
Specificity 100.0 Specificity 100.0 Specificity 100.0 Specificity 100.0 
FP rate 0.0 FP rate 0.0 FP rate 0.0 FP rate 0.0 
FN rate 33.2 FN rate 19.4 FN rate 30.8 FN rate 40.3 
ppy 100.0 PPV 100.0 ppy 100.0 ppy 100.0 
NPV 75.4 NPV 84.0 NPV 76.7 NPV 71.6 
Percent 83.5 Percent 90.4 Percent 84.7 Percent 80.0 
agreement agreement agreement agreement 
Kappa 0.670 Kappa 0.808 Kappa 0.693 Kappa 0.599 
Kappa 0.61- Kappa 0.76- Kappa 0.63- Kappa 0.53-
95%C1 0.73 95%CI 0.86 95%CI 0.75 95%CI 0.66 
>= 1 hospital OR >= 1 hospital OR >= 1 hospital OR (>= 1 hospital OR 
At least I At least 2 At least 3 >= 1 PSY) OR at 
physician AND physician AND physician AND least I GP visit for 
Anti-depressant Anti-depressant Anti-depressant 311 AND Anti-
meds AND Anti- meds AND Anti- meds AND Anti- depressant meds 
depressant meds depressant meds depressant meds within first 1 year 
within first 4 within first 4 within first 4 
years years _years 
Sens i ti vi ty 80.6 Sensitivity 71.9 Sensitivity 62.8 Sensitivity 80.6 
Specificity 100.0 Specificity 100.0 Specificity 100.0 Specificity 100.0 
FP rate 0.0 FP rate 0.0 FP rate 0.0 FP rate 0.0 
FN rate 19.4 FN rate 28.1 FN rate 37.2 FN rate 19.4 
ppy 100.0 ppy 100.0 ppy 100.0 ppy 100.0 
NPV 84.0 NPV 78.4 NPV 73.2 NPV 84.0 
Percent 90.4 Percent 86.1 Percent 81.6 Percent 90.4 
agreement agreement agreement agreement 
Kappa 0.808 Kappa 0.721 Kappa 0.630 Kappa 0.808 
Kappa 0.76- Kappa 0.66- Kappa 0.57- Kappa 0.76-
95%CI 0.86 95%CI 0.78 95%CJ 0.69 95%CI 0.86 
(>= 1 hospital OR (>= 1 hospital OR (>= I hospital OR (>= I hospital OR 
>= 1 PSY) OR at >= 1 PSY) OR at >= 1 PSY) OR at >= I PSY) OR at 
least 2 GP visit least I GP visit least 2 G P visit least 3 GP visit for 
for 311 AND for 311 AND for 311 AND 311 AND Anti-
Anti-depressant Anti-depressant Anti-depressant depressant meds 
meds within first meds within first meds within first within first 2 
1 year 2 years 2 years years 
Sensitivity 64.8 Sensitivity 80.6 Sensitivity 68.8 Sens itivity 59.3 
Specificity 100.0 Specificity 100.0 Specificity 100.0 Specificity 100.0 
FP rate 0.0 FP rate 0.0 FP rate 0.0 FP rate 0.0 
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FN rate 35.2 FN rate 19.4 FN rate 31.2 FN rate 40.7 
PPV 100.0 ppy 100.0 PPV 100.0 PPV 100.0 
NPV 74.3 NPV 84.0 NPV 76.5 NPV 7 1.4 
Percent 82.5 Percent 90.4 Percent 84.5 Percent 79.8 
agreement agreement agreement agreement 
Kappa 0.650 Kappa 0.808 Kappa 0.689 Kappa 0.595 
Kappa 0.59- Kappa 0.76- Kappa 0.63- Kappa 0.53-
95%Cl 0.71 95%Cl 0.86 95%CI 0.75 95%C l 0.66 
(>= 1 hospital OR (>= 1 hospital OR (>= 1 hospital OR (>= l hospital OR 
>= 1 PSY) OR at >= 1 PSY) OR at >= 1 PSY) OR at >= 1 PSY) OR at 
least 1 GP visit least 2 GP visit least 3 GP visit least 1 GP visit for 
for 311 AND for 311 AND for 311 AND 311 AND Anti-
Anti-depressant Anti-depressant Anti-depressant depressant meds 
meds within first meds within first meds within first within first 4 
3 years 3 years 3 years years 
Sensitivity 70.4 Sensitivity 70.4 Sensitivity 61.3 Sensitivity 80.6 
Specific ity 100.0 Specificity 100.0 Specifici ty 100.0 Specific ity 100.0 
FP rate 0.0 FP rate 0.0 FP rate 0.0 FP rate 0.0 
FN rate 29.6 FN rate 29.6 FN rate 38.7 FN rate 19.4 
ppy 100.0 PPV 100.0 ppy 100.0 PPV 100.0 
NPV 77.4 NPV 77.4 NPV 72.4 NPV 84.0 
Percent 85.3 Percent 85.3 Percent 80.8 Percent 90.4 
ag reement agreement agreement agreement 
Kappa 0.705 Kappa 0.705 Kappa 0.6 15 Kappa 0.808 
Kappa 0.65- Kappa 0.65- Kappa 0.55- Kappa 0.76-
95%CI 0.76 95%CI 0.76 95%CI 0.68 95%Cl 0.86 
(>= l hospital OR (>= 1 hospita l OR 
>= 1 PSY) OR at >= 1 PSY) OR at 
least 2 GP visit least 3 GP visit 
for 311 AND for 311 AND 
Anti-depressant Anti-depressant 
meds within first meds within first 
4 years 4 years 
Sensitivity 72.7 Sensitivity 64.4 
Specific ity 100.0 Specificity 100.0 
FP rate 0.0 FP rate 0.0 
FN rate 27.3 FN rate 35.6 
PPV 100.0 PPV 100.0 
NPV 78.8 NPV 74.1 
Percent 86.5 Percent 82.4 
agreement agreement 
Kappa 0.729 Kappa 0.646 
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Kappa 
95%CI 
>= 1 hospital OR 
At least 1 
physician OR 
Anti-depressant 
meds over 12 
years 
Sensitivity 99.2 
Specificity 81.3 
FP 1 rate 18.7 
FNL rate 0.8 
ppyJ 83.9 
NPYq 99.1 
Percent 90.2 
agreement 
Kappa .804 
Kappa 0.75-
95%CI 0.85 
>= 1 hospital OR 
At least 5 
physician OR 
Anti-depressant 
meds over 12 
years 
Sensitivity 98.4 
Specificity 93.8 
FP rate 6.2 
FN rate 1.6 
ppy 94.0 
NPY 98.4 
Percent 96.1 
agreement 
Kappa 0.922 
Kappa 0.89-
95%CI 0.96 
>= 1 hospital OR 
At least 2 
physician AND 
Anti-depressant 
Kappa 
95%CI 
>= 1 hospital OR 
At least 2 
physician OR 
Anti-depressant 
meds over 12 
years 
Sensitivity 99.2 
Specificity 90.3 
FP rate 9.7 
FN rate 0.8 
PPY 90.9 
NPY 99.1 
Percent 94.7 
agreement 
Kappa 0.894 
Kappa 0.86-
95%CI 0.93 
>= 1 hospital OR 
At least 1 
physician OR 
Anti-depressant 
meds within first 1 
year 
Sensitivity 100.0 
Specificity 81.5 
FP rate 18.5 
FN rate 0.0 
PPV 83.9 
NPY 100.0 
Percent 90.6 
agreement 
Kappa 0.81 2 
Kappa 0.76-
95%CI 0.86 
>= 1 hospital OR 
At least 1 
physician AND 
Anti-depressant 
>= 1 hospital OR 
At least 3 
physician OR 
Anti-depressant 
meds over 12 
years 
Sensitivity 99.2 
Specificity 91.8 
FP rate 8.2 
FN rate 0.8 
PPY 92.3 
NPY 99.2 
Percent 95.5 
agreement 
Kappa 0.910 
Kappa 0.87-
95%CI 0.95 
>= 1 hospital OR 
At least 2 
physician OR 
Anti-depressant 
meds within first 
1 year 
Sensitivity 100.0 
Specificity 92.7 
FP rate 7.3 
FN rate 0.0 
ppy 92.9 
NPY 100.0 
Percent 96.3 
agreement 
Kappa 0.926 
Kappa 0.89-
95%CI 0.96 
>= 1 hospital OR 
At least 2 
physician AND 
Anti-depressant 
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>= 1 hospital OR 
At least 4 
physician OR 
Anti-depressant 
meds over 12 
years 
Sensitivity 98.8 
Specificity 92.6 
FP rate 7.4 
FN rate 1.2 
ppy 92.9 
NPY 98.8 
Percent 95.7 
agreement 
Kappa 0.914 
Kappa 0.88-
95%CI 0.95 
>= 1 hospital OR 
At least 1 
physician AND 
Anti-depressant 
meds OR Anti-
depressant meds 
within first 2 
years 
Sensitivity 100.0 
Specificity 81.5 
FP rate 18.5 
FN rate 0.0 
PPY 83.9 
NPY 100.0 
Percent 90.6 
agreement 
Kappa 0.812 
Kappa 0.76-
95%CI 0.86 
>= 1 hospital OR 
At least 3 
physician AND 
Anti-depressant 
meds OR Anti- meds OR Anti- meds OR Anti- meds OR Anti-
depressant meds depressant meds depressant meds depressant meds 
within first 2 within first 3 years within first 3 within first 3 
years years years 
Sensitivity 100.0 Sensitivity 100.0 Sensitivity 100.0 Sensitivity 100.0 
Specificity 91.9 Specificity 81.5 Specifici ty 91.5 Specificity 93. 1 
FP rate 8.1 FP rate 18.5 FP rate 8.5 FP rate 6 .9 
FN rate 0.0 FN rate 0.0 FN rate 0.0 FN rate 0.0 
ppy 92.3 ppy 83.9 PPV 9 1.9 PPV 93.3 
NPV 100.0 NPV 100.0 NPV 100.0 NPV 100.0 
Percent 95.9 Percent 90.6 Percent 95.7 Percent 96.5 
agreement agreement agreement agreement 
Kappa 0.918 Kappa 0.812 Kappa 0.914 Kappa 0.929 
Kappa 0.88- Kappa 0.76- Kappa 0.88- Kappa 0.90-
95%CI 0.95 95%CI 0.86 95%CI 0.95 95%CI 0.96 
>= I hospital OR >= 1 hospital OR >= I hospital OR (>= I hospita l OR 
At least 1 At least 2 At least 3 >= I PSY) OR at 
physician AND physician AND physician AND least 1 GP visit 
Anti-depressant Anti-depressant Anti-depressant for 311 OR Anti-
meds OR Anti- meds OR Anti- meds OR Anti- depressant meds 
depressant meds depressant meds depressant meds within first 1 
within first 4 within first 4 years within first 4 year 
years years 
Sensitivity 100.0 Sensitivity 100.0 Sensitivity 100.0 Sensitivity 100.0 
Specificity 81.5 Specificity 90.3 Specific ity 92.3 Spec ific ity 8 1.5 
FP rate 18.5 FP rate 9.7 FP rate 7.7 FP rate 18.5 
FN rate 0.0 FN rate 0.0 FN rate 0.0 FN rate 0.0 
PPV 83 .9 PPV 90.9 ppy 92.6 PPV 83.9 
NPY 100.0 NPV 100.0 NPV 100.0 NPV 100.0 
Percent 90.6 Percent 95.1 Percent 96.1 Percent 90.6 
agreement agreement agreement agreement 
Kappa 0.812 Kappa 0.902 Kappa 0.922 Kappa 0.812 
Kappa 0.76- Kappa 0.86- Kappa 0.89- Kappa 0.76-
95%CI 0.86 95%CI 0.94 95%CI 0.96 95%CI 0.86 
(>= 1 hospital OR (>= 1 hospital OR (>= 1 hospital OR (>= 1 hospital OR 
>= 1 PSY) OR at >= 1 PSY) OR at >= 1 PSY) OR at >= I PSY) OR at 
least 2 GP visit least 1 GP visit for least 2 GP visit least 3 GP visit 
for 311 OR Anti- 311 OR Anti- for 311 OR Anti- for 311 OR Anti-
depressant meds depressant meds depressant meds depressant meds 
within first 1 within first 2 years within first 2 within first 2 
year years years 
Sensitivity 100.0 Sensitivity 100.0 Sensitivity 100.0 Sensitivity 100.0 
Specificity 92.3 Specificity 81.5 Specificity 9 1.9 Specific ity 92.7 
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FP rate 7.7 FP rate 18.5 FP rate 8.1 FP rate 7.3 
FN rate 0.0 FN rate 0.0 FN rate 0.0 FN rate 0.0 
ppy 92.6 PPY 83.9 PPY 92.3 ppy 92.9 
NPY 100.0 NPY 100.0 NPY 100.0 NPY 100.0 
Percent 96.1 Percent 90.6 Percent 95.9 Percent 96.3 
agreement agreement agreement agreement 
Kappa 0.922 Kappa 0.812 Kappa 0.918 Kappa 0.926 
Kappa 0.89- Kappa 0.76- Kappa 0.88- Kappa 0.89-
95%CI 0.96 95%CI 0.86 95%CI 0.95 95%CI 0.96 
(>= 1 hospital OR (>= 1 hospital OR (>= 1 hospital OR (>= 1 hospital OR 
>= 1 PSY) OR at >= 1 PSY) OR at >= 1 PSY) OR at >= 1 PSY) OR at 
least 1 GP visit least 2 GP visit for least 3 GP visit least 1 GP visit 
for 311 OR Anti- 311 OR Anti- for 311 OR Anti- for 311 OR Anti-
depressant meds depressant meds depressant meds depressant meds 
within first 3 within first 3 years within first 3 within first 4 
years years years 
Sensitivity 100.0 Sensitivity 100.0 Sensitivity 100.0 Sensitivity 100.0 
Specificity 91.5 Specificity 91.5 Specificity 92.3 Specificity 81.5 
FP rate 8.5 FP rate 8.5 FP rate 7.7 FP rate 18.5 
FN rate 0.0 FN rate 0.0 FN rate 0.0 FN rate 0.0 
PPY 91.9 PPY 91.9 PPY 92.6 ppy 83.9 
NPY 100.0 NPY 100.0 NPY 100.0 NPY 100.0 
Percent 95.7 Percent 95.7 Percent 96.1 Percent 90.6 
agreement agreement agreement agreement 
Kappa 0.914 Kappa 0.914 Kappa 0.922 Kappa 0.812 
Kappa 0.88- Kappa 0.88- Kappa 0.89- Kappa 0.76-
95%CI 0.95 95%CI 0.95 95%CI 0.96 95%CI 0.86 
(>= 1 hospital OR (>= 1 hospital OR 
>= 1 PSY) OR at >= 1 PSY) OR at 
least 2 GP visit least 3 GP visit for 
for 311 OR Anti- 311 OR Anti-
depressant meds depressant meds 
within first 4 within first 4 years 
years 
Sensitivity 100.0 Sensitivity 100.0 
Specificity 90.3 Specificity 91.5 
FP rate 9.7 FP rate 8.5 
FN rate 0.0 FN rate 0.0 
PPY 90.9 PPY 91.9 
NPY 100.0 NPY 100.0 
Percent 95.1 Percent 95.7 
agreement agreement 
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Kappa 0.902 
Kappa 0.86-
95%CI 0.94 
I .. False positive rate 
2 False negative rate 
Kappa 
Kappa 
95%CJ 
3 Positive predictive value 
4 Negative predictive value 
5 Psychiatrist visit 
6 General practitioner visit 
0.914 
0.88-
0.95 
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